BioMed Realty Trust, Inc.
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Form 10-K
ANNUAL REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2007
Commission file
number: 1-32261
BIOMED REALTY TRUST,
INC.
(Exact name of registrant as
specified in its charter)
|
|
|
Maryland
|
|
20-1142292
|
(State or other jurisdiction
of
|
|
(I.R.S. Employer Identification
No.)
|
incorporation or
organization)
|
|
|
17190 Bernardo Center Drive
|
|
92128
|
San Diego, California
|
|
(Zip Code)
|
(Address of Principal Executive
Offices)
|
|
|
(858) 485-9840
(Registrants telephone
number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
|
|
|
Title of Each Class
|
|
Name of Each Exchange on Which Registered
|
|
Common Stock, $0.01 Par Value
|
|
New York Stock Exchange
|
7.375% Series A Cumulative Redeemable Preferred Stock,
$0.01 Par Value
|
|
New York Stock Exchange
|
Securities
registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities
Act of
1933. Yes þ No o
Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or 15(d) of the Securities
Exchange Act of
1934. Yes o No þ
Indicate by check mark whether the registrant: (1) has
filed all reports required to be filed by Section 13 or
15(d) of the Exchange Act during the preceding 12 months
(or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing
requirements for the past
90 days. Yes þ No o
Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of
Regulation S-K
is not contained herein, and will not be contained, to the best
of the registrants knowledge, in definitive proxy or
information statements incorporated by reference in
Part III of this
Form 10-K
or any amendment to this
Form 10-K. o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in
Rule 12b-2
of the Exchange Act. (Check one):
|
|
|
|
Large
accelerated
filer þ
|
Accelerated
filer o
|
Non-accelerated
filer o
|
Smaller
reporting
company o
|
(Do
not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Exchange
Act). Yes o No þ
The aggregate market value of the 65,153,088 shares of
common stock held by non-affiliates of the registrant was
$1,636,645,571 based upon the last reported sale price of $25.12
per share on the New York Stock Exchange on June 29, 2007,
the last business day of its most recently completed second
quarter.
The number of outstanding shares of the registrants common
stock, par value $0.01 per share, as of February 28, 2008
was 65,592,685.
DOCUMENTS
INCORPORATED BY REFERENCE
Portions of the registrants Proxy Statement with respect
to its May 21, 2008 Annual Meeting of Stockholders to be
filed not later than 120 days after the end of the
registrants fiscal year are incorporated by reference into
Part III hereof.
BIOMED
REALTY TRUST, INC.
FORM 10-K
ANNUAL REPORT
FOR THE YEAR ENDED DECEMBER 31, 2007
TABLE OF
CONTENTS
1
PART I
Forward-Looking
Statements
We make statements in this report that are forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995 (set forth in Section 27A of
the Securities Act of 1933, as amended, or the Securities Act,
and Section 21E of the Securities Exchange Act of 1934, as
amended, or the Exchange Act). In particular, statements
pertaining to our capital resources, portfolio performance and
results of operations contain forward-looking statements.
Likewise, our statements regarding anticipated growth in our
funds from operations and anticipated market conditions,
demographics and results of operations are forward-looking
statements. Forward-looking statements involve numerous risks
and uncertainties, and you should not rely on them as
predictions of future events. Forward-looking statements depend
on assumptions, data or methods which may be incorrect or
imprecise, and we may not be able to realize them. We do not
guarantee that the transactions and events described will happen
as described (or that they will happen at all). You can identify
forward-looking statements by the use of forward-looking
terminology such as believes, expects,
may, will, should,
seeks, approximately,
intends, plans, estimates or
anticipates or the negative of these words and
phrases or similar words or phrases. You can also identify
forward-looking statements by discussions of strategy, plans or
intentions. The following factors, among others, could cause
actual results and future events to differ materially from those
set forth or contemplated in the forward-looking statements:
|
|
|
|
|
adverse economic or real estate developments in the life science
industry or in our target markets,
|
|
|
|
general economic conditions,
|
|
|
|
our ability to compete effectively,
|
|
|
|
defaults on or non-renewal of leases by tenants,
|
|
|
|
increased interest rates and operating costs,
|
|
|
|
our failure to obtain necessary outside financing,
|
|
|
|
our ability to successfully complete real estate acquisitions,
developments and dispositions,
|
|
|
|
risks and uncertainties affecting property development and
construction,
|
|
|
|
our failure to successfully operate acquired properties and
operations,
|
|
|
|
our failure to maintain our status as a real estate investment
trust, or REIT,
|
|
|
|
government approvals, actions and initiatives, including the
need for compliance with environmental requirements,
|
|
|
|
financial market fluctuations, and
|
|
|
|
changes in real estate and zoning laws and increases in real
property tax rates.
|
While forward-looking statements reflect our good faith beliefs,
they are not guarantees of future performance. We disclaim any
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise. For a further discussion of these and other factors
that could impact our future results, performance or
transactions, see the section below entitled Item 1A.
Risk Factors.
General
As used herein, the terms we, us,
our or the Company refer to BioMed
Realty Trust, Inc., a Maryland corporation, and any of our
subsidiaries, including BioMed Realty, L.P., a Maryland limited
partnership (our Operating Partnership), and 201
Industrial Road, L.P., our predecessor. We are a REIT focused on
acquiring, developing, owning, leasing and managing laboratory
and office space for the life science industry. Our tenants
primarily include biotechnology and pharmaceutical companies,
scientific research institutions, government
2
agencies and other entities involved in the life science
industry. Our properties are generally located in markets with
well established reputations as centers for scientific research,
including Boston, San Diego, San Francisco, Seattle,
Maryland, Pennsylvania and New York/New Jersey.
We were incorporated in Maryland on April 30, 2004 and
commenced operations on August 11, 2004, after completing
our initial public offering. As of December 31, 2007, we
owned or had interests in 67 properties, consisting of 103
buildings with approximately 8.5 million rentable square
feet of laboratory and office space. Our operating portfolio,
comprising approximately 6.6 million rentable square feet,
was 93.8% leased to 112 tenants, not including approximately
1.8 million square feet that was available for
redevelopment. In addition, we have properties with
approximately 1.9 million rentable square feet under
construction and undeveloped land that we estimate can support
up to an additional 1.3 million rentable square feet of
laboratory and office space.
Our senior management team has significant experience in the
real estate industry, principally focusing on properties
designed for life science tenants. We operate as a fully
integrated, self-administered and self-managed REIT, providing
property management, leasing, development and administrative
services to our properties. As of February 28, 2008, we had
113 employees.
Our principal offices are located at 17190 Bernardo Center
Drive, San Diego, California 92128. Our telephone number at
that location is
(858) 485-9840.
Our website is located at www.biomedrealty.com. We make
available through our website our annual report on
Form 10-K,
quarterly reports on
Form 10-Q,
current reports on
Form 8-K
and amendments to such reports filed or furnished pursuant to
Sections 13(a) or 15(d) of the Exchange Act as soon as
reasonably practicable after we electronically file such
material with, or furnish it to, the Securities and Exchange
Commission. You can also access on our website our Code of
Business Conduct and Ethics, Corporate Governance Guidelines,
Audit Committee Charter, Compensation Committee Charter, and
Nominating and Corporate Governance Committee Charter.
2007
Highlights
During 2007, we executed 53 leasing transactions representing
approximately 1.5 million square feet, including 40 new
leases totaling approximately 661,000 square feet and 13
leases amended to extend their terms and totaling approximately
839,000 square feet. On January 26, 2007, we signed a
new, long-term lease and amended an existing lease with
Illumina, Inc. for approximately 193,000 square feet of
office and laboratory space at our Towne Centre Drive property
in San Diego, California. Under the new lease, Illumina
will expand into a new 84,000 square foot building being
constructed at the property. Once completed and occupied,
Illumina will lease the new building for a
15-year
term. In addition, Illumina extended its lease for the
109,270 square feet it currently occupies at Towne Centre
Drive by nine years to 2023 to correspond with the new
15-year
lease on the building being constructed. On November 16,
2007, we signed a new, six-year lease and amended an existing
lease with Centocor, Inc. (a subsidiary of Johnson &
Johnson) for approximately 374,000 square feet at our King
of Prussia property in Pennsylvania. Under the new lease,
Centocor will expand into an additional 43,000 square feet
at the property. In addition, Centocor extended its lease for
the 331,000 square feet it currently occupies by four
years, to 2014, to correspond with the new six-year lease.
On January 18, 2007, we completed the issuance of
9,200,000 shares, including the exercise of an
over-allotment option of 1,200,000 shares, of 7.375%
Series A cumulative redeemable preferred stock at $25.00
per share, resulting in net proceeds of approximately
$222.4 million.
On April 2, 2007, we promoted Karen A. Sztraicher to the
position of Vice President, Finance and Treasurer and appointed
Greg Lubushkin to serve as Vice President Chief
Accounting Officer.
On April 4, 2007, we formed two limited liability companies
with Prudential Real Estate Investors (PREI), which
we refer to as PREI I LLC and PREI II LLC. PREI I LLC and PREI
II LLC subsequently acquired a portfolio of stabilized and
development properties totaling approximately
470,000 rentable square feet, primarily located in
Cambridge, Massachusetts, with a development parcel in Houston,
Texas, and a laboratory/office building and leasehold interests
in surrounding properties in New Haven, Connecticut, for a
purchase price of approximately $506.7 million, excluding
closing costs. The acquired properties also included an
operating garage facility with 503 spaces, an operating below
grade garage facility with approximately 1,400 spaces, and an
additional below grade
3
garage facility at one of the buildings under construction that
we estimate can support up to 560 spaces upon completion.
On August 1, 2007, we amended our unsecured revolving line
of credit, increasing the borrowing capacity from
$500.0 million to $600.0 million, reducing the
interest rate, and extending the maturity date to August 1,
2011. We may increase the borrowing capacity to
$1.0 billion subject to certain conditions. In addition, we
may extend the maturity date of the unsecured line of credit to
August 1, 2012 after satisfying certain conditions and
paying an extension fee based on the then current facility
commitment. Also, on August 1, 2007, we amended our secured
term loan, reducing the interest rate and extending the maturity
date to August 1, 2012.
On December 12, 2007, we appointed Richard Gilchrist to our
board of directors. Mr. Gilchrist is the President of the
Investment Properties Group for The Irvine Company, a
privately-held real estate investment company.
During 2007, including our investments in limited liability
companies with PREI, we acquired 14 properties, consisting of
1.0 million rentable square feet of laboratory and office
space, as well as approximately 700,000 rentable square
feet under construction and undeveloped land, for an aggregate
purchase price of approximately $653.8 million, excluding
closing costs. Also during 2007, we disposed of four non-core
properties representing 378,000 rentable square feet,
including one undeveloped land parcel, for approximately
$60.6 million, excluding closing costs.
In addition to our investments with PREI, we acquired the
following properties during the year ended December 31,
2007 (dollars in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rentable
|
|
|
|
|
Property
|
|
Acquisition Date
|
|
Square Feet
|
|
|
Purchase Price
|
|
|
Torreyana Road
|
|
March 22, 2007
|
|
|
81,204
|
|
|
$
|
33,000
|
|
6114-6154
Nancy Ridge Drive
|
|
May 2, 2007
|
|
|
112,000
|
|
|
|
50,100
|
|
9920 Belward Campus Drive
|
|
May 8, 2007
|
|
|
51,181
|
|
|
|
15,000
|
|
Pacific Center Boulevard
|
|
August 24, 2007
|
|
|
66,745
|
|
|
|
16,500
|
|
Forbes Boulevard
|
|
September 5, 2007
|
|
|
237,984
|
|
|
|
32,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
549,114
|
|
|
$
|
147,100
|
|
|
|
|
|
|
|
|
|
|
|
|
During 2007, we declared aggregate dividends on our common stock
of $1.24 per common share and aggregate dividends on our
preferred stock of $1.83352 per preferred share.
Subsequent
Events
On February 13, 2008, a wholly owned entity of PREI I LLC
entered into a secured construction loan facility with Wachovia
Bank, National Association and certain other lenders to provide
borrowings of up to approximately $245.0 million in
connection with the construction of 650 East Kendall Street
(Kendall B), a life sciences building located in Cambridge,
Massachusetts. Proceeds from the secured construction loan were
used in part to repay a portion of the secured acquisition and
interim loan facility held by the PREI limited liability
companies and will also be used to fund the balance of the
anticipated cost to complete construction of the project. In
addition, on February 19, 2008, the PREI limited liability
companies extended the term of the secured acquisition and
interim loan facility by one year to April 3, 2009, with no
additional changes to the pricing or terms of the facility.
Growth
Strategy
Our success and future growth potential are based upon the
unique real estate opportunities within the life science
industry. Our growth strategy is designed to meet the sizable
demand and specialized requirements of life science tenants by
leveraging the knowledge and expertise of a management team
focused on serving this large and fast growing industry.
Our internal growth strategy includes:
|
|
|
|
|
negotiating leases with contractual rental rate increases in
order to provide predictable and consistent earnings growth,
|
4
|
|
|
|
|
creating strong relationships with our tenants to enable us to
identify and capitalize on opportunities to renew or extend
existing leases or to provide expansion space,
|
|
|
|
redeveloping currently owned non-laboratory space into higher
yielding laboratory facilities, and
|
|
|
|
developing new laboratory and office space on land we have
acquired for development.
|
Our external growth strategy includes:
|
|
|
|
|
acquiring well-located properties leased to high-quality life
science tenants with attractive in-place yields and long-term
growth potential,
|
|
|
|
investing in properties with leasing opportunities, capitalizing
on our industry relationships to enter into new leases, and
|
|
|
|
investing in redevelopment and development projects,
capitalizing on our development platform that we believe will
serve as an additional catalyst for future growth.
|
Target
Markets
Our target markets Boston, San Diego,
San Francisco, Seattle, Maryland, Pennsylvania, New
York/New Jersey and research parks near or adjacent to
universities have emerged as the primary hubs for
research, development and production in the life science
industry. Each of these markets benefits from the presence of
mature life science companies, which provide scale and stability
to the market, as well as academic and university environments
and government entities to contribute innovation, research,
personnel and capital to the private sector. In addition, the
clustered research environments within these target markets
typically provide a high quality of life for the research
professionals and a fertile ground for new life science ideas
and ventures.
Positive
Life Science Industry Trends
We expect continued growth in the life science industry due to
several factors:
|
|
|
|
|
the aging of the U.S. population resulting from the
transition of baby boomers to senior citizens, which has
increased the demand for new drugs and health care treatment
alternatives,
|
|
|
|
the existing high level of, and continuing increase in, research
and development expenditures, as represented by a Pharmaceutical
Research and Manufacturers of America (PhRMA) survey indicating
that research and development spending by its members climbed to
a record $43.0 billion in 2006 from $39.9 billion in
the prior year, and when combined with non-member companies,
totaled a record $55.2 billion in 2006, and
|
|
|
|
escalating health care costs, which drive the demand for better
drugs, less expensive treatments and more services in an attempt
to manage such costs.
|
We are uniquely positioned to benefit from these favorable
dynamics through the demand for space for research, development
and production by our life science industry tenants.
Experienced
Management
We have created and continue to develop a premier life science
real estate-oriented management team, dedicated to maximizing
current and long-term returns and growth for our stockholders.
Our executive officers have acquired, developed, owned, leased
and managed in excess of $4.0 billion in life science real
estate. Through this experience, our management team has
established extensive industry relationships among life science
tenants, property owners and real estate brokers. In addition,
our experienced independent board members provide management
with a broad range of knowledge in real estate, the sciences,
life science company operations, and large public company
finance and management.
Regulation
General
Our properties are subject to various laws, ordinances and
regulations, including regulations relating to common areas. We
believe that we have the necessary permits and approvals to
operate each of our properties.
5
Americans
with Disabilities Act
Our properties must comply with Title III of the Americans
with Disabilities Act, or ADA, to the extent that such
properties are public accommodations as defined by
the ADA. The ADA may require removal of structural barriers to
access by persons with disabilities in certain public areas of
our properties where such removal is readily achievable. We
believe that our properties are in substantial compliance with
the ADA and that we will not be required to make substantial
capital expenditures to address the requirements of the ADA. The
tenants are generally responsible for any additional amounts
required to conform their construction projects to the ADA.
However, noncompliance with the ADA could result in imposition
of fines or an award of damages to private litigants. The
obligation to make readily achievable accommodations is an
ongoing one, and we will continue to assess our properties and
to make alterations as appropriate in this respect.
Environmental
Matters
Under various federal, state and local environmental laws and
regulations, a current or previous owner, operator or tenant of
real estate may be required to investigate and remediate
releases or threats of releases of hazardous or toxic substances
or petroleum products at such property, and may be held liable
for property damage, personal injury damages and investigation,
clean-up and
monitoring costs incurred in connection with the actual or
threatened contamination. Such laws typically impose
clean-up
responsibility and liability without regard to fault, or whether
the owner, operator or tenant knew of or caused the presence of
the contamination. The liability under such laws may be joint
and several for the full amount of the investigation,
clean-up and
monitoring costs incurred or to be incurred or actions to be
undertaken, although a party held jointly and severally liable
may obtain contributions from the other identified, solvent,
responsible parties of their fair share toward these costs.
These costs may be substantial, and can exceed the value of the
property. The presence of contamination, or the failure to
properly remediate contamination, on a property may adversely
affect the ability of the owner, operator or tenant to sell or
rent that property or to borrow using such property as
collateral, and may adversely impact our investment in that
property.
Federal asbestos regulations and certain state laws and
regulations require building owners and those exercising control
over a buildings management to identify and warn, via
signs, labels or other notices, of potential hazards posed by
the actual or potential presence of asbestos-containing
materials, or ACMs, in their building. The regulations also set
forth employee training, record-keeping and due diligence
requirements pertaining to ACMs and potential ACMs. Significant
fines can be assessed for violating these regulations. Building
owners and those exercising control over a buildings
management may be subject to an increased risk of personal
injury lawsuits by workers and others exposed to ACMs and
potential ACMs as a result of these regulations. The regulations
may affect the value of a building containing ACMs and potential
ACMs in which we have invested. Federal, state and local laws
and regulations also govern the removal, encapsulation,
disturbance, handling
and/or
disposal of ACMs and potential ACMs when such materials are in
poor condition or in the event of construction, remodeling,
renovation or demolition of a building. Such laws may impose
liability for improper handling or a release to the environment
of ACMs and potential ACMs and may provide for fines to, and for
third parties to seek recovery from, owners or operators of real
properties for personal injury or improper work exposure
associated with ACMs and potential ACMs. See Risk
Factors Risks Related to the Real Estate
Industry We could incur significant costs related to
governmental regulation and private litigation over
environmental matters involving asbestos-containing materials,
which could adversely affect our operations, the value of our
properties, and our ability to make distributions to our
stockholders under Item 1A. below.
Federal, state and local environmental laws and regulations also
require removing or upgrading certain underground storage tanks
and regulate the discharge of storm water, wastewater and other
pollutants; the emission of air pollutants; the generation,
management and disposal of hazardous or toxic chemicals,
substances or wastes; and workplace health and safety. Life
science industry tenants, including certain of our tenants,
engage in various research and development activities involving
the controlled use of hazardous materials, chemicals, biological
and radioactive compounds. Although we believe that the
tenants activities involving such materials comply in all
material respects with applicable laws and regulations, the risk
of contamination or injury from these materials cannot be
completely eliminated. In the event of such contamination or
injury, we could be held liable for any damages that result, and
any such liability could exceed our resources and our
environmental remediation insurance
6
coverage. Licensing requirements governing use of radioactive
materials by tenants may also restrict the use of or ability to
transfer space in buildings we own. See Risk
Factors Risks Related to the Real Estate
Industry We could incur significant costs related to
government regulation and private litigation over environmental
matters involving the presence, discharge or threat of discharge
of hazardous or toxic substances, which could adversely affect
our operations, the value of our properties, and our ability to
make distributions to our stockholders under Item 1A.
below.
In addition, our leases generally provide that (1) the
tenant is responsible for all environmental liabilities relating
to the tenants operations, (2) we are indemnified for
such liabilities and (3) the tenant must comply with all
environmental laws and regulations. Such a contractual
arrangement, however, does not eliminate our statutory liability
or preclude claims against us by governmental authorities or
persons who are not parties to such an arrangement.
Noncompliance with environmental or health and safety
requirements may also result in the need to cease or alter
operations at a property, which could affect the financial
health of a tenant and its ability to make lease payments. In
addition, if there is a violation of such a requirement in
connection with a tenants operations, it is possible that
we, as the owner of the property, could be held accountable by
governmental authorities (or other injured parties) for such
violation and could be required to correct the violation and pay
related fines. In certain situations, we have agreed to
indemnify tenants for conditions preceding their lease term, or
that do not result from their operations.
Prior to closing any property acquisition, we obtain
environmental assessments in a manner we believe prudent in
order to attempt to identify potential environmental concerns at
such properties. These assessments are carried out in accordance
with an appropriate level of due diligence and generally include
a physical site inspection, a review of relevant federal, state
and local environmental and health agency database records, one
or more interviews with appropriate site-related personnel,
review of the propertys chain of title and review of
historic aerial photographs and other information on past uses
of the property. We may also conduct limited subsurface
investigations and test for substances of concern where the
results of the first phase of the environmental assessments or
other information indicate possible contamination or where our
consultants recommend such procedures.
While we may purchase our properties on an as is
basis, most of our purchase contracts contain an environmental
contingency clause, which permits us to reject a property
because of any environmental hazard at such property. We receive
environmental reports on all prospective properties.
We believe that our properties comply in all material respects
with all federal and state regulations regarding hazardous or
toxic substances and other environmental matters.
Insurance
We carry comprehensive general liability, fire and extended
coverage, terrorism and loss of rental income insurance covering
all of our properties under a blanket portfolio policy, with the
exception of property insurance on our McKellar Court, Science
Center Drive, 9911 Belward Campus Drive and Shady Grove Road
locations, which is carried directly by the tenants in
accordance with the terms of their respective leases, and
builders risk policies for any projects under
construction. In addition, we carry workers compensation
coverage for injury to our employees. We believe the policy
specifications and insured limits are adequate given the
relative risk of loss, cost of the coverage and standard
industry practice. We also carry environmental remediation
insurance for our properties. This insurance, subject to certain
exclusions and deductibles, covers the cost to remediate
environmental damage caused by unintentional future spills or
the historic presence of previously undiscovered hazardous
substances, as well as third-party bodily injury and property
damage claims related to the release of hazardous substances. We
intend to carry similar insurance with respect to future
acquisitions as appropriate. A substantial portion of our
properties are located in areas subject to earthquake loss, such
as San Diego and San Francisco, California and
Seattle, Washington. Although we presently carry earthquake
insurance on our properties, the amount of earthquake insurance
coverage we carry may not be sufficient to fully cover losses
from earthquakes. In addition, we may discontinue earthquake,
terrorism or other insurance, or may elect not to procure such
insurance, on some or all of our properties in the future if the
cost of the premiums for any of these policies exceeds, in our
judgment, the value of the coverage discounted for the risk of
loss. See Risk Factors Risks Related to the
Real Estate Industry
7
Uninsured and underinsured losses could adversely affect our
operating results and our ability to make distributions to our
stockholders under Item 1A. below.
Competition
We face competition from various entities for investment
opportunities in properties for life science tenants, including
other REITs, such as health care REITs and suburban office
property REITs, pension funds, insurance companies, investment
funds and companies, partnerships, and developers. Because
properties designed for life science tenants typically contain
improvements that are specific to tenants operating in the life
science industry, we believe that we will be able to maximize
returns on investments as a result of:
|
|
|
|
|
our expertise in understanding the real estate needs of life
science industry tenants,
|
|
|
|
our ability to identify, acquire and develop properties with
generic laboratory infrastructure that appeal to a wide range of
life science industry tenants, and
|
|
|
|
our expertise in identifying and evaluating life science
industry tenants.
|
However, some of our competitors have greater financial
resources than we do and may be able to accept more risks,
including risks with respect to the creditworthiness of a tenant
or the geographic proximity of its investments. In the future,
competition from these entities may reduce the number of
suitable investment opportunities offered to us or increase the
bargaining power of property owners seeking to sell. Further, as
a result of their greater resources, those entities may have
more flexibility than we do in their ability to offer rental
concessions to attract tenants. These concessions could put
pressure on our ability to maintain or raise rents and could
adversely affect our ability to attract or retain tenants.
Additionally, our ability to compete depends upon, among other
factors, trends of the national and local economies, investment
alternatives, financial condition and operating results of
current and prospective tenants, availability and cost of
capital, construction and renovation costs, taxes, governmental
regulations, legislation and population trends.
Foreign
Operations
We do not engage in any foreign operations or derive any revenue
from foreign sources.
For purposes of this section, the term stockholders
means the holders of shares of our common stock and our
preferred stock.
Risks
Related to Our Properties, Our Business and Our Growth
Strategy
Because we lease our properties to a limited number of
tenants, and to the extent we depend on a limited number of
tenants in the future, the inability of any single tenant to
make its lease payments could adversely affect our business and
our ability to make distributions to our stockholders.
As of December 31, 2007, we had 117 tenants in 67 total
properties. Two of our tenants, Human Genome Sciences and Vertex
Pharmaceuticals, represented 20.3% and 13.1%, respectively, of
our annualized base rent as of December 31, 2007, and 10.9%
and 8.1%, respectively, of our total leased rentable square
footage. While we evaluate the creditworthiness of our tenants
by reviewing available financial and other pertinent
information, there can be no assurance that any tenant will be
able to make timely rental payments or avoid defaulting under
its lease. If a tenant defaults, we may experience delays in
enforcing our rights as landlord and may incur substantial costs
in protecting our investment. Because we depend on rental
payments from a limited number of tenants, the inability of any
single tenant to make its lease payments could adversely affect
us and our ability to make distributions to our stockholders.
We may be unable to acquire, develop or operate new
properties successfully, which could harm our financial
condition and ability to pay distributions to our
stockholders.
8
We continue to evaluate the market for available properties and
may acquire office, laboratory and other properties when
opportunities exist. We also may develop or substantially
renovate office and other properties. Acquisition, development
and renovation activities are subject to significant risks,
including:
|
|
|
|
|
changing market conditions, including competition from others,
may diminish our opportunities for acquiring a desired property
on favorable terms or at all. Even if we enter into agreements
for the acquisition of properties, these agreements are subject
to customary conditions to closing, including completion of due
diligence investigations to our satisfaction,
|
|
|
|
we may be unable to obtain financing on favorable terms (or at
all),
|
|
|
|
we may spend more time or money than we budget to improve or
renovate acquired properties or to develop new properties,
|
|
|
|
we may be unable to quickly and efficiently integrate new
properties, particularly if we acquire portfolios of properties,
into our existing operations,
|
|
|
|
we may fail to obtain the financial results expected from the
properties we acquire or develop, making them unprofitable or
less profitable than we had expected,
|
|
|
|
market and economic conditions may result in higher than
expected vacancy rates and lower than expected rental rates,
|
|
|
|
we may fail to retain tenants that have pre-leased our
properties under development if we do not complete the
construction of these properties in a timely manner or to the
tenants specifications,
|
|
|
|
we have a limited history in conducting
ground-up
construction activities,
|
|
|
|
if we develop properties, we may encounter delays or refusals in
obtaining all necessary zoning, land use, building, occupancy
and other required governmental permits and authorizations,
|
|
|
|
acquired and developed properties may have defects we do not
discover through our inspection processes, including latent
defects that may not reveal themselves until many years after we
put a property in service, and
|
|
|
|
we may acquire land, properties or entities owning properties,
which are subject to liabilities and for which, in the case of
unknown liabilities, we may have limited or no recourse.
|
As of December 31, 2007, five of the properties we owned or
had interests in were under development, constituting
approximately 1.9 million square feet. As a result of these
projects, we may face increased risk with respect to our
development activities.
The realization of any of the above risks could significantly
and adversely affect our financial condition, results of
operations, cash flow, per share trading price of our
securities, ability to satisfy our debt service obligations and
ability to pay distributions to our stockholders.
Tenants in the life science industry face high levels of
regulation, expense and uncertainty that may adversely affect
their ability to pay us rent and consequently adversely affect
our business.
Life science entities comprise the vast majority of our tenant
base. Because of our dependence on a single industry, adverse
conditions affecting that industry will more adversely affect
our business, and thus our ability to make distributions to our
stockholders, than if our business strategy included a more
diverse tenant base. Life science industry tenants, particularly
those involved in developing and marketing drugs and drug
delivery technologies, fail from time to time as a result of
various factors. Many of these factors are particular to the
life science industry. For example:
|
|
|
|
|
Our tenants require significant outlays of funds for the
research and development and clinical testing of their products
and technologies. If private investors, the government, public
markets or other sources of funding are unavailable to support
such development, a tenants business may fail.
|
9
|
|
|
|
|
The research and development, clinical testing, manufacture and
marketing of some of our tenants products require federal,
state and foreign regulatory approvals. The approval process is
typically long, expensive and uncertain. Even if our tenants
have sufficient funds to seek approvals, one or all of their
products may fail to obtain the required regulatory approvals on
a timely basis or at all. Furthermore, our tenants may only have
a small number of products under development. If one product
fails to receive the required approvals at any stage of
development, it could significantly adversely affect our
tenants entire business and its ability to pay rent.
|
|
|
|
Our tenants with marketable products may be adversely affected
by health care reform efforts and the reimbursement policies of
government or private health care payers.
|
|
|
|
Our tenants may be unable to adequately protect their
intellectual property under patent, copyright or trade secret
laws. Failure to do so could jeopardize their ability to profit
from their efforts and to protect their products from
competition.
|
|
|
|
Collaborative relationships with other life science entities may
be crucial to the development, manufacturing, distribution or
marketing of our tenants products. If these other entities
fail to fulfill their obligations under these collaborative
arrangements, our tenants businesses will suffer.
|
We cannot assure you that our tenants in the life science
industry will be successful in their businesses. If our
tenants businesses are adversely affected, they may have
difficulty paying us rent.
Because particular upgrades are required for life science
tenants, improvements to our properties involve greater
expenditures than traditional office space, which costs may not
be covered by the rents our tenants pay.
The improvements generally required for our properties
infrastructure are more costly than for other property types.
Typical infrastructural improvements include the following:
|
|
|
|
|
reinforced concrete floors,
|
|
|
|
upgraded roof structures for greater load capacity,
|
|
|
|
increased
floor-to-ceiling
clear heights,
|
|
|
|
heavy-duty HVAC systems,
|
|
|
|
enhanced environmental control technology,
|
|
|
|
significantly upgraded electrical, gas and plumbing
infrastructure, and
|
|
|
|
laboratory benchwork.
|
Our tenants generally pay higher rent on our properties than
tenants in traditional office space. However, we cannot assure
you that our tenants will continue to do so in the future or
that the rents paid will cover the additional costs of upgrading
the properties.
Because of the unique and specific improvements required for
our life science tenants, we may be required to incur
substantial renovation costs to make our properties suitable for
other life science tenants or other office tenants, which could
adversely affect our operating performance.
We acquire or develop properties that include laboratory space
and other features that we believe are generally desirable for
life science industry tenants. However, different life science
industry tenants may require different features in their
properties, depending on each tenants particular focus
within the life science industry. If a current tenant is unable
to pay rent and vacates a property, we may incur substantial
expenditures to modify the property before we are able to
re-lease the space to another life science industry tenant. This
could hurt our operating performance and the value of your
investment. Also, if the property needs to be renovated to
accommodate multiple tenants, we may incur substantial
expenditures before we are able to re-lease the space.
10
Additionally, our properties may not be suitable for lease to
traditional office tenants without significant expenditures or
renovations. Accordingly, any downturn in the life science
industry may have a substantial negative impact on our
properties values.
The geographic concentration of our consolidated properties
in Boston, Maryland and California makes our business
particularly vulnerable to adverse conditions affecting these
markets.
Twelve of our properties are located in the Boston area. As of
December 31, 2007, these properties represented 24.6% of
our annualized base rent and 15.4% of our total rentable square
footage. Five of our properties are located in Maryland. As of
December 31, 2007, these properties represented 22.3% of
our annualized base rent and 13.5% of our total rentable square
footage. In addition, 26 of our properties are located in
California, with 15 in San Diego and eleven in
San Francisco. As of December 31, 2007, these
properties represented 24.7% of our annualized base rent and
42.6% of our total rentable square footage. Because of this
concentration in three geographic regions, we are particularly
vulnerable to adverse conditions affecting Boston, Maryland and
California, including general economic conditions, increased
competition, a downturn in the local life science industry, real
estate conditions, terrorist attacks, earthquakes and wildfires
and other natural disasters occurring in these regions. In
addition, we cannot assure you that these markets will continue
to grow or remain favorable to the life science industry. The
performance of the life science industry and the economy in
general in these geographic markets may affect occupancy, market
rental rates and expenses, and thus may affect our performance
and the value of our properties. We are also subject to greater
risk of loss from earthquakes or wildfires because of our
properties concentration in California. The close
proximity of our eleven properties in San Francisco to a
fault line makes them more vulnerable to earthquakes than
properties in many other parts of the country. In addition, the
wildfires occurring in the San Diego area, most recently in
2003 and in 2007, may make the 15 properties we own in the
San Diego area more vulnerable to fire damage or
destruction than properties in many other parts of the country.
Our tax indemnification and debt maintenance obligations
require us to make payments if we sell certain properties or
repay certain debt, which could limit our operating
flexibility.
In our formation transactions, certain of our executive
officers, Alan D. Gold, Gary A. Kreitzer, John F.
Wilson, II and Matthew G. McDevitt, and certain other
individuals contributed six properties to our Operating
Partnership. If we were to dispose of these contributed assets
in a taxable transaction, Messrs. Gold, Kreitzer, Wilson
and McDevitt and the other contributors of those assets would
suffer adverse tax consequences. In connection with these
contribution transactions, we agreed to indemnify those
contributors against such adverse tax consequences for a period
of ten years. This indemnification will help those contributors
to preserve their tax positions after their contributions. The
tax indemnification provisions were not negotiated in an
arms length transaction but were determined by our
management team. We have also agreed to use reasonable best
efforts consistent with our fiduciary duties to maintain at
least $8.0 million of debt, some of which must be property
specific, that the contributors can guarantee in order to defer
any taxable gain they may incur if our Operating Partnership
repays existing debt. These tax indemnification and debt
maintenance obligations may affect the way in which we conduct
our business. During the indemnification period, these
obligations may impact the timing and circumstances under which
we sell the contributed properties or interests in entities
holding the properties. For example, these tax indemnification
payments could effectively reduce or eliminate any gain we might
otherwise realize upon the sale or other disposition of the
related properties. Accordingly, even if market conditions might
otherwise dictate that it would be desirable to dispose of these
properties, the existence of the tax indemnification obligations
could result in a decision to retain the properties in our
portfolio to avoid having to pay the tax indemnity payments. The
existence of the debt maintenance obligations could require us
to maintain debt at a higher level than we might otherwise
choose. Higher debt levels could adversely affect our ability to
make distributions to our stockholders.
While we may seek to enter into tax-efficient joint ventures
with third-party investors, we currently have no intention of
disposing of these properties or interests in entities holding
the properties in transactions that would trigger our tax
indemnification obligations. The involuntary condemnation of one
or more of these properties during the indemnification period
could, however, trigger the tax indemnification obligations
described above. The tax indemnity would equal the amount of the
federal and state income tax liability the contributor would
incur with respect to the gain allocated to the contributor. The
calculation of the indemnity payment would not be reduced due
11
to the time value of money or the time remaining within the
indemnification period. The terms of the contribution agreements
also require us to gross up the tax indemnity payment for the
amount of income taxes due as a result of the tax indemnity
payment. Messrs. Gold, Kreitzer, Wilson and McDevitt are
potential recipients of these indemnification payments. Because
of these potential payments their personal interests may diverge
from those of our stockholders.
Our expansion strategy may not yield the returns expected,
may result in disruptions to our business, may strain our
management resources and may adversely affect our operations.
We own properties principally in Boston, San Diego,
San Francisco, Seattle, Maryland, Pennsylvania and
New York/New Jersey, each of which is currently a leading
market in the United States for the life science industry. We
cannot assure you that these markets will remain favorable to
the life science industry, that these markets will continue to
grow or that we will be successful expanding in these markets.
In addition to the 13 properties we acquired in connection with
our initial public offering in August 2004, as of
December 31, 2007, we had acquired or had acquired an
interest in an additional 54 properties (net of property
dispositions), and we expect to continue to expand. This
anticipated growth will require substantial attention from our
existing management team, which may divert managements
attention from our current properties. Implementing our growth
plan will also require that we expand our management and staff
with qualified and experienced personnel and that we implement
administrative, accounting and operational systems sufficient to
integrate new properties into our portfolio. We also must manage
future property acquisitions without incurring unanticipated
costs or disrupting the operations at our existing properties.
Managing new properties requires a focus on leasing and
retaining tenants. If we fail to successfully integrate future
acquisitions into our portfolio, or if newly acquired properties
fail to perform as we expect, our results of operations,
financial condition and ability to pay distributions could
suffer.
Our success depends on key personnel with extensive
experience dealing with the real estate needs of life science
tenants, and the loss of these key personnel could threaten our
ability to operate our business successfully.
Our future success depends, to a significant extent, on the
continued services of our management team. In particular, we
depend on the efforts of Mr. Gold, our Chairman, President
and Chief Executive Officer, Mr. Kreitzer, our Executive
Vice President, General Counsel and Secretary, Mr. Wilson,
our Executive Vice President, Mr. McDevitt, our Regional
Executive Vice President, and Mr. Griffin, our Chief
Financial Officer. Among the reasons that Messrs. Gold,
Kreitzer, Wilson, McDevitt and Griffin are important to our
success are that they have extensive real estate and finance
experience, and strong reputations within the life science
industry. Our management team has developed informal
relationships through past business dealings with numerous
members of the scientific community, life science investors,
current and prospective life science industry tenants, and real
estate brokers. We expect that their reputations will continue
to attract business and investment opportunities before the
active marketing of properties and will assist us in
negotiations with lenders, existing and potential tenants, and
industry personnel. If we lost their services, our relationships
with such lenders, existing and prospective tenants, and
industry personnel could suffer. We have entered into employment
agreements with each of Messrs. Gold, Kreitzer, Wilson,
McDevitt and Griffin, but we cannot guarantee that they will not
terminate their employment prior to the end of the term.
The bankruptcy of a tenant may adversely affect the income
produced by and the value of our properties.
The bankruptcy or insolvency of a tenant may adversely affect
the income produced by our properties. If any tenant becomes a
debtor in a case under the Bankruptcy Code, we cannot evict the
tenant solely because of the bankruptcy. The bankruptcy court
also might authorize the tenant to reject and terminate its
lease with us, which would generally result in any unpaid,
pre-bankruptcy rent being treated as an unsecured claim. In
addition, our claim against the tenant for unpaid, future rent
would be subject to a statutory cap equal to the greater of
(1) one year of rent or (2) 15% of the remaining rent
on the lease (not to exceed three years of rent). This cap might
be substantially less than the remaining rent actually owed
under the lease. Additionally, a Bankruptcy Court may require us
to turn over to the estate all or a portion of any deposits,
amounts in escrow, or prepaid rents. Our claim for
12
unpaid, pre-bankruptcy rent, our lease termination damages and
claims relating to damages for which we hold deposits or other
amounts that we were forced to repay would likely not be paid in
full.
Future acts of terrorism or war or the risk of war may have a
negative impact on our business.
The continued threat of terrorism and the potential for military
action and heightened security measures in response to this
threat may cause significant disruption to commerce. There can
be no assurance that the armed hostilities will not escalate or
that these terrorist attacks, or the United States
responses to them, will not lead to further acts of terrorism
and civil disturbances, which may further contribute to economic
instability. Any armed conflict, civil unrest or additional
terrorist activities, and the attendant political instability
and societal disruption, may adversely affect our results of
operations, financial condition and future growth.
Risks
Related to the Real Estate Industry
Significant competition may decrease or prevent increases in
our properties occupancy and rental rates and may reduce
our investment opportunities.
We face competition from various entities for investment
opportunities in properties for life science tenants, including
other REITs, such as health care REITs and suburban office
property REITs, pension funds, insurance companies, investment
funds and companies, partnerships, and developers. Many of these
entities have substantially greater financial resources than we
do and may be able to accept more risk than we can prudently
manage, including risks with respect to the creditworthiness of
a tenant or the geographic location of its investments. In the
future, competition from these entities may reduce the number of
suitable investment opportunities offered to us or increase the
bargaining power of property owners seeking to sell. Further, as
a result of their greater resources, those entities may have
more flexibility than we do in their ability to offer rental
concessions to attract tenants. This could put pressure on our
ability to maintain or raise rents and could adversely affect
our ability to attract or retain tenants. As a result, our
financial condition, results of operations, cash flow, per share
trading price of our common stock or preferred stock, ability to
satisfy our debt service obligations and ability to pay
distributions to our stockholders may be adversely affected.
Uninsured and underinsured losses could adversely affect our
operating results and our ability to make distributions to our
stockholders.
We carry comprehensive general liability, fire and extended
coverage, terrorism and loss of rental income insurance covering
all of our properties under a blanket portfolio policy, with the
exception of property insurance on our McKellar Court, Science
Center Drive, 9911 Belward Campus Drive and Shady Grove Road
locations, which is carried directly by the tenants in
accordance with the terms of their respective leases, and
builders risk policies for any projects under
construction. In addition, we carry workers compensation
coverage for injury to our employees. We believe the policy
specifications and insured limits are adequate given the
relative risk of loss, cost of the coverage and standard
industry practice. We also carry environmental remediation
insurance for our properties. This insurance, subject to certain
exclusions and deductibles, covers the cost to remediate
environmental damage caused by unintentional future spills or
the historic presence of previously undiscovered hazardous
substances, as well as third-party bodily injury and property
damage claims related to the release of hazardous substances. We
intend to carry similar insurance with respect to future
acquisitions as appropriate. A substantial portion of our
properties are located in areas subject to earthquake loss, such
as San Diego and San Francisco, California and
Seattle, Washington. Although we presently carry earthquake
insurance on our properties, the amount of earthquake insurance
coverage we carry may not be sufficient to fully cover losses
from earthquakes. In addition, we may discontinue earthquake,
terrorism or other insurance, or may elect not to procure such
insurance, on some or all of our properties in the future if the
cost of the premiums for any of these policies exceeds, in our
judgment, the value of the coverage discounted for the risk of
loss.
If we experience a loss that is uninsured or that exceeds policy
limits, we could lose the capital invested in the damaged
properties as well as the anticipated future cash flows from
those properties. In addition, if the damaged properties are
subject to recourse indebtedness, we would continue to be liable
for the indebtedness, even if these properties were irreparably
damaged.
13
Our performance and value are subject to risks associated
with the ownership and operation of real estate assets and with
factors affecting the real estate industry.
Our ability to make expected distributions to our stockholders
depends on our ability to generate revenues in excess of
expenses, our scheduled principal payments on debt and our
capital expenditure requirements. Events and conditions that are
beyond our control may decrease our cash available for
distribution and the value of our properties. These events
include:
|
|
|
|
|
local oversupply, increased competition or reduced demand for
life science office and laboratory space,
|
|
|
|
inability to collect rent from tenants,
|
|
|
|
vacancies or our inability to rent space on favorable terms,
|
|
|
|
increased operating costs, including insurance premiums,
utilities and real estate taxes,
|
|
|
|
the ongoing need for capital improvements, particularly in older
structures,
|
|
|
|
unanticipated delays in the completion of our development or
redevelopment projects,
|
|
|
|
costs of complying with changes in governmental regulations,
including tax laws,
|
|
|
|
the relative illiquidity of real estate investments,
|
|
|
|
changing submarket demographics, and
|
|
|
|
civil unrest, acts of war and natural disasters, including
earthquakes, floods and fires, which may result in uninsured and
underinsured losses.
|
In addition, we could experience a general decline in rents or
an increased incidence of defaults under existing leases if any
of the following occur:
|
|
|
|
|
periods of economic slowdown or recession,
|
|
|
|
rising interest rates,
|
|
|
|
declining demand for real estate, or
|
|
|
|
the public perception that any of these events may occur.
|
Any of these events could adversely affect our financial
condition, results of operations, cash flow, per share trading
price of our common stock or preferred stock, ability to satisfy
our debt service obligations and ability to pay distributions to
our stockholders.
Illiquidity of real estate investments may make it difficult
for us to sell properties in response to market conditions and
could harm our financial condition and ability to make
distributions.
Equity real estate investments are relatively illiquid and
therefore will tend to limit our ability to vary our portfolio
promptly in response to changing economic or other conditions.
To the extent the properties are not subject to
triple-net
leases, some significant expenditures such as real estate taxes
and maintenance costs are generally not reduced when
circumstances cause a reduction in income from the investment.
Should these events occur, our income and funds available for
distribution could be adversely affected. If any of the parking
leases or licenses associated with our Cambridge portfolio were
to expire, or if we were unable to assign these leases to a
buyer, it would be more difficult for us to sell these
properties and would adversely affect our ability to retain
current tenants or attract new tenants at these properties. In
addition, as a REIT, we may be subject to a 100% tax on net
income derived from the sale of property considered to be held
primarily for sale to customers in the ordinary course of our
business. We may seek to avoid this tax by complying with
certain safe harbor rules that generally limit the number of
properties we may sell in a given year, the aggregate
expenditures made on such properties prior to their disposition,
and how long we retain such properties before disposing of them.
However, we can provide no assurance that we will always be able
to comply with these safe harbors. If compliance is possible,
the safe harbor rules may restrict our ability to sell assets in
the future and achieve liquidity that may be necessary to fund
distributions.
14
We may be unable to renew leases, lease vacant space or
re-lease space as leases expire, which could adversely affect
our business and our ability to pay distributions to our
stockholders.
If we cannot renew leases, we may be unable to re-lease our
properties at rates equal to or above the current rate. Even if
we can renew leases, tenants may be able to negotiate lower
rates as a result of market conditions. Market conditions may
also hinder our ability to lease vacant space in newly developed
properties. In addition, we may enter into or acquire leases for
properties that are specially suited to the needs of a
particular tenant. Such properties may require renovations,
tenant improvements or other concessions in order to lease them
to other tenants if the initial leases terminate. Any of these
factors could adversely impact our financial condition, results
of operations, cash flow, per share trading price of our common
stock or preferred stock, our ability to satisfy our debt
service obligations and our ability to pay distributions to our
stockholders.
We could incur significant costs related to government
regulation and private litigation over environmental matters
involving the presence, discharge or threat of discharge of
hazardous or toxic substances, which could adversely affect our
operations, the value of our properties, and our ability to make
distributions to our stockholders.
Our properties may be subject to environmental liabilities.
Under various federal, state and local laws, a current or
previous owner, operator or tenant of real estate can face
liability for environmental contamination created by the
presence, discharge or threat of discharge of hazardous or toxic
substances. Liabilities can include the cost to investigate,
clean up and monitor the actual or threatened contamination and
damages caused by the contamination (or threatened
contamination). Environmental laws typically impose such
liability on the current owner regardless of:
|
|
|
|
|
the owners knowledge of the contamination,
|
|
|
|
the timing of the contamination,
|
|
|
|
the cause of the contamination, or
|
|
|
|
the party responsible for the contamination.
|
The liability under such laws may be strict, joint and several,
meaning that we may be liable regardless of whether we knew of,
or were responsible for, the presence of the contaminants, and
the government entity or private party may seek recovery of the
entire amount from us even if there are other responsible
parties. Liabilities associated with environmental conditions
may be significant and can sometimes exceed the value of the
affected property. The presence of hazardous substances on a
property may adversely affect our ability to sell or rent that
property or to borrow using that property as collateral.
Some of our properties have had contamination in the past that
required cleanup. In most cases, we believe the contamination
has been effectively remediated, and that any remaining
contamination either does not require remediation or that the
costs associated with such remediation will not be material to
us. However, we cannot guarantee that additional contamination
will not be discovered in the future or any identified
contamination will not continue to pose a threat to the
environment or that we will not have continued liability in
connection with such prior contamination. Our 675 West
Kendall and 500 Kendall Street properties are located on the
site of a former manufactured gas plant. Various remedial
actions were performed on these properties, including soil
stabilization to control the spread of oil and hazardous
materials in the soil. Another of our properties, Elliott
Avenue, has known soil contamination beneath a portion of the
building located on the property. Based on environmental
consultant reports, management does not believe any remediation
of the Elliott Avenue property would be required unless major
structural changes were made to the building that resulted in
the soil becoming exposed. In addition, in connection with our
acquisition of certain properties through our investment in
limited liability companies with PREI, PREI II LLC assumed an
obligation related to the remediation of environmental
conditions at off-site parcels located in Cambridge,
Massachusetts. PREI II LLC has estimated the costs of the
remediation to be $3.6 million, but we cannot provide any
assurance that the actual remediation costs will not be higher
than this estimate. We do not expect these matters to materially
adversely affect such properties value or the cash flows
related to such properties, but we can provide no assurances to
that effect.
15
Environmental laws also:
|
|
|
|
|
may require the removal or upgrade of underground storage tanks,
|
|
|
|
regulate the discharge of storm water, wastewater and other
pollutants,
|
|
|
|
regulate air pollutant emissions,
|
|
|
|
regulate hazardous materials generation, management and
disposal, and
|
|
|
|
regulate workplace health and safety.
|
Life science industry tenants, our primary tenant industry
focus, frequently use hazardous materials, chemicals, heavy
metals, and biological and radioactive compounds. Our
tenants controlled use of these materials subjects us and
our tenants to laws that govern using, manufacturing, storing,
handling and disposing of such materials and certain byproducts
of those materials. We are unaware of any of our existing
tenants violating applicable laws and regulations, but we and
our tenants cannot completely eliminate the risk of
contamination or injury from these materials. If our properties
become contaminated, or if a party is injured, we could be held
liable for any damages that result. Such liability could exceed
our resources and any environmental remediation insurance
coverage we have, which could adversely affect our operations,
the value of our properties, and our ability to make
distributions to our stockholders. Licensing requirements
governing use of radioactive materials by tenants may also
restrict the use of or ability to transfer space in buildings we
own.
We could incur significant costs related to governmental
regulation and private litigation over environmental matters
involving asbestos-containing materials, which could adversely
affect our operations, the value of our properties, and our
ability to make distributions to our stockholders.
Environmental laws also govern the presence, maintenance and
removal of asbestos-containing materials, or ACMs, and may
impose fines and penalties if we fail to comply with these
requirements. Failure to comply with these laws, or even the
presence of ACMs, may expose us to third-party liability. Some
of our properties contain ACMs, and we could be liable for such
fines or penalties, as described above in Item 1.
Business Regulation Environmental
Matters.
Our properties may contain or develop harmful mold, which
could lead to liability for adverse health effects and costs of
remediating the problem, which could adversely affect the value
of the affected property and our ability to make distributions
to our stockholders.
When excessive moisture accumulates in buildings or on building
materials, mold growth may occur, particularly if the moisture
problem remains undiscovered or is not addressed over a period
of time. Some molds may produce airborne toxins or irritants.
Concern about indoor exposure to mold has been increasing
because exposure to mold may cause a variety of adverse health
effects and symptoms, including allergic or other reactions. As
a result, the presence of significant mold at any of our
properties could require us to undertake a costly remediation
program to contain or remove the mold from the affected
property. In addition, the presence of significant mold could
expose us to liability to our tenants, their or our employees,
and others if property damage or health concerns arise.
Compliance with the Americans with Disabilities Act and
similar laws may require us to make significant unanticipated
expenditures.
All of our properties are required to comply with the ADA. The
ADA requires that all public accommodations must meet federal
requirements related to access and use by disabled persons.
Although we believe that our properties substantially comply
with present requirements of the ADA, we have not conducted an
audit of all of such properties to determine compliance. If one
or more properties are not in compliance with the ADA, then we
would be required to bring the offending properties into
compliance. Compliance with the ADA could require removing
access barriers. Non-compliance could result in imposition of
fines by the U.S. government or an award of damages to
private litigants, or both. Additional federal, state and local
laws also may require us to modify properties or could restrict
our ability to renovate properties. Complying with the ADA or
other legislation could be very expensive. If we incur
substantial costs to comply with such laws, our financial
condition, results of operations,
16
cash flow, per share trading price of our common stock or
preferred stock, our ability to satisfy our debt service
obligations and our ability to pay distributions to our
stockholders could be adversely affected.
We may incur significant unexpected costs to comply with
fire, safety and other regulations, which could adversely impact
our financial condition, results of operations, and ability to
make distributions.
Our properties are subject to various federal, state and local
regulatory requirements, such as state and local fire and safety
requirements, building codes and land use regulations. Failure
to comply with these requirements could subject us to
governmental fines or private litigant damage awards. We believe
that our properties are currently in material compliance with
all applicable regulatory requirements. However, we do not know
whether existing requirements will change or whether future
requirements will require us to make significant unanticipated
expenditures that will adversely impact our financial condition,
results of operations, cash flow, the per share trading price of
our common stock or preferred stock, our ability to satisfy our
debt service obligations and our ability to pay distributions to
our stockholders.
Risks
Related to Our Capital Structure
Debt obligations expose us to increased risk of property
losses and may have adverse consequences on our business
operations and our ability to make distributions.
We have used and will continue to use debt to finance property
acquisitions. Our use of debt may have adverse consequences,
including the following:
|
|
|
|
|
Required payments of principal and interest may be greater than
our cash flow from operations.
|
|
|
|
We may be forced to dispose of one or more of our properties,
possibly on disadvantageous terms, to make payments on our debt.
|
|
|
|
If we default on our debt obligations, the lenders or mortgagees
may foreclose on our properties that secure those loans.
Further, if we default under a mortgage loan, we will
automatically be in default on any other loan that has
cross-default provisions, and we may lose the properties
securing all of these loans.
|
|
|
|
A foreclosure on one of our properties will be treated as a sale
of the property for a purchase price equal to the outstanding
balance of the secured debt. If the outstanding balance of the
secured debt exceeds our tax basis in the property, we would
recognize taxable income on foreclosure without realizing any
accompanying cash proceeds to pay the tax (or to make
distributions based on REIT taxable income).
|
|
|
|
We may not be able to refinance or extend our existing debt. If
we cannot repay, refinance or extend our debt at maturity, in
addition to our failure to repay our debt, we may be unable to
make distributions to our stockholders at expected levels or at
all.
|
|
|
|
Even if we are able to refinance or extend our existing debt,
the terms of any refinancing or extension may not be as
favorable as the terms of our existing debt. If the refinancing
involves a higher interest rate, it could adversely affect our
cash flow and ability to make distributions to stockholders.
|
As of December 31, 2007, we had outstanding mortgage
indebtedness of $368.8 million, excluding
$10.9 million of debt premium; $250 million of
borrowings under our secured term loan, secured by 14 of our
properties; $2.2 million of mortgage indebtedness and
$83.3 million of borrowings under a secured loan
representing our proportionate share of indebtedness at our
unconsolidated partnerships; $175 million of outstanding
aggregate principal amount of 4.50% Exchangeable Senior Notes
due 2026; $270.9 million in outstanding borrowings under
our $600 million unsecured line of credit; and
$425.2 million in outstanding borrowings under our
$550 million secured construction loan, which is secured by
our Center for Life
Science | Boston
property. We expect to incur additional debt in connection with
future acquisitions and development. Our organizational
documents do not limit the amount or percentage of debt that we
may incur.
17
Recent disruptions in the financial markets could affect our
ability to obtain debt financing on reasonable terms and have
other adverse effects on us.
The U.S. credit markets have recently experienced
significant dislocations and liquidity disruptions which have
caused the spreads on prospective debt financings to widen
considerably. These circumstances have materially impacted
liquidity in the debt markets, making financing terms for
borrowers less attractive, and in certain cases have resulted in
the unavailability of certain types of debt financing. Continued
uncertainty in the credit markets may negatively impact our
ability to access additional debt financing or to refinance
existing debt maturities on favorable terms (or at all), which
may negatively affect our ability to make acquisitions and fund
current and future development and redevelopment projects. In
addition, the financial position of the lenders under our credit
facilities may worsen to the point that they default on their
obligations to make available to us the funds under those
facilities. A prolonged downturn in the credit markets may cause
us to seek alternative sources of potentially less attractive
financing, and may require us to adjust our business plan
accordingly. In addition, these factors may make it more
difficult for us to sell properties or may adversely affect the
price we receive for properties that we do sell, as prospective
buyers may experience increased costs of debt financing or
difficulties in obtaining debt financing. These events in the
credit markets have also had an adverse effect on other
financial markets in the United States, which may make it more
difficult or costly for us to raise capital through the issuance
of common stock, preferred stock or other equity securities.
These disruptions in the financial markets may have other
adverse effects on us or the economy generally, which could
cause our stock price to decline.
Our credit facilities include restrictive covenants relating
to our operations, which could limit our ability to respond to
changing market conditions and our ability to make distributions
to our stockholders.
Our credit facilities impose restrictions on us that affect our
distribution and operating policies and our ability to incur
additional debt. For example, we are subject to a maximum
leverage ratio requirement (as defined) during the terms of the
loans, which could reduce our ability to incur additional debt
and consequently reduce our ability to make distributions to our
stockholders. Our credit facilities also contain limitations on
our ability to make distributions to our stockholders in excess
of those required to maintain our REIT status. Specifically, our
credit facilities limit distributions to 95% of funds from
operations, but not less than the minimum necessary to enable us
to meet our REIT income distribution requirements. In addition,
our credit facilities contain covenants that, among other
things, limit our ability to further mortgage our properties or
reduce insurance coverage, and that require us to maintain
specified levels of net worth. These or other limitations may
adversely affect our flexibility and our ability to achieve our
operating plans.
We have and may continue to engage in hedging transactions,
which can limit our gains and increase exposure to losses.
We have and may continue to enter into hedging transactions to
protect us from the effects of interest rate fluctuations on
floating rate debt. Our hedging transactions may include
entering into interest rate swap agreements or interest rate cap
or floor agreements, or other interest rate exchange contracts.
Hedging activities may not have the desired beneficial impact on
our results of operations or financial condition. No hedging
activity can completely insulate us from the risks associated
with changes in interest rates. Moreover, interest rate hedging
could fail to protect us or adversely affect us because, among
other things:
|
|
|
|
|
Available interest rate hedging may not correspond directly with
the interest rate risk for which we seek protection.
|
|
|
|
The duration of the hedge may not match the duration of the
related liability.
|
|
|
|
The party owing money in the hedging transaction may default on
its obligation to pay.
|
|
|
|
The credit quality of the party owing money on the hedge may be
downgraded to such an extent that it impairs our ability to sell
or assign our side of the hedging transaction.
|
|
|
|
The value of derivatives used for hedging may be adjusted from
time to time in accordance with accounting rules to reflect
changes in fair value. Downward adjustments, or
mark-to-market losses, would reduce our
stockholders equity.
|
Hedging involves risk and typically involves costs, including
transaction costs, that may reduce our overall returns on our
investments. These costs increase as the period covered by the
hedging increases and during periods
18
of rising and volatile interest rates. These costs will also
limit the amount of cash available for distribution to
stockholders. We generally intend to hedge as much of the
interest rate risk as management determines is in our best
interests given the cost of such hedging transactions. The REIT
qualification rules may limit our ability to enter into hedging
transactions by requiring us to limit our income from hedges. If
we are unable to hedge effectively because of the REIT rules, we
will face greater interest rate exposure than may be
commercially prudent.
As of December 31, 2007, we had five interest rate swaps
with an aggregate notional amount of $785.0 million under
which, at each monthly settlement date, we either
(1) receive the difference between a fixed interest rate
(the Strike Rate) and one-month LIBOR if the Strike
Rate is less than LIBOR or (2) pay such difference if the
Strike Rate is greater than LIBOR. In addition, in connection
with entering into the acquisition and construction loan secured
by our Center for Life
Science | Boston
property, we entered into four forward starting interest rate
swap agreements, which are valued on the accompanying
consolidated balance sheets at the net present value of the of
the expected future cash flows on the swaps. At maturity of the
forward starting interest rate swaps, we will either
(a) receive payment from the counterparties if the
accumulated balance is an asset, or (b) make payment to the
counterparties if the accumulated balance is a liability with
the resulting receipt or payment deferred and amortized as an
increase or decrease to interest expense over the term of the
forecasted borrowing. Other than these interest rate swaps, we
have not entered into any hedging transactions. The fair value
of our interest rate swaps was approximately
($21.8) million at December 31, 2007 and is included
in other liabilities on the accompanying consolidated financial
statements.
Increases in interest rates could increase the amount of our
debt payments and adversely affect our ability to pay
distributions to our stockholders.
Interest we pay could reduce cash available for distributions.
Additionally, if we incur variable rate debt, including
borrowings under our $550 million secured construction
loan, our $250 million secured term loan and our
$600 million unsecured line of credit, to the extent not
adequately hedged, increases in interest rates would increase
our interest costs. These increased interest costs would reduce
our cash flows and our ability to make distributions to our
stockholders. In addition, if we need to repay existing debt
during a period of rising interest rates, we could be required
to liquidate one or more of our investments in properties at
times that may not permit realization of the maximum return on
such investments.
If we fail to obtain external sources of capital, which is
outside of our control, we may be unable to make distributions
to our stockholders, maintain our REIT qualification, or fund
growth.
In order to maintain our qualification as a REIT, we are
required to distribute annually at least 90% of our REIT taxable
income, excluding any net capital gain. In addition, we will be
subject to income tax at regular corporate rates to the extent
that we distribute less than 100% of our net taxable income,
including any net capital gains. Because of these distribution
requirements, we may not be able to fund future capital needs,
including any necessary acquisition financing, from operating
cash flow. Consequently, we rely on third-party sources to fund
our capital needs. We may not be able to obtain financings on
favorable terms or at all. Our access to third-party sources of
capital depends, in part, on:
|
|
|
|
|
general market conditions,
|
|
|
|
the markets perception of our growth potential,
|
|
|
|
with respect to acquisition financing, the markets
perception of the value of the properties to be acquired,
|
|
|
|
our current debt levels,
|
|
|
|
our current and expected future earnings,
|
|
|
|
our cash flow and cash distributions, and
|
|
|
|
the market price per share of our common stock or preferred
stock.
|
Our inability to obtain capital from third-party sources will
adversely affect our business and limit our growth. Without
sufficient capital, we may not be able to acquire or develop
properties when strategic opportunities exist, satisfy our debt
service obligations or make the cash distributions to our
stockholders necessary to maintain our qualification as a REIT.
19
Risks
Related to Our Organizational Structure
Our charter and Maryland law contain provisions that may
delay, defer or prevent a change of control transaction and may
prevent stockholders from receiving a premium for their
shares.
Our charter and the articles supplementary with respect to
our preferred stock contain 9.8% ownership limits that may
delay, defer or prevent a change of control
transaction. Our charter, with certain
exceptions, authorizes our directors to take such actions as are
necessary and desirable to preserve our qualification as a REIT.
Unless exempted by our board of directors, no person may own
more than 9.8% of the value of our outstanding shares of capital
stock or more than 9.8% in value or number (whichever is more
restrictive) of the outstanding shares of our common stock or
Series A preferred stock. The board may not grant such an
exemption to any proposed transferee whose ownership of in
excess of 9.8% of the value of our outstanding shares would
result in the termination of our status as a REIT. These
restrictions on transferability and ownership will not apply if
our board of directors determines that it is no longer in our
best interests to attempt to qualify as a REIT. The ownership
limit may delay or impede a transaction or a change of control
that might involve a premium price for our common stock or
otherwise be in the best interest of our stockholders.
We could authorize and issue stock without stockholder
approval that may delay, defer or prevent a change of control
transaction. Our charter authorizes us to
issue additional authorized but unissued shares of our common
stock or preferred stock. In addition, our board of directors
may classify or reclassify any unissued shares of our common
stock or preferred stock and may set the preferences, rights and
other terms of the classified or reclassified shares. The board
may also, without stockholder approval, amend our charter to
increase the authorized number of shares of our common stock or
our preferred stock that we may issue. The board of directors
could establish a series of common stock or preferred stock that
could, depending on the terms of such series, delay, defer or
prevent a transaction or a change of control that might involve
a premium price for our common stock or otherwise be in the best
interests of our stockholders.
Certain provisions of Maryland law could inhibit changes
in control that may delay, defer or prevent a change of control
transaction. Certain provisions of the
Maryland General Corporation Law, or the MGCL, may have the
effect of inhibiting a third party from making a proposal to
acquire us or of impeding a change of control. In some cases,
such an acquisition or change of control could provide our
stockholders with the opportunity to realize a premium over the
then-prevailing market price of their shares. These MGCL
provisions include:
|
|
|
|
|
business combination provisions that, subject to
limitations, prohibit certain business combinations between us
and an interested stockholder for certain periods.
An interested stockholder is generally any person
who beneficially owns 10% or more of the voting power of our
shares or an affiliate or associate of ours who, at any time
within the two-year period prior to the date in question, was
the beneficial owner of 10% or more of the voting power of our
then outstanding voting stock. A person is not an interested
stockholder under the statute if the board of directors approved
in advance the transaction by which he otherwise would have
become an interested stockholder. The business combinations are
prohibited for five years after the most recent date on which
the stockholder becomes an interested stockholder. After that
period, the MGCL imposes special voting requirements on such
combinations, and
|
|
|
|
control share provisions that provide that
control shares of our company acquired in a
control share acquisition have no voting rights
unless holders of two-thirds of our voting stock (excluding
interested shares) consent. Control shares are
shares that, when aggregated with other shares controlled by the
stockholder, entitle the stockholder to exercise one of three
increasing ranges of voting power in electing directors. A
control share acquisition is the direct or indirect
acquisition of ownership or control of control
shares.
|
In the case of the business combination provisions of the MGCL,
we opted out by resolution of our board of directors with
respect to any business combination between us and any person
provided such business combination is first approved by our
board of directors (including a majority of directors who are
not affiliates or associates of such person). In the case of the
control share provisions of the MGCL, we opted out pursuant to a
provision in our bylaws. However, our board of directors may by
resolution elect to opt in to the business combination
provisions of
20
the MGCL. Further, we may opt in to the control share provisions
of the MGCL in the future by amending our bylaws, which our
board of directors can do without stockholder approval.
The partnership agreement of our Operating Partnership, Maryland
law, and our charter and bylaws also contain other provisions
that may delay, defer or prevent a transaction or a change of
control that might involve a premium price for our common stock
or otherwise be in the best interest of our stockholders.
Our board of directors may amend our investing and financing
policies without stockholder approval, and, accordingly, our
stockholders would have limited control over changes in our
policies that could increase the risk we default under our debt
obligations or that could harm our business, results of
operations and share price.
Our board of directors has adopted a policy of limiting our
indebtedness to approximately 60% of our total market
capitalization. Total market capitalization is defined as the
sum of the market value of our outstanding common stock (which
may decrease, thereby increasing our debt-to-total
capitalization ratio), plus the aggregate value of operating
partnership units we do not own, plus the liquidation preference
of outstanding preferred stock, plus the book value of our total
consolidated indebtedness. However, our organizational documents
do not limit the amount or percentage of debt that we may incur,
nor do they limit the types of properties we may acquire or
develop. Our board of directors may alter or eliminate our
current policy on borrowing or investing at any time without
stockholder approval. Changes in our strategy or in our
investment or leverage policies could expose us to greater
credit risk and interest rate risk and could also result in a
more leveraged balance sheet. These factors could result in an
increase in our debt service and could adversely affect our cash
flow and our ability to make expected distributions to our
stockholders. Higher leverage also increases the risk we would
default on our debt.
We may invest in properties with other entities, and our lack
of sole decision-making authority or reliance on a
co-venturers financial condition could make these joint
venture investments risky.
We have in the past and may continue in the future to co-invest
with third parties through partnerships, joint ventures or other
entities. We may acquire non-controlling interests or share
responsibility for managing the affairs of a property,
partnership, joint venture or other entity. In such events, we
would not be in a position to exercise sole decision-making
authority regarding the property or entity. Investments in
entities may, under certain circumstances, involve risks not
present were a third party not involved. These risks include the
possibility that partners or co-venturers:
|
|
|
|
|
might become bankrupt or fail to fund their share of required
capital contributions,
|
|
|
|
may have economic or other business interests or goals that are
inconsistent with our business interests or goals, and
|
|
|
|
may be in a position to take actions contrary to our policies or
objectives.
|
Such investments may also have the potential risk of impasses on
decisions, such as a sale, because neither we nor the partner or
co-venturer would have full control over the partnership or
joint venture. Disputes between us and partners or co-venturers
may result in litigation or arbitration that would increase our
expenses and prevent our officers
and/or
directors from focusing their time and effort on our business.
In addition, we may in certain circumstances be liable for the
actions of our third-party partners or co-venturers if:
|
|
|
|
|
we structure a joint venture or conduct business in a manner
that is deemed to be a general partnership with a third party,
in which case we could be liable for the acts of that third
party,
|
|
|
|
third-party managers incur debt or other liabilities on behalf
of a joint venture which the joint venture is unable to pay, and
the joint venture agreement provides for capital calls, in which
case we could be liable to make contributions as set forth in
any such joint venture agreement, or
|
|
|
|
we agree to cross-default provisions or to cross-collateralize
our properties with the properties in a joint venture, in which
case we could face liability if there is a default relating to
those properties in the joint venture or the obligations
relating to those properties.
|
21
We have investments in limited liability companies with PREI,
which were formed in the second quarter of 2007. While we, as
managing member, are authorized to carry out the day-to-day
management of the business and affairs of the PREI limited
liability companies, PREIs prior written consent is
required for certain decisions, including decisions relating to
financing, budgeting and the sale or pledge of interests in the
properties owned by the PREI limited liability companies.
In addition, each of the PREI operating agreements includes a
put/call option whereby either member can cause the limited
liability company to sell certain properties in which it holds
leasehold interests to us at any time after the fifth
anniversary and before the seventh anniversary of the
acquisition date. The put/call option may be exercised at a time
we do not deem favorable for financial or other reasons,
including the availability of cash at such time and the impact
of tax consequences resulting from any sale.
Risks
Related to Our REIT Status
Our failure to qualify as a REIT under the Code would result
in significant adverse tax consequences to us and would
adversely affect our business and the value of our stock.
We believe that we have operated and intend to continue
operating in a manner intended to allow us to qualify as a REIT
for federal income tax purposes under the Internal Revenue Code
of 1986, as amended, or the Code. Qualification as a REIT
involves the application of highly technical and complex Code
provisions for which there are only limited judicial and
administrative interpretations. The fact that we hold
substantially all of our assets through a partnership further
complicates the application of the REIT requirements. Even a
seemingly minor technical or inadvertent mistake could
jeopardize our REIT status. Our REIT status depends upon various
factual matters and circumstances that may not be entirely
within our control. For example, in order to qualify as a REIT,
at least 95% of our gross income in any year must be derived
from qualifying sources, and we must satisfy a number of
requirements regarding the composition of our assets. Also, we
must make distributions to stockholders aggregating annually at
least 90% of our REIT taxable income, excluding capital gains.
In addition, new legislation, regulations, administrative
interpretations or court decisions, each of which could have
retroactive effect, may make it more difficult or impossible for
us to qualify as a REIT, or could reduce the desirability of an
investment in a REIT relative to other investments. We have not
requested and do not plan to request a ruling from the IRS that
we qualify as a REIT, and the statements in this report are not
binding on the IRS or any court. Accordingly, we cannot be
certain that we have qualified or will continue to qualify as a
REIT.
If we fail to qualify as a REIT in any taxable year, we will
face serious adverse tax consequences that would substantially
reduce the funds available for distribution to our stockholders
because:
|
|
|
|
|
we would not be allowed to deduct distributions to stockholders
in computing our taxable income and would be subject to federal
income tax at regular corporate rates,
|
|
|
|
we could also be subject to the federal alternative minimum tax
and possibly increased state and local taxes, and
|
|
|
|
unless we are entitled to relief under applicable statutory
provisions, we could not elect to be taxed as a REIT for four
taxable years following the year in which we were disqualified.
|
In addition, if we fail to qualify as a REIT, we will not be
required to make distributions to stockholders, and all
distributions to stockholders will be subject to tax as ordinary
corporate distributions. As a result of all these factors, our
failure to qualify as a REIT could impair our ability to expand
our business and raise capital and would adversely affect the
value of our common stock and our preferred stock.
To maintain our REIT status, we may be forced to borrow funds
during unfavorable market conditions to make distributions to
our stockholders.
To qualify as a REIT, we must distribute to our stockholders
certain amounts each year based on our income as described
above. At times, we may not have sufficient funds to satisfy
these distribution requirements and may need
22
to borrow funds to maintain our REIT status or to avoid the
payment of income and excise taxes. These borrowing needs could
result from:
|
|
|
|
|
differences in timing between the actual receipt of cash and
inclusion of income for federal income tax purposes,
|
|
|
|
the effect of non-deductible capital expenditures,
|
|
|
|
the creation of reserves, or
|
|
|
|
required debt or amortization payments.
|
We may need to borrow funds at times when the then-prevailing
market conditions are not favorable for borrowing. These
borrowings could increase our costs or reduce our equity and
adversely affect the value of our common stock or preferred
stock.
To maintain our REIT status, we may be forced to forego
otherwise attractive opportunities.
To qualify as a REIT, we must satisfy tests concerning, among
other things, the sources of our income, the nature and
diversification of our assets, the amounts we distribute to our
stockholders and the ownership of our stock. We may be required
to make distributions to stockholders at times when it would be
more advantageous to reinvest cash in our business or when we do
not have funds readily available for distribution. Thus,
compliance with the REIT requirements may hinder our ability to
operate solely on the basis of maximizing profits.
Risks
Related to the Ownership of Our Stock
The market price and trading volume of our common stock may
be volatile.
The market price of our common stock may be volatile. In
addition, the trading volume in our common stock may fluctuate
and cause significant price variations to occur. We cannot
assure you that the market price of our common stock will not
fluctuate or decline significantly in the future.
Some of the factors that could negatively affect our share price
or result in fluctuations in the price or trading volume of our
common stock include:
|
|
|
|
|
actual or anticipated variations in our quarterly operating
results or dividends,
|
|
|
|
changes in our funds from operations or earnings estimates,
|
|
|
|
publication of research reports about us or the real estate
industry,
|
|
|
|
increases in market interest rates that lead purchasers of our
shares to demand a higher yield,
|
|
|
|
changes in market valuations of similar companies,
|
|
|
|
adverse market reaction to any additional debt we incur or
acquisitions we make in the future,
|
|
|
|
additions or departures of key management personnel,
|
|
|
|
actions by institutional stockholders,
|
|
|
|
speculation in the press or investment community,
|
|
|
|
the realization of any of the other risk factors presented in
this report, and
|
|
|
|
general market and economic conditions.
|
An increase in market interest rates may have an adverse
effect on the market price of our securities.
Changes in market interest rates have historically affected the
trading prices of equity securities issued by REITs. One of the
factors that will influence the price of our common stock and
preferred stock will be the dividend yield on such stock (as a
percentage of the price of the stock) relative to market
interest rates. An increase in market interest rates, which are
currently at low levels relative to historical rates, may lead
prospective purchasers of our common stock or series A
preferred stock to expect a higher dividend yield. Further,
higher interest rates would
23
likely increase our borrowing costs and potentially decrease
funds available for distribution. Thus, higher market interest
rates could harm our financial condition and results of
operations and could cause the market price of our common stock
and series A preferred stock to fall.
Broad market fluctuations could negatively impact the market
price of our common stock or preferred stock.
The stock market has experienced extreme price and volume
fluctuations that have affected the market price of many
companies in industries similar or related to ours and that have
been unrelated to these companies operating performance.
These broad market fluctuations could reduce the market price of
our common stock or preferred stock. Furthermore, our operating
results and prospects may be below the expectations of public
market analysts and investors or may be lower than those of
companies with comparable market capitalizations. Either of
these factors could lead to a material decline in the market
price of our common stock or preferred stock.
Our distributions to stockholders may decline at any time.
We may not continue our current level of distributions to
stockholders. Our board of directors will determine future
distributions based on a number of factors, including:
|
|
|
|
|
cash available for distribution,
|
|
|
|
operating results,
|
|
|
|
our financial condition, especially in relation to our
anticipated future capital needs,
|
|
|
|
then current expansion plans,
|
|
|
|
the distribution requirements for REITs under the Code, and
|
|
|
|
other factors our board deems relevant.
|
The number of shares of our common stock available for future
sale could adversely affect the market price of our common
stock.
We cannot predict whether future issuances of shares of our
common stock or the availability of shares for resale in the
open market will decrease the market price per share of our
common stock. As of December 31, 2007, we had outstanding
65,571,304 shares of our common stock, as well as units in
our operating partnership and long-term incentive plan
(LTIP) units, which may be exchanged for
2,863,564 shares and 454,716 shares, respectively, of
our common stock. In addition, as of December 31, 2007, we
had reserved an additional 1,345,230 shares of common stock
for future issuance under our incentive award plan.
Furthermore, under the rules adopted by the Securities and
Exchange Commission in December 2005 regarding registration and
offering procedures, if we meet the definition of a
well-known seasoned issuer under Rule 405 of
the Securities Act, we are permitted to file an automatic shelf
registration statement that will be immediately effective upon
filing. On September 15, 2006, we filed such an automatic
shelf registration statement, which may permit us, from time to
time, to offer and sell debt securities, common stock, preferred
stock, warrants and other securities to the extent necessary or
advisable to meet our liquidity needs.
Any of the following could have an adverse effect on the market
price of our common stock:
|
|
|
|
|
sales of substantial amounts of shares of our common stock in
the public market, or the perception that such sales might occur,
|
|
|
|
the exchange of units for common stock,
|
|
|
|
the exercise of any options granted to certain directors,
executive officers and other employees under our incentive award
plan,
|
|
|
|
issuances of preferred stock with liquidation or distribution
preferences, and
|
|
|
|
other issuances of our common stock.
|
24
Additionally, the existence of units, options and shares of our
common stock reserved for issuance upon exchange of units may
adversely affect the terms upon which we may be able to obtain
additional capital through the sale of equity securities. In
addition, future sales of shares of our common stock may be
dilutive to existing stockholders.
From time to time we also may issue shares of our common stock
or operating partnership units in connection with property,
portfolio or business acquisitions. We may grant additional
demand or piggyback registration rights in connection with these
issuances. Sales of substantial amounts of our common stock, or
the perception that these sales could occur, may adversely
affect the prevailing market price of our common stock or may
adversely affect the terms upon which we may be able to obtain
additional capital through the sale of equity securities.
|
|
Item 1B.
|
Unresolved
Staff Comments
|
None.
Existing
Portfolio
At December 31, 2007, our portfolio consisted of 67
properties, which included 103 buildings with an aggregate of
approximately 11.7 million rentable square feet of
laboratory and office space (including our construction in
progress and land parcel properties). We owned eight undeveloped
land parcels adjacent to our existing properties that we
estimate can support up to 1.3 million rentable square feet
of laboratory and office space. We also had five properties
under construction representing approximately 1.9 million
rentable square feet of laboratory and office space.
The following reflects the classification of our properties
between stabilized properties (operating properties in which
more than 90% of the rentable square footage is under lease),
lease up properties (operating properties in which less than 90%
of the rentable square footage is under lease), repositioning
and redevelopment properties (properties that are currently
being prepared for their intended use), construction in progress
(properties that are currently under development through ground
up construction), and land parcels (representing
managements estimates of rentable square footage if
development of these properties was undertaken) at
December 31, 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Portfolio
|
|
|
Unconsolidated Partnership Portfolio
|
|
|
Total Portfolio
|
|
|
|
|
|
|
|
|
|
Percent of
|
|
|
|
|
|
|
|
|
Percent of
|
|
|
|
|
|
|
|
|
Percent of
|
|
|
|
|
|
|
Rentable
|
|
|
Rentable
|
|
|
|
|
|
Rentable
|
|
|
Rentable
|
|
|
|
|
|
Rentable
|
|
|
Rentable
|
|
|
|
|
|
|
Square
|
|
|
Square
|
|
|
|
|
|
Square
|
|
|
Square
|
|
|
|
|
|
Square
|
|
|
Square
|
|
|
|
Properties
|
|
|
Feet
|
|
|
Feet Leased
|
|
|
Properties
|
|
|
Feet
|
|
|
Feet Leased
|
|
|
Properties
|
|
|
Feet
|
|
|
Feet Leased
|
|
|
Stabilized properties
|
|
|
40
|
|
|
|
5,472,851
|
|
|
|
99.2
|
%
|
|
|
4
|
|
|
|
257,308
|
|
|
|
100.0
|
%
|
|
|
44
|
|
|
|
5,730,159
|
|
|
|
99.2
|
%
|
Lease up properties(1)
|
|
|
10
|
|
|
|
896,564
|
|
|
|
59.5
|
%
|
|
|
1
|
|
|
|
n/a
|
|
|
|
n/a
|
|
|
|
11
|
|
|
|
896,564
|
|
|
|
59.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating portfolio
|
|
|
50
|
|
|
|
6,369,415
|
|
|
|
93.6
|
%
|
|
|
5
|
|
|
|
257,308
|
|
|
|
100.0
|
%
|
|
|
55
|
|
|
|
6,626,723
|
|
|
|
93.8
|
%
|
Repositioning and redevelopment properties
|
|
|
7
|
|
|
|
1,828,546
|
|
|
|
17.8
|
%
|
|
|
|
|
|
|
|
|
|
|
n/a
|
|
|
|
7
|
|
|
|
1,828,546
|
|
|
|
17.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current portfolio
|
|
|
57
|
|
|
|
8,197,961
|
|
|
|
76.7
|
%
|
|
|
5
|
|
|
|
257,308
|
|
|
|
100.0
|
%
|
|
|
62
|
|
|
|
8,455,269
|
|
|
|
77.4
|
%
|
Construction in progress(2)
|
|
|
3
|
|
|
|
1,241,000
|
|
|
|
72.0
|
%
|
|
|
2
|
|
|
|
700,000
|
|
|
|
16.1
|
%
|
|
|
5
|
|
|
|
1,941,000
|
|
|
|
51.8
|
%
|
Land parcels
|
|
|
n/a
|
|
|
|
1,293,000
|
|
|
|
n/a
|
|
|
|
|
|
|
|
|
|
|
|
n/a
|
|
|
|
|
|
|
|
1,293,000
|
|
|
|
n/a
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Portfolio/Weighted-Average(3)
|
|
|
60
|
|
|
|
10,731,961
|
|
|
|
76.1
|
%
|
|
|
7
|
|
|
|
957,308
|
|
|
|
38.6
|
%
|
|
|
67
|
|
|
|
11,689,269
|
|
|
|
73.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The unconsolidated partnership portfolio property within the
lease up property category is the 301 Binney garage, which is
not yet fully leased pending completion of development
activities at the 301 Binney Street building. |
|
(2) |
|
We are currently developing a portion of our Landmark at
Eastview property. However, we have not separated this
previously undeveloped portion into a separate property for
legal and accounting purposes. Therefore, we still classify the
Landmark at Eastview property as a stabilized property on the
above schedule although it is also included in our discussion of
development properties. |
|
(3) |
|
Percent of rentable square feet leased excludes undeveloped land
parcels. |
25
Our current portfolio by market at December 31, 2007 was as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percent
|
|
|
|
|
|
|
|
|
|
|
|
Annualized
|
|
|
|
|
|
|
|
|
|
|
|
|
of
|
|
|
|
|
|
|
|
|
Percent of
|
|
|
Base Rent
|
|
|
|
|
|
|
Number
|
|
|
Rentable
|
|
|
Rentable
|
|
|
|
|
|
Annualized
|
|
|
Annualized
|
|
|
per Leased
|
|
|
|
|
|
|
of
|
|
|
Square
|
|
|
Square
|
|
|
Percent
|
|
|
Base Rent
|
|
|
Base Rent
|
|
|
Square Foot
|
|
|
|
|
Market
|
|
Properties
|
|
|
Feet
|
|
|
Feet
|
|
|
Leased(1)
|
|
|
Current(2)
|
|
|
Current
|
|
|
Current
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Boston
|
|
|
12
|
|
|
|
1,297,166
|
|
|
|
15.4
|
%
|
|
|
97.3
|
%
|
|
$
|
48,876
|
|
|
|
24.6
|
%
|
|
$
|
38.71
|
|
|
|
|
|
Maryland
|
|
|
5
|
|
|
|
1,144,968
|
|
|
|
13.5
|
%
|
|
|
100.0
|
%
|
|
|
44,336
|
|
|
|
22.3
|
%
|
|
|
38.72
|
|
|
|
|
|
San Francisco
|
|
|
11
|
|
|
|
2,655,594
|
|
|
|
31.4
|
%
|
|
|
44.9
|
%
|
|
|
25,658
|
|
|
|
12.9
|
%
|
|
|
21.50
|
|
|
|
|
|
San Diego
|
|
|
15
|
|
|
|
945,318
|
|
|
|
11.2
|
%
|
|
|
84.3
|
%
|
|
|
23,458
|
|
|
|
11.8
|
%
|
|
|
26.97
|
|
|
|
|
|
New York/New Jersey
|
|
|
3
|
|
|
|
873,369
|
|
|
|
10.3
|
%
|
|
|
87.1
|
%
|
|
|
15,753
|
|
|
|
7.9
|
%
|
|
|
20.71
|
|
|
|
|
|
Pennsylvania
|
|
|
7
|
|
|
|
778,251
|
|
|
|
9.2
|
%
|
|
|
92.7
|
%
|
|
|
14,920
|
|
|
|
7.5
|
%
|
|
|
20.69
|
|
|
|
|
|
Seattle
|
|
|
4
|
|
|
|
253,788
|
|
|
|
3.0
|
%
|
|
|
62.0
|
%
|
|
|
5,740
|
|
|
|
3.0
|
%
|
|
|
36.46
|
|
|
|
|
|
University Related Other
|
|
|
3
|
|
|
|
249,507
|
|
|
|
3.0
|
%
|
|
|
100.0
|
%
|
|
|
7,349
|
|
|
|
3.8
|
%
|
|
|
29.46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Consolidated Portfolio/Weighted-Average
|
|
|
60
|
|
|
|
8,197,961
|
|
|
|
97.0
|
%
|
|
|
76.7
|
%
|
|
|
186,090
|
|
|
|
93.8
|
%
|
|
|
29.60
|
|
|
|
|
|
Unconsolidated Partnership Portfolio(3)
|
|
|
7
|
|
|
|
257,308
|
|
|
|
3.0
|
%
|
|
|
100.0
|
%
|
|
|
12,283
|
|
|
|
6.2
|
%
|
|
|
47.74
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Portfolio/Weighted-Average
|
|
|
67
|
|
|
|
8,455,269
|
|
|
|
100.0
|
%
|
|
|
77.4
|
%
|
|
$
|
198,373
|
|
|
|
100.0
|
%
|
|
$
|
30.31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Percentage of leasable square footage in current portfolio
subject to an existing lease. |
|
(2) |
|
In this and other tables, annualized current base rent is the
monthly contractual rent under existing leases at
December 31, 2007, multiplied by 12 months. Includes
contractual amounts to be received pursuant to master lease
agreements with the sellers on certain properties, which are not
included in rental income for U.S. generally accepted accounting
principles, or GAAP. |
|
(3) |
|
Includes a portfolio of properties in Cambridge, Massachusetts
and the McKellar Court property in San Diego, California.
We are a member of the unconsolidated limited liability
companies that own a portfolio of properties in Cambridge,
Massachusetts, and we are entitled to approximately 20% of the
operating cash flows. We also own the general partnership
interest in the unconsolidated limited partnership that owns the
McKellar Court property, which entitles us to 75% of the gains
upon a sale of the property and 21% of the operating cash flows. |
Properties we owned, or had an ownership interest in, at
December 31, 2007 were as follows:
|
|
|
|
|
|
|
|
|
|
|
Rentable
|
|
|
Percent
|
|
|
|
Square Feet
|
|
|
Leased
|
|
|
Boston
|
|
|
|
|
|
|
|
|
Albany Street
|
|
|
75,003
|
|
|
|
100.0
|
%
|
Center for Life
Science | Boston(1)
|
|
|
|
|
|
|
|
|
Charles Street
|
|
|
47,912
|
|
|
|
100.0
|
%
|
Coolidge Avenue
|
|
|
37,400
|
|
|
|
100.0
|
%
|
21 Erie Street
|
|
|
48,627
|
|
|
|
100.0
|
%
|
40 Erie Street
|
|
|
100,854
|
|
|
|
100.0
|
%
|
47 Erie Street Parking Structure
|
|
|
447 Stalls
|
|
|
|
n/a
|
|
Fresh Pond Research Park
|
|
|
90,702
|
|
|
|
78.7
|
%
|
675 West Kendall Street (Kendall A)
|
|
|
302,919
|
|
|
|
96.7
|
%
|
500 Kendall Street (Kendall D)
|
|
|
349,325
|
|
|
|
98.5
|
%
|
Sidney Street
|
|
|
191,904
|
|
|
|
100.0
|
%
|
Vassar Street
|
|
|
52,520
|
|
|
|
100.0
|
%
|
26
|
|
|
|
|
|
|
|
|
|
|
Rentable
|
|
|
Percent
|
|
|
|
Square Feet
|
|
|
Leased
|
|
|
Maryland
|
|
|
|
|
|
|
|
|
Beckley Street
|
|
|
77,225
|
|
|
|
100.0
|
%
|
9911 Belward Campus Drive
|
|
|
289,912
|
|
|
|
100.0
|
%
|
9920 Belward Campus Drive
|
|
|
51,181
|
|
|
|
100.0
|
%
|
Shady Grove Road(2)
|
|
|
635,058
|
|
|
|
100.0
|
%
|
Tributary Street
|
|
|
91,592
|
|
|
|
100.0
|
%
|
San Francisco
|
|
|
|
|
|
|
|
|
Ardentech Court(3)
|
|
|
55,588
|
|
|
|
100.0
|
%
|
Ardenwood Venture(4)
|
|
|
72,500
|
|
|
|
0.0
|
%
|
Bayshore Boulevard
|
|
|
183,344
|
|
|
|
100.0
|
%
|
Bridgeview Technology Park I
|
|
|
212,673
|
|
|
|
93.1
|
%
|
Bridgeview Technology Park II
|
|
|
50,400
|
|
|
|
100.0
|
%
|
Dumbarton Circle
|
|
|
44,000
|
|
|
|
100.0
|
%
|
Eccles Avenue
|
|
|
152,145
|
|
|
|
100.0
|
%
|
Forbes Boulevard
|
|
|
237,984
|
|
|
|
100.0
|
%
|
Industrial Road
|
|
|
169,490
|
|
|
|
100.0
|
%
|
Kaiser Drive
|
|
|
87,953
|
|
|
|
0.0
|
%
|
Pacific Research Center(3)
|
|
|
1,389,517
|
|
|
|
7.4
|
%
|
San Diego
|
|
|
|
|
|
|
|
|
Balboa Avenue
|
|
|
35,344
|
|
|
|
100.0
|
%
|
Bernardo Center Drive(5)
|
|
|
61,286
|
|
|
|
100.0
|
%
|
Faraday Avenue
|
|
|
28,704
|
|
|
|
100.0
|
%
|
John Hopkins Court(3)
|
|
|
69,946
|
|
|
|
0.0
|
%
|
6114-6154
Nancy Ridge Drive
|
|
|
112,000
|
|
|
|
100.0
|
%
|
6828 Nancy Ridge Drive
|
|
|
42,138
|
|
|
|
100.0
|
%
|
Pacific Center Boulevard
|
|
|
66,745
|
|
|
|
100.0
|
%
|
Road to the Cure
|
|
|
67,998
|
|
|
|
43.3
|
%
|
San Diego Science Center
|
|
|
105,364
|
|
|
|
73.9
|
%
|
Science Center Drive
|
|
|
53,740
|
|
|
|
100.0
|
%
|
Sorrento Valley Boulevard
|
|
|
54,924
|
|
|
|
86.3
|
%
|
Torreyana Road
|
|
|
81,204
|
|
|
|
100.0
|
%
|
9865 Towne Centre Drive(1)
|
|
|
|
|
|
|
|
|
9885 Towne Centre Drive
|
|
|
115,870
|
|
|
|
100.0
|
%
|
Waples Street(6)
|
|
|
50,055
|
|
|
|
90.0
|
%
|
New York/New Jersey
|
|
|
|
|
|
|
|
|
Graphics Drive
|
|
|
72,300
|
|
|
|
44.3
|
%
|
Landmark at Eastview(2)
|
|
|
751,648
|
|
|
|
97.0
|
%
|
One Research Way(3)
|
|
|
49,421
|
|
|
|
0.0
|
%
|
Pennsylvania
|
|
|
|
|
|
|
|
|
Eisenhower Road
|
|
|
27,750
|
|
|
|
0.0
|
%
|
George Patterson Boulevard
|
|
|
71,500
|
|
|
|
100.0
|
%
|
King of Prussia
|
|
|
427,109
|
|
|
|
100.0
|
%
|
Phoenixville Pike
|
|
|
104,400
|
|
|
|
74.2
|
%
|
Spring Mill Drive
|
|
|
76,378
|
|
|
|
96.9
|
%
|
900 Uniqema Boulevard(7)
|
|
|
11,293
|
|
|
|
100.0
|
%
|
1000 Uniqema Boulevard(7)
|
|
|
59,821
|
|
|
|
100.0
|
%
|
27
|
|
|
|
|
|
|
|
|
|
|
Rentable
|
|
|
Percent
|
|
|
|
Square Feet
|
|
|
Leased
|
|
|
Seattle
|
|
|
|
|
|
|
|
|
Elliott Avenue(5)
|
|
|
134,989
|
|
|
|
47.3
|
%
|
Fairview Avenue(1)(8)
|
|
|
|
|
|
|
|
|
Monte Villa Parkway
|
|
|
51,000
|
|
|
|
100.0
|
%
|
217th Place(5)
|
|
|
67,799
|
|
|
|
62.9
|
%
|
University Related Other
|
|
|
|
|
|
|
|
|
Lucent Drive(9)
|
|
|
21,500
|
|
|
|
100.0
|
%
|
Trade Centre Avenue(10)
|
|
|
78,023
|
|
|
|
100.0
|
%
|
Walnut Street(11)
|
|
|
149,984
|
|
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
Total Consolidated Portfolio/Weighted-Average
|
|
|
8,197,961
|
|
|
|
76.7
|
%
|
|
|
|
|
|
|
|
|
|
Unconsolidated Portfolio:
|
|
|
|
|
|
|
|
|
McKellar Court(12)
|
|
|
72,863
|
|
|
|
100.0
|
%
|
320 Bent Street(13)
|
|
|
184,445
|
|
|
|
100.0
|
%
|
301 Binney Street(1)(13)
|
|
|
|
|
|
|
|
|
301 Binney Garage(13)
|
|
|
503 Stalls
|
|
|
|
n/a
|
|
650 E. Kendall Street (Kendall B)(1)(13)
|
|
|
|
|
|
|
|
|
350 E. Kendall Street Garage (Kendall F)(13)
|
|
|
1,409 Stalls
|
|
|
|
n/a
|
|
Kendall Crossing Apartments(13)
|
|
|
37 Apts.
|
|
|
|
n/a
|
|
|
|
|
|
|
|
|
|
|
Total Portfolio/Weighted-Average
|
|
|
8,455,269
|
|
|
|
77.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The entire property was under development at December 31,
2007. |
|
(2) |
|
A previously undeveloped portion of the property was undergoing
development at December 31, 2007. |
|
(3) |
|
The entire property was undergoing redevelopment at
December 31, 2007. |
|
(4) |
|
We own an 87.5% membership interest in the limited liability
company that owns this property. |
|
(5) |
|
A portion of the property was undergoing redevelopment at
December 31, 2007. |
|
(6) |
|
We own 70% of the limited liability company that owns the Waples
Street property, which entitles us to 90% of the cash flow from
operations up to a 9.5% cumulative annual return, and then 75%
of such distributions thereafter. |
|
(7) |
|
Located in New Castle, Delaware. |
|
(8) |
|
We own a 70% membership interest in the limited liability
company that owns this property. |
|
(9) |
|
Located in Lebanon, New Hampshire. |
|
(10) |
|
Located in Longmont, Colorado. |
|
(11) |
|
Located in Boulder, Colorado. |
|
(12) |
|
We own the general partnership interest in the limited
partnership that owns the McKellar Court property, which
entitles us to 75% of the gains upon a sale of the property and
21% of the operating cash flows. The property is located in
San Diego, California. |
|
(13) |
|
We are a member of the limited liability companies that own a
portfolio of properties in Cambridge, Massachusetts, which
entitles us to approximately 20% of the operating cash flows. |
Tenant
Information
As of December 31, 2007, our consolidated and
unconsolidated properties were leased to 117 tenants, and 89% of
our annualized base rent was derived from tenants that were
public companies or government agencies or their
28
subsidiaries. The following is a summary of our ten largest
tenants based on percentage of our annualized base rent as of
December 31, 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annualized
|
|
|
Percent of
|
|
|
|
|
|
|
|
|
|
|
|
Base Rent
|
|
|
Annualized
|
|
|
|
|
|
|
|
|
Annualized
|
|
|
per Leased
|
|
|
Base Rent -
|
|
|
Lease
|
|
|
Leased
|
|
|
Base Rent
|
|
|
Square Foot
|
|
|
Current
|
|
|
Expiration
|
Tenant
|
|
Square Feet
|
|
|
Current
|
|
|
Current
|
|
|
Total Portfolio
|
|
|
Date(s)
|
|
|
|
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
Human Genome Sciences, Inc.
|
|
|
924,970
|
|
|
$
|
40,290
|
|
|
$
|
43.56
|
|
|
|
20.3
|
%
|
|
May 2026
|
Vertex Pharmaceuticals
|
|
|
685,286
|
|
|
|
25,948
|
|
|
|
37.86
|
|
|
|
13.1
|
%
|
|
Multiple(1)
|
Genzyme Corporation
|
|
|
343,000
|
|
|
|
15,457
|
|
|
|
45.06
|
|
|
|
7.8
|
%
|
|
July 2018
|
Centocor, Inc. (Johnson & Johnson)
|
|
|
374,387
|
|
|
|
8,387
|
|
|
|
22.40
|
|
|
|
4.2
|
%
|
|
March 2014
|
Schering Corporation(2)
|
|
|
136,067
|
|
|
|
7,609
|
|
|
|
55.92
|
|
|
|
3.8
|
%
|
|
August 2016
|
Array BioPharma, Inc.
|
|
|
228,007
|
|
|
|
6,801
|
|
|
|
29.83
|
|
|
|
3.4
|
%
|
|
Multiple(3)
|
Nektar Therapeutics
|
|
|
100,040
|
|
|
|
4,533
|
|
|
|
45.32
|
|
|
|
2.3
|
%
|
|
October 2016
|
Arena Pharmaceuticals, Inc.
|
|
|
112,000
|
|
|
|
4,513
|
|
|
|
40.30
|
|
|
|
2.3
|
%
|
|
May 2027
|
Regeneron Pharmaceuticals, Inc.
|
|
|
230,911
|
|
|
|
4,355
|
|
|
|
18.86
|
|
|
|
2.2
|
%
|
|
Multiple(4)
|
Illumina, Inc.
|
|
|
109,270
|
|
|
|
4,178
|
|
|
|
38.24
|
|
|
|
2.1
|
%
|
|
October 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total/Weighted-Average(5)
|
|
|
3,243,938
|
|
|
$
|
122,071
|
|
|
$
|
37.63
|
|
|
|
61.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
191,904 square feet expires August 2010,
100,854 square feet expires December 2010,
20,608 square feet expires May 2012, 81,204 square
feet expires September 2013, and 290,716 square feet
expires April 2018. |
|
(2) |
|
We own 20% of the limited liability company that owns the
property that this tenant occupies. |
|
(3) |
|
149,984 square feet expires July 2016 and
78,023 square feet expires August 2016. |
|
(4) |
|
203,890 square feet expires March 2009, which will be
replaced with a
15-year
230,000 square foot lease at the new buildings to be
constructed at the Landmark at Eastview property, and
27,021 square feet expires March 2024. |
|
(5) |
|
Without regard to any lease terminations and/or renewal options. |
Lease
Distribution
Our leases are typically structured for terms of five to
15 years, with extension options, and include a fixed
rental rate with scheduled annual escalations. The leases are
generally
triple-net.
Triple-net
leases are those in which tenants pay not only base rent, but
also some or all real estate taxes and operating expenses of the
leased property. Tenants typically reimburse us for the full
direct cost, without regard to a base year or expense stop, for
use of lighting, heating and air conditioning, and certain
capital improvements necessary to maintain the property in its
original condition. We are generally responsible for structural
repairs.
|
|
Item 3.
|
Legal
Proceedings
|
Although we are involved in legal proceedings arising in the
ordinary course of business, we are not currently a party to any
legal proceedings nor, to our knowledge, is any legal proceeding
threatened against us that we believe would have a material
adverse effect on our financial position, results of operations
or liquidity.
|
|
Item 4.
|
Submission
of Matters to a Vote of Security Holders
|
None.
29
PART II
|
|
Item 5.
|
Market
for Registrants Common Equity, Related Stockholder Matters
and Issuer Purchases of Equity Securities
|
Our common stock has been listed on the New York Stock Exchange
under the symbol BMR since August 6, 2004. On
February 27, 2008, the reported closing sale price per
share for our common stock on the NYSE was $21.20 and there were
approximately 129 holders of record. The following table sets
forth, for the periods indicated, the high, low and last sale
prices in dollars on the NYSE for our common stock and the
distributions we declared per share.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Dividend
|
|
Period
|
|
High
|
|
|
Low
|
|
|
Last
|
|
|
per Common Share
|
|
|
First Quarter 2006
|
|
$
|
29.86
|
|
|
$
|
23.75
|
|
|
$
|
29.64
|
|
|
$
|
0.29
|
|
Second Quarter 2006
|
|
$
|
29.94
|
|
|
$
|
25.95
|
|
|
$
|
29.94
|
|
|
$
|
0.29
|
|
Third Quarter 2006
|
|
$
|
31.99
|
|
|
$
|
28.28
|
|
|
$
|
30.34
|
|
|
$
|
0.29
|
|
Fourth Quarter 2006
|
|
$
|
32.41
|
|
|
$
|
27.71
|
|
|
$
|
28.60
|
|
|
$
|
0.29
|
|
First Quarter 2007
|
|
$
|
31.20
|
|
|
$
|
25.59
|
|
|
$
|
26.30
|
|
|
$
|
0.31
|
|
Second Quarter 2007
|
|
$
|
29.94
|
|
|
$
|
24.13
|
|
|
$
|
25.12
|
|
|
$
|
0.31
|
|
Third Quarter 2007
|
|
$
|
26.20
|
|
|
$
|
21.00
|
|
|
$
|
24.10
|
|
|
$
|
0.31
|
|
Fourth Quarter 2007
|
|
$
|
26.25
|
|
|
$
|
20.89
|
|
|
$
|
23.17
|
|
|
$
|
0.31
|
|
We intend to continue to declare quarterly distributions on our
common stock. The actual amount and timing of distributions,
however, will be at the discretion of our board of directors and
will depend upon our financial condition in addition to the
requirements of the Code, and no assurance can be given as to
the amounts or timing of future distributions. In addition, our
credit facilities limit our ability to pay distributions to our
common stockholders. The limitation is based on 95% of funds
from operations, but not less than the minimum necessary to
enable us to meet our REIT income distribution requirements. We
do not anticipate that our ability to pay distributions will be
impaired by the terms of our credit facilities. However, there
can be no assurances in that regard.
Subject to the distribution requirements applicable to REITs
under the Code, we intend, to the extent practicable, to invest
substantially all of the proceeds from sales and refinancings of
our assets in real estate-related assets and other assets. We
may, however, under certain circumstances, make a distribution
of capital or of assets. Such distributions, if any, will be
made at the discretion of our board of directors. Distributions
will be made in cash to extent that cash is available for
distribution.
On December 7, 2007, our Operating Partnership issued
22,050 LTIP units to certain of our officers pursuant to our
2004 incentive award plan. The LTIP units are subject to vesting
requirements, which lapse over a five-year period. Upon vesting,
the LTIP units may be redeemed for an equal number of shares of
our common stock or cash, at our election. The LTIP units were
issued in reliance on the exemption provided by Rule 506
promulgated by the Securities and Exchange Commission under the
Securities Act. Each officer who received an award of LTIP units
is an accredited investor and had access, through employment and
other relationships, to adequate information about us and our
Operating Partnership.
Information about our equity compensation plans is incorporated
by reference in Item 12 of Part III of this Annual
Report on
Form 10-K.
|
|
Item 6.
|
Selected
Financial Data
|
The following sets forth selected consolidated financial and
operating information for BioMed Realty Trust, Inc. and for 201
Industrial Road, L.P., our predecessor. We have not presented
historical information for BioMed Realty Trust, Inc. prior to
August 11, 2004, the date on which we consummated our
initial public offering, because during the period from our
formation until our initial public offering, we did not have
material corporate activity. The following data should be read
in conjunction with our financial statements and notes thereto
and Managements Discussion and Analysis of Financial
Condition and Results of Operations included in
Item 7 of this report.
30
BIOMED
REALTY TRUST, INC. AND BIOMED REALTY TRUST, INC. PREDECESSOR
(Dollars in thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BioMed Realty Trust, Inc.
|
|
|
Predecessor
|
|
|
|
|
|
|
|
|
|
|
|
|
Period
|
|
|
Period
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
August 11,
|
|
|
January 1,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2004 through
|
|
|
2004 through
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
December 31,
|
|
|
August 17,
|
|
|
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2004
|
|
|
2003
|
|
|
Statements of Income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
$
|
266,109
|
|
|
$
|
218,735
|
|
|
$
|
138,784
|
|
|
$
|
28,654
|
|
|
$
|
3,714
|
|
|
$
|
7,019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rental operations and real estate taxes
|
|
|
71,142
|
|
|
|
60,999
|
|
|
|
46,358
|
|
|
|
11,619
|
|
|
|
353
|
|
|
|
830
|
|
Depreciation and amortization
|
|
|
72,202
|
|
|
|
65,063
|
|
|
|
39,378
|
|
|
|
7,853
|
|
|
|
600
|
|
|
|
955
|
|
General and administrative
|
|
|
21,870
|
|
|
|
18,085
|
|
|
|
13,278
|
|
|
|
3,130
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
165,214
|
|
|
|
144,147
|
|
|
|
99,014
|
|
|
|
22,602
|
|
|
|
953
|
|
|
|
1,785
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations
|
|
|
100,895
|
|
|
|
74,588
|
|
|
|
39,770
|
|
|
|
6,052
|
|
|
|
2,761
|
|
|
|
5,234
|
|
Equity in net (loss)/income of unconsolidated partnerships
|
|
|
(893
|
)
|
|
|
83
|
|
|
|
119
|
|
|
|
(11
|
)
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
990
|
|
|
|
1,102
|
|
|
|
1,333
|
|
|
|
190
|
|
|
|
|
|
|
|
1
|
|
Interest expense
|
|
|
(27,654
|
)
|
|
|
(40,672
|
)
|
|
|
(23,226
|
)
|
|
|
(1,180
|
)
|
|
|
(1,760
|
)
|
|
|
(2,901
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before minority interests
|
|
|
73,338
|
|
|
|
35,101
|
|
|
|
17,996
|
|
|
|
5,051
|
|
|
|
1,001
|
|
|
|
2,334
|
|
Minority interests in continuing operations of consolidated
partnerships
|
|
|
(45
|
)
|
|
|
137
|
|
|
|
267
|
|
|
|
145
|
|
|
|
|
|
|
|
|
|
Minority interests in continuing operations of operating
partnership
|
|
|
(2,412
|
)
|
|
|
(1,670
|
)
|
|
|
(1,271
|
)
|
|
|
(414
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
70,881
|
|
|
|
33,568
|
|
|
|
16,992
|
|
|
|
4,782
|
|
|
|
1,001
|
|
|
|
2,334
|
|
Income from discontinued operations before gain on sale of
assets and minority interests
|
|
|
639
|
|
|
|
1,542
|
|
|
|
57
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on sale of real estate assets
|
|
|
1,087
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Minority interests attributable to discontinued operations
|
|
|
(74
|
)
|
|
|
(77
|
)
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations
|
|
|
1,652
|
|
|
|
1,465
|
|
|
|
54
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
72,533
|
|
|
|
35,033
|
|
|
|
17,046
|
|
|
|
4,782
|
|
|
|
1,001
|
|
|
|
2,334
|
|
Preferred stock dividends
|
|
|
(16,868
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income available to common stockholders
|
|
$
|
55,665
|
|
|
$
|
35,033
|
|
|
$
|
17,046
|
|
|
$
|
4,782
|
|
|
$
|
1,001
|
|
|
$
|
2,334
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations per share available to common
stockholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share
|
|
$
|
0.83
|
|
|
$
|
0.60
|
|
|
$
|
0.44
|
|
|
$
|
0.15
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share
|
|
$
|
0.83
|
|
|
$
|
0.60
|
|
|
$
|
0.43
|
|
|
$
|
0.15
|
|
|
|
|
|
|
|
|
|
Net income per share available to common stockholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share
|
|
$
|
0.85
|
|
|
$
|
0.63
|
|
|
$
|
0.44
|
|
|
$
|
0.15
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share
|
|
$
|
0.85
|
|
|
$
|
0.62
|
|
|
$
|
0.44
|
|
|
$
|
0.15
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
65,302,794
|
|
|
|
55,928,595
|
|
|
|
38,913,103
|
|
|
|
30,965,178
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
68,269,985
|
|
|
|
59,018,004
|
|
|
|
42,091,195
|
|
|
|
33,767,575
|
|
|
|
|
|
|
|
|
|
Cash dividends declared per common share
|
|
$
|
1.24
|
|
|
$
|
1.16
|
|
|
$
|
1.08
|
|
|
$
|
0.4197
|
|
|
|
|
|
|
|
|
|
Cash dividends declared per preferred share
|
|
$
|
1.83
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance Sheet Data (at period end):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investments in real estate, net
|
|
$
|
2,805,983
|
|
|
$
|
2,457,538
|
|
|
$
|
1,129,371
|
|
|
$
|
468,530
|
|
|
|
|
|
|
$
|
47,025
|
|
Total assets
|
|
|
3,057,268
|
|
|
|
2,692,642
|
|
|
|
1,337,310
|
|
|
|
581,723
|
|
|
|
|
|
|
|
50,056
|
|
Total indebtedness
|
|
|
1,500,787
|
|
|
|
1,343,356
|
|
|
|
513,233
|
|
|
|
102,236
|
|
|
|
|
|
|
|
37,208
|
|
Total liabilities
|
|
|
1,653,052
|
|
|
|
1,458,610
|
|
|
|
586,162
|
|
|
|
137,639
|
|
|
|
|
|
|
|
37,597
|
|
Minority interests
|
|
|
17,280
|
|
|
|
19,319
|
|
|
|
20,673
|
|
|
|
22,267
|
|
|
|
|
|
|
|
|
|
Stockholders equity and partners capital
|
|
|
1,386,936
|
|
|
|
1,214,713
|
|
|
|
730,475
|
|
|
|
421,817
|
|
|
|
|
|
|
|
12,459
|
|
Other Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from/(used in):(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating activities
|
|
|
114,843
|
|
|
|
101,535
|
|
|
|
54,762
|
|
|
|
14,497
|
|
|
|
|
|
|
|
2,416
|
|
Investing activities
|
|
|
(409,300
|
)
|
|
|
(1,339,463
|
)
|
|
|
(601,805
|
)
|
|
|
(457,218
|
)
|
|
|
|
|
|
|
(105
|
)
|
Financing activities
|
|
|
282,273
|
|
|
|
1,243,280
|
|
|
|
539,486
|
|
|
|
470,433
|
|
|
|
|
|
|
|
(2,666
|
)
|
|
|
|
(1) |
|
Cash flow information for 2004 is combined for BioMed Realty
Trust, Inc. and our predecessor. |
31
|
|
Item 7.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
|
The following discussion should be read in conjunction with
the financial statements and notes thereto appearing elsewhere
in this report. We make statements in this section that are
forward-looking statements within the meaning of the federal
securities laws. For a complete discussion of forward-looking
statements, see the section above entitled Item 1.
Business Forward-Looking Statements. Certain
risk factors may cause our actual results, performance or
achievements to differ materially from those expressed or
implied by the following discussion. For a discussion of such
risk factors, see the section above entitled Item 1A.
Risk Factors.
Overview
As used herein, the terms we, us,
our or the Company refer to BioMed
Realty Trust, Inc., a Maryland corporation, and any of our
subsidiaries, including BioMed Realty, L.P., a Maryland limited
partnership (our Operating Partnership). We operate
as a fully integrated, self-administered and self-managed real
estate investment trust (REIT) focused on acquiring,
developing, owning, leasing and managing laboratory and office
space for the life science industry. Our tenants primarily
include biotechnology and pharmaceutical companies, scientific
research institutions, government agencies and other entities
involved in the life science industry. Our properties are
generally located in markets with well established reputations
as centers for scientific research, including Boston,
San Diego, San Francisco, Seattle, Maryland,
Pennsylvania and New York/New Jersey.
We were formed on April 30, 2004 and completed our initial
public offering on August 11, 2004.
At December 31, 2007, our portfolio consisted of 67
properties, which included 103 buildings with an aggregate of
approximately 11.7 million rentable square feet of
laboratory and office space (including our construction in
progress and land parcel properties). We owned eight undeveloped
land parcels adjacent to our existing properties that we
estimate can support up to 1.3 million rentable square feet
of laboratory and office space. We also had five properties
under construction representing approximately 1.9 million
rentable square feet of laboratory and office space.
Factors
Which May Influence Future Operations
Our corporate strategy is to continue to focus on acquiring,
developing, owning, leasing and managing laboratory and office
space for the life science industry. As of December 31,
2007, our operating portfolio was 93.8% leased to 112 tenants.
Leases representing approximately 5.6% of our rentable square
footage expire during 2008 and leases representing approximately
5.6% of our rentable square footage expire during 2009. Our
leasing strategy for 2008 focuses on leasing currently vacant
space and negotiating renewals for leases scheduled to expire
during the year, and identifying new tenants or existing tenants
seeking additional space to occupy the spaces for which we are
unable to negotiate such renewals. We also intend to proceed
with additional new developments, as real estate market
conditions permit.
Redevelopment/Development
Properties
We are actively engaged in the redevelopment and development of
certain properties in our portfolio. We believe that these
activities will ultimately result in a return on our additional
investment once the redevelopment and development activities
have been completed and the properties are leased. However,
redevelopment and development activities involve inherent risks
and assumptions relating to our ability to fully lease the
properties. Our expectation is that these properties will be
fully leased upon completion of the construction activities.
However, our ability to fully lease the properties may be
adversely affected by changing market conditions, including
periods of economic slowdown or recession, rising interest
rates, declining demand for life science office and laboratory
space, local oversupply of real estate assets, or competition
from others, which may diminish our opportunities for leasing
the property on favorable terms or at all. In addition, we may
fail to retain tenants that have pre-leased our properties, or
may face significant monetary penalties, if we do not complete
the construction of these properties in a timely manner or to
the tenants specifications. Further, our competitors with
greater resources may have more flexibility that we do in their
ability to offer rental concessions to attract tenants to their
properties, which could put pressure on our ability to attract
tenants at rental rates that will provide an expected return on
our additional
32
investment in these properties. As a result, we may be unable to
fully lease some of our redevelopment/development properties in
a timely manner upon the completion of major construction
activities.
We also rely on external sources of debt and equity funding to
provide capital for our redevelopment and development projects.
Although we believe that we currently have sufficient borrowing
capacity and will be able to obtain additional funding as
necessary, we may be unable to obtain financing on favorable
terms (or at all) or we may be forced to seek alternative
sources of potentially less attractive financing, which may
require us to adjust our business and construction plans
accordingly. Further, we may spend more time or money than
anticipated to redevelop or develop our properties due to delays
or refusals in obtaining all necessary zoning, land use,
building, occupancy and other required governmental permits and
authorizations or other unanticipated delays in the construction.
The following summarizes our consolidated properties under
repositioning or redevelopment at December 31, 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Property
|
|
|
Percent
|
|
|
Estimated
|
|
|
|
Rentable
|
|
|
Leased or
|
|
|
In-Service
|
|
Property
|
|
Square Feet
|
|
|
Pre-Leased
|
|
|
Date(1)
|
|
|
Ardentech Court
|
|
|
55,588
|
|
|
|
100.0
|
%
|
|
|
Q1 2008
|
|
Bernardo Center Drive(2)
|
|
|
61,286
|
|
|
|
100.0
|
%
|
|
|
Q1 2008
|
|
Elliott Avenue(3)
|
|
|
134,989
|
|
|
|
47.3
|
%
|
|
|
Q4 2009
|
|
John Hopkins Court
|
|
|
69,946
|
|
|
|
0.0
|
%
|
|
|
Q3 2008
|
|
One Research Way
|
|
|
49,421
|
|
|
|
0.0
|
%
|
|
|
Q2 2008
|
|
Pacific Research Center
|
|
|
1,389,517
|
|
|
|
7.4
|
%
|
|
|
Q2 2009
|
|
217th Place
|
|
|
67,799
|
|
|
|
62.9
|
%
|
|
|
Q3 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total/Weighted-Average
|
|
|
1,828,546
|
|
|
|
17.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Our estimate of the time in which redevelopment will be
substantially complete. A project is considered substantially
complete and held available for its intended use upon the
completion of tenant improvements, but no later than one year
from the cessation of major construction activities. We
currently estimate that we will invest up to an additional
$185.0 million before the redevelopment on these properties
is substantially complete. |
|
(2) |
|
Includes 51,980 square feet leased to our Operating
Partnership for use as our corporate headquarters. No revenue
will be recognized with respect to this related party lease. |
|
(3) |
|
We anticipate that the property will be vacant upon the
expiration of the remaining lease in the first quarter of 2008. |
The following summarizes our consolidated properties under
development at December 31, 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Estimated
|
|
|
|
|
|
|
|
|
Estimated
|
|
|
Estimated
|
|
|
|
Rentable
|
|
|
Percent
|
|
|
Investment
|
|
|
Total
|
|
|
In-Service
|
|
Property
|
|
Square Feet
|
|
|
Pre-Leased
|
|
|
to Date
|
|
|
Investment
|
|
|
Date(1)
|
|
|
|
|
|
|
|
|
|
(Dollars in thousands)
|
|
|
|
|
|
Center for Life
Science | Boston
|
|
|
703,000
|
|
|
|
81.1
|
%
|
|
$
|
664,000
|
|
|
$
|
730,000
|
|
|
|
Q1 2009
|
|
Fairview Avenue(2)
|
|
|
94,000
|
|
|
|
17.9
|
%
|
|
|
20,700
|
|
|
|
44,000
|
|
|
|
Q1 2009
|
|
Landmark at Eastview(3)
|
|
|
360,000
|
|
|
|
63.8
|
%
|
|
|
42,000
|
|
|
|
145,000
|
|
|
|
Q2 2009
|
|
9865 Towne Centre Drive
|
|
|
84,000
|
|
|
|
100.0
|
%
|
|
|
13,800
|
|
|
|
30,000
|
|
|
|
Q3 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total/Weighted-Average
|
|
|
1,241,000
|
|
|
|
72.0
|
%
|
|
$
|
740,500
|
|
|
$
|
949,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Our estimate of the time in which development will be
substantially complete. A project is considered substantially
complete and held available for its intended use upon the
completion of tenant improvements, but no later than one year
from the cessation of major construction activities. |
|
(2) |
|
We own a 70% membership interest in the limited liability
company that owns this property. |
|
(3) |
|
We are currently developing a portion of our Landmark at
Eastview property. However, we have not separated this
previously undeveloped portion into a separate property for
legal and accounting purposes. Therefore, we still classify the
Landmark at Eastview property as a stabilized property although
it is also included in our discussion of development properties. |
33
Lease
Expirations
The following is a summary of lease expirations over the next
ten calendar years for leases in place at December 31,
2007. This table assumes that none of the tenants exercise
renewal options or early termination rights, if any, at or prior
to the scheduled expirations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rentable
|
|
|
Percent of
|
|
|
|
|
|
|
|
|
Annualized
|
|
|
|
Square
|
|
|
Total Rentable
|
|
|
|
|
|
Percent of
|
|
|
Base Rent
|
|
|
|
Feet of
|
|
|
Square Feet of
|
|
|
Annualized
|
|
|
Annualized
|
|
|
per Leased
|
|
|
|
Expiring
|
|
|
Expiring
|
|
|
Base Rent
|
|
|
Base Rent
|
|
|
Square Foot
|
|
Year of Lease Expiration
|
|
Leases
|
|
|
Leases
|
|
|
Current
|
|
|
Current
|
|
|
Current
|
|
|
|
|
|
|
|
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
2008(1)
|
|
|
358,248
|
|
|
|
5.6
|
%
|
|
$
|
8,195
|
|
|
|
4.2
|
%
|
|
$
|
22.87
|
|
2009
|
|
|
366,332
|
|
|
|
5.6
|
%
|
|
|
6,987
|
|
|
|
3.5
|
%
|
|
|
19.07
|
|
2010
|
|
|
753,846
|
|
|
|
11.5
|
%
|
|
|
16,979
|
|
|
|
8.6
|
%
|
|
|
22.52
|
|
2011
|
|
|
360,856
|
|
|
|
5.5
|
%
|
|
|
12,519
|
|
|
|
6.3
|
%
|
|
|
34.69
|
|
2012
|
|
|
407,964
|
|
|
|
6.2
|
%
|
|
|
9,116
|
|
|
|
4.6
|
%
|
|
|
22.34
|
|
2013
|
|
|
507,067
|
|
|
|
7.7
|
%
|
|
|
9,930
|
|
|
|
5.0
|
%
|
|
|
19.58
|
|
2014
|
|
|
562,771
|
|
|
|
8.6
|
%
|
|
|
12,211
|
|
|
|
6.2
|
%
|
|
|
21.70
|
|
2015
|
|
|
84,157
|
|
|
|
1.3
|
%
|
|
|
2,671
|
|
|
|
1.3
|
%
|
|
|
31.73
|
|
2016
|
|
|
603,067
|
|
|
|
9.2
|
%
|
|
|
22,295
|
|
|
|
11.2
|
%
|
|
|
36.97
|
|
2017
|
|
|
147,266
|
|
|
|
2.3
|
%
|
|
|
2,424
|
|
|
|
1.2
|
%
|
|
|
16.46
|
|
Thereafter
|
|
|
2,392,453
|
|
|
|
36.5
|
%
|
|
|
95,047
|
|
|
|
47.9
|
%
|
|
|
39.73
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Portfolio/Weighted-Average
|
|
|
6,544,027
|
|
|
|
100.0
|
%
|
|
$
|
198,374
|
|
|
|
100.0
|
%
|
|
$
|
30.31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Includes current month-to-month leases. |
The success of our leasing and development strategy will be
dependent upon the general economic conditions and more
specifically real estate market conditions and life science
industry trends in the United States and in our target markets
of Boston, San Diego, San Francisco, Seattle,
Maryland, Pennsylvania, New York/New Jersey and research parks
near or adjacent to universities. We cannot give any assurance
that leases will be renewed or that available space will be
released at rental rates equal to or above the current
contractual rental rates or at all.
Critical
Accounting Policies
The preparation of financial statements in conformity with GAAP
requires management to use judgment in the application of
accounting policies, including making estimates and assumptions.
We base our estimates on historical experience and on various
other assumptions believed to be reasonable under the
circumstances. These judgments affect the reported amounts of
assets and liabilities and disclosure of contingent assets and
liabilities at the dates of the financial statements and the
reported amounts of revenue and expenses during the reporting
periods. If our judgment or interpretation of the facts and
circumstances relating to various transactions had been
different, it is possible that different accounting policies
would have been applied resulting in a different presentation of
our financial statements. On an ongoing basis, we evaluate our
estimates and assumptions. In the event estimates or assumptions
prove to be different from actual results, adjustments are made
in subsequent periods to reflect more current information. Below
is a discussion of accounting policies that we consider critical
in that they address the most material parts of our financial
statements, require complex judgment in their application or
require estimates about matters that are inherently uncertain.
34
Investments
in Real Estate
Investments in real estate are carried at depreciated cost.
Depreciation and amortization are recorded on a straight-line
basis over the estimated useful lives of the assets as follows:
|
|
|
Buildings and improvements
|
|
15-40 years
|
Ground lease
|
|
Term of the related lease
|
Tenant improvements
|
|
Shorter of the useful lives or the terms of the related leases
|
Furniture, fixtures, and equipment
|
|
3 to 5 years
|
Acquired in-place leases
|
|
Non-cancelable term of the related lease
|
Acquired management agreements
|
|
Non-cancelable term of the related agreement
|
Our estimates of useful lives have a direct impact on our net
income. If expected useful lives of our investments in real
estate were shortened, we would depreciate the assets over a
shorter time period, resulting in an increase to depreciation
expense and a corresponding decrease to net income on an annual
basis.
Management must make significant assumptions in determining the
value of assets and liabilities acquired. The use of different
assumptions in the allocation of the purchase cost of the
acquired properties would affect the timing of recognition of
the related revenue and expenses. The fair value of tangible
assets of an acquired property (which includes land, buildings,
and improvements) is determined by valuing the property as if it
were vacant, and the as-if-vacant value is then
allocated to land, buildings and improvements based on
managements determination of the relative fair value of
these assets. Factors considered by us in performing these
analyses include an estimate of the carrying costs during the
expected
lease-up
periods, current market conditions and costs to execute similar
leases. In estimating carrying costs, we include real estate
taxes, insurance and other operating expenses and estimates of
lost rental revenue during the expected
lease-up
periods based on current market demand.
The aggregate value of other acquired intangible assets
consisting of acquired in-place leases and acquired management
agreements are recorded based on a variety of considerations
including, but not necessarily limited to: (a) the value
associated with avoiding the cost of originating the acquired
in-place leases (i.e. the market cost to execute a lease,
including leasing commissions and legal fees, if any);
(b) the value associated with lost revenue related to
tenant reimbursable operating costs estimated to be incurred
during the assumed
lease-up
period (i.e. real estate taxes and insurance); and (c) the
value associated with lost rental revenue from existing leases
during the assumed
lease-up
period. The fair value assigned to the acquired management
agreements are recorded at the present value (using a discount
rate which reflects the risks associated with the management
agreements acquired) of the acquired management agreements with
certain tenants of the acquired properties. The values of
in-place leases and management agreements are amortized to
expense over the remaining non-cancelable period of the
respective leases or agreements. If a lease were to be
terminated prior to its stated expiration, all unamortized
amounts related to that lease would be written off.
Costs incurred in connection with the acquisition, development
or construction of properties and improvements are capitalized.
Capitalized costs include pre-construction costs essential to
the development of the property, development costs, construction
costs, interest costs, real estate taxes, salaries and related
costs and other direct costs incurred during the period of
development. We capitalize costs on land and buildings under
development until construction is substantially complete and the
property is held available for occupancy. The determination of
when a development project is substantially complete and when
capitalization must cease involves a degree of judgment. We
consider a construction project as substantially complete and
held available for occupancy upon the completion of tenant
improvements, but no later than one year from cessation of major
construction activity. We cease capitalization on the portion
substantially completed and occupied or held available for
occupancy, and capitalize only those costs associated with any
remaining portion under construction. Capitalized costs
associated with unsuccessful acquisitions are charged to expense
when an acquisition is no longer considered probable.
Repair and maintenance costs are charged to expense as incurred
and significant replacements and betterments are capitalized.
Repairs and maintenance costs include all costs that do not
extend the useful life of an asset or increase its operating
efficiency. Significant replacement and betterments represent
costs that extend an assets useful life or increase its
operating efficiency.
35
When circumstances such as adverse market conditions indicate a
possible impairment of the value of a property, we review the
recoverability of the propertys carrying value. The review
of recoverability is based on an estimate of the future
undiscounted cash flows (excluding interest charges) expected to
result from the long-lived assets use and eventual
disposition. These cash flows consider factors such as expected
future operating income, trends and prospects, as well as the
effects of leasing demand, competition and other factors. If
impairment exists due to the inability to recover the carrying
value of a long-lived asset, an impairment loss is recorded to
the extent that the carrying value exceeds the estimated
fair-value of the property. We are required to make subjective
assessments as to whether there are impairments in the values of
our investments in long-lived assets. These assessments have a
direct impact on our net income because recording an impairment
loss results in an immediate negative adjustment to net income.
The evaluation of anticipated cash flows is highly subjective
and is based in part on assumptions regarding future occupancy,
rental rates and capital requirements that could differ
materially from actual results in future periods. Although our
strategy is to hold our properties over the long-term, if our
strategy changes or market conditions otherwise dictate an
earlier sale date, an impairment loss may be recognized to
reduce the property to the lower of the carrying amount or
fair-value less costs to sell, and such loss could be material.
If we determine that impairment has occurred, the affected
assets must be reduced to their fair-value.
Revenue
Recognition
We commence revenue recognition on our leases based on a number
of factors. In most cases, revenue recognition under a lease
begins when the lessee takes possession of or controls the
physical use of the leased asset. Generally, this occurs on the
lease commencement date. In determining what constitutes the
leased asset, we evaluate whether we or the lessee is the owner,
for accounting purposes, of the tenant improvements. If we are
the owner, for accounting purposes, of the tenant improvements,
then the leased asset is the finished space and revenue
recognition begins when the lessee takes possession of the
finished space, typically when the improvements are
substantially complete. If we conclude we are not the owner, for
accounting purposes, of the tenant improvements (the lessee is
the owner), then the leased asset is the unimproved space and
any tenant improvement allowances funded under the lease are
treated as lease incentives which reduce revenue recognized over
the term of the lease. In these circumstances, we begin revenue
recognition when the lessee takes possession of the unimproved
space for the lessee to construct improvements. The
determination of who is the owner, for accounting purposes, of
the tenant improvements determines the nature of the leased
asset and when revenue recognition under a lease begins. We
consider a number of different factors to evaluate whether we or
the lessee is the owner of the tenant improvements for
accounting purposes. These factors include:
|
|
|
|
|
whether the lease stipulates how and on what a tenant
improvement allowance may be spent;
|
|
|
|
whether the tenant or landlord retain legal title to the
improvements;
|
|
|
|
the uniqueness of the improvements;
|
|
|
|
the expected economic life of the tenant improvements relative
to the length of the lease;
|
|
|
|
the responsible party for construction cost overruns; and
|
|
|
|
who constructs or directs the construction of the improvements.
|
The determination of who owns the tenant improvements, for
accounting purposes, is subject to significant judgment. In
making that determination we consider all of the above factors.
However, no one factor is determinative in reaching a conclusion.
All leases are classified as operating leases and minimum rents
are recognized on a straight-line basis over the term of the
related lease. The excess of rents recognized over amounts
contractually due pursuant to the underlying leases is included
in accrued straight-line rents on the accompanying consolidated
balance sheets and contractually due but unpaid rents are
included in accounts receivable. Existing leases at acquired
properties are reviewed at the time of acquisition to determine
if contractual rents are above or below current market rents for
the acquired property. An identifiable lease intangible asset or
liability is recorded based on the present value (using a
discount rate that reflects the risks associated with the
acquired leases) of the difference between (1) the
contractual amounts to be paid pursuant to the in-place leases
and (2) our estimate of the fair market lease rates for the
corresponding in-
36
place leases at acquisition, measured over a period equal to the
remaining non-cancelable term of the leases and any fixed rate
renewal periods (based on our assessment of the likelihood that
the renewal periods will be exercised). The capitalized
above-market lease values are amortized as a reduction of rental
income over the remaining non-cancelable terms of the respective
leases. The capitalized below-market lease values are amortized
as an increase to rental income over the remaining
non-cancelable terms of the respective leases. If a tenant
vacates its space prior to the contractual termination of the
lease and no rental payments are being made on the lease, any
unamortized balance of the related intangible will be written
off.
Substantially all rental operations expenses, consisting of real
estate taxes, insurance and common area maintenance costs are
recoverable from tenants under the terms of our lease
agreements. Amounts recovered are dependent on several factors,
including occupancy and lease terms. Tenant recovery revenue is
recognized in the period the expenses are incurred. The
reimbursements are recognized and presented in accordance with
Emerging Issues Tax Force Issue (EITF)
No. 99-19,
Reporting Revenue Gross as a Principal versus Net as an Agent
(EITF 99-19).
EITF 99-19
requires that these reimbursements be recorded gross, as the
Company is generally the primary obligor with respect to
purchasing goods and services from third-party suppliers, has
discretion in selecting the supplier and bears the credit risk.
Lease termination fees are recognized when the related leases
are canceled, collectibility is assured, and we have no
continuing obligation to provide space to former tenants.
We maintain an allowance for doubtful accounts for estimated
losses resulting from the inability of tenants to make required
rent and tenant recovery payments or defaults. We may also
maintain an allowance for accrued straight-line rents and
amounts due from lease terminations based on our assessment of
the collectibility of the balance.
Payments received under master lease agreements entered into
with the sellers of properties to lease space that was not
producing rent at the time of the acquisition are recorded as a
reduction to buildings and improvements rather than as rental
income in accordance with
EITF 85-27,
Recognition of Receipts from
Made-Up
Rental Shortfalls.
Investments
in Partnerships
We evaluate our investments in limited liability companies and
partnerships under Financial Accounting Standards Board
(FASB) Interpretation No. 46 (revised December
2003), Consolidation of Variable Interest Entities
(FIN 46R), an interpretation of Accounting
Research Bulletin No. 51, Consolidated Financial
Statements. FIN 46R provides guidance on the
identification of entities for which control is achieved through
means other than voting rights (variable interest
entities) and the determination of which business
enterprise should consolidate the variable interest entity (the
primary beneficiary). Generally, FIN 46R
applies when either (1) the equity investors (if any) lack
one or more of the essential characteristics of a controlling
financial interest, (2) the equity investment at risk is
insufficient to finance that entitys activities without
additional subordinated financial support or (3) the equity
investors have voting rights that are not proportionate to their
economic interests and the activities of the entity involve or
are conducted on behalf of an investor with a disproportionately
small voting interest.
If FIN 46R does not apply, we consider EITF Issue
No. 04-5,
Determining Whether a General Partner, or the General
Partners as a Group, Controls a Limited Partnership or Similar
Entity When the Limited Partners Have Certain Rights
(EITF 04-5),
which provides guidance in determining whether a general partner
controls a limited partnership.
EITF 04-5 states
that the general partner in a limited partnership is presumed to
control that limited partnership. The presumption may be
overcome if the limited partners have either (1) the
substantive ability to dissolve the limited partnership or
otherwise remove the general partner without cause or
(2) substantive participating rights, which provide the
limited partners with the ability to effectively participate in
significant decisions that would be expected to be made in the
ordinary course of the limited partnerships business and
thereby preclude the general partner from exercising unilateral
control over the partnership. If the criteria in
EITF 04-5
are met, the consolidation of the partnership or limited
liability company is required.
37
Except for investments that are consolidated in accordance with
FIN 46R or
EITF 04-5,
we account for investments in entities over which we exercise
significant influence, but do not control, under the equity
method of accounting. These investments are recorded initially
at cost and subsequently adjusted for equity in earnings and
cash contributions and distributions. Under the equity method of
accounting, our net equity in the investment is reflected in the
consolidated balance sheets and our share of net income or loss
is included in our consolidated statements of income.
On a periodic basis, we assess whether there are any indicators
that the carrying value of our investments in partnerships or
limited liability companies may be impaired on a more than
temporary basis. An investment is impaired only if our estimate
of the fair-value of the investment is less than the carrying
value of the investment on a more than temporary basis. To the
extent impairment has occurred, the loss shall be measured as
the excess of the carrying value of the investment over the
fair-value of the investment.
Derivative
Instruments
We record all derivatives on the balance sheet at fair-value.
The accounting for changes in the fair-value of derivatives
depends on the intended use of the derivative and the resulting
designation. Derivatives used to hedge the exposure to changes
in the fair-value of an asset, liability, or firm commitment
attributable to a particular risk, such as interest rate risk,
are considered fair-value hedges. Derivatives used to hedge the
exposure to variability in expected future cash flows, or other
types of forecasted transactions, are considered cash flow
hedges.
For derivatives designated as cash flow hedges, the effective
portion of changes in the fair-value of the derivative is
initially reported in other comprehensive income (outside of
earnings) and subsequently reclassified to earnings when the
hedged transaction affects earnings, and the ineffective portion
of changes in the fair-value of the derivative is recognized
directly in earnings. We assess the effectiveness of each
hedging relationship by comparing the changes in cash flows of
the derivative hedging instrument with the changes in cash flows
of the designated hedged item or transaction.
Our objective in using derivatives is to add stability to
interest expense and to manage its exposure to interest rate
movements or other identified risks. To accomplish this
objective, we use interest rate swaps as part of our cash flow
hedging strategy. Interest rate swaps designated as cash flow
hedges involve the receipt of variable-rate amounts in exchange
for fixed-rate payments over the life of the agreements without
exchange of the underlying principal amount. During 2007 and
2006, such derivatives were used to hedge the variable cash
flows associated with existing variable-rate debt and future
variability in the interest related cash flows from forecasted
issuances of debt. We formally document the hedging
relationships for all derivative instruments, account for all of
our interest rate swap agreements as cash flow hedges, and do
not use derivatives for trading or speculative purposes.
38
Results
of Operations
The following is a comparison, for the years ended
December 31, 2007 and 2006 and for the years ended
December 31, 2006 and 2005, of the consolidated operating
results of BioMed Realty Trust, Inc.
Comparison
of the Year Ended December 31, 2007 to the Year Ended
December 31, 2006
The following table sets forth the basis for presenting the
historical financial information for same properties (all
properties except redevelopment and new properties and
discontinued operations), redevelopment/development properties
(properties that were under redevelopment or development during
either of the years ended December 31, 2007 or 2006), and
new properties (properties that were not owned for each of the
full years ended December 31, 2007 and 2006 and were not
under redevelopment/development), in thousands:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Redevelopment/Development
|
|
|
|
|
|
|
Same Properties
|
|
|
Properties
|
|
|
New Properties
|
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
Rental
|
|
$
|
109,485
|
|
|
$
|
107,367
|
|
|
$
|
16,957
|
|
|
$
|
21,944
|
|
|
$
|
69,554
|
|
|
$
|
35,176
|
|
Tenant recoveries
|
|
|
48,992
|
|
|
|
46,798
|
|
|
|
6,837
|
|
|
|
5,317
|
|
|
|
5,906
|
|
|
|
2,045
|
|
Other income
|
|
|
1,194
|
|
|
|
84
|
|
|
|
7,184
|
|
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
$
|
159,671
|
|
|
$
|
154,249
|
|
|
$
|
30,978
|
|
|
$
|
27,265
|
|
|
$
|
75,460
|
|
|
$
|
37,221
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rental operations
|
|
$
|
42,457
|
|
|
$
|
37,356
|
|
|
$
|
5,236
|
|
|
$
|
2,596
|
|
|
$
|
3,096
|
|
|
$
|
671
|
|
Real estate taxes
|
|
|
13,417
|
|
|
|
15,288
|
|
|
|
2,896
|
|
|
|
3,494
|
|
|
|
4,040
|
|
|
|
1,594
|
|
Depreciation and amortization
|
|
|
43,465
|
|
|
|
44,233
|
|
|
|
10,446
|
|
|
|
11,929
|
|
|
|
18,291
|
|
|
|
8,901
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
$
|
99,339
|
|
|
$
|
96,877
|
|
|
$
|
18,578
|
|
|
$
|
18,019
|
|
|
$
|
25,427
|
|
|
$
|
11,166
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rental Revenues. Rental revenues increased
$31.5 million to $196.0 million for the year ended
December 31, 2007 compared to $164.5 million for the
year ended December 31, 2006. The increase was primarily
due to acquisitions in 2006 and 2007, partially offset by
properties that generated revenues during 2006 and subsequently
entered into redevelopment. Same property rental revenues
increased $2.1 million, or 2.0%, for the year ended
December 31, 2007 compared to the same period in 2006. The
increase in same property rental revenues was primarily a result
of a full year of rental revenues in 2007 for new leases at our
21 Erie Street, Industrial Road, Landmark at Eastview, and 6828
Nancy Ridge Drive properties, partially offset by the loss of
rental revenues related to higher vacancy rates at certain
properties.
Tenant Recoveries. Revenues from tenant
reimbursements increased $7.6 million to $61.7 million
for the year ended December 31, 2007 compared to
$54.1 million for the year ended December 31, 2006.
The increase was primarily due to acquisitions during 2006 and
2007 and redevelopment properties that were placed in service in
2007. Same property tenant recoveries increased
$2.2 million, or 4.7%, for the year ended December 31,
2007 compared to the same period in 2006 primarily as a result
of tenant recoveries for new leases in 2007, partially offset by
a decrease in real estate tax expense at certain properties.
Other Income. Other income was
$8.4 million for the year ended December 31, 2007
compared to $88,000 for the year ended December 31, 2006.
Other income for the year ended December 31, 2007 included
$7.7 million of gains on early termination of leases and
$739,000 of development fees earned from the PREI limited
liability companies.
Rental Operations Expense. Rental operations
expense increased $10.2 million to $50.8 million for
the year ended December 31, 2007 compared to
$40.6 million for the year ended December 31, 2006.
The increase was primarily due to the inclusion of rental
operations expense for acquired and redevelopment properties
(net of amounts capitalized) during 2006 and 2007 and an
increase in same property rental operations expense of
$5.1 million, or 13.7%, for the year ended
December 31, 2007 compared to 2006. The increase in same
property rental operations expense is primarily due to the
hiring of additional property management personnel and related
expansion of our operations in 2006 and 2007 and increased
operating expenses at certain properties.
39
Real Estate Tax Expense. Real estate tax
expense was $20.4 million for the years ended
December 31, 2007 and 2006. Real estate tax expense
increased as a result of the inclusion of property taxes for the
properties acquired in 2006 and 2007, but was offset by a
decrease in same property real estate tax expense of
$1.9 million, or 12.2%, for the year ended
December 31, 2007 compared to the same period in 2006. The
decrease in same property real estate tax expense is primarily
due to the capitalization of property taxes in connection with
properties that were operating in 2006 and subsequently entered
into redevelopment, the development of new buildings on a
portion of our Landmark at Eastview property, and a reassessment
of property taxes due to successful appeals at certain of our
properties.
Depreciation and Amortization
Expense. Depreciation and amortization expense
increased $7.1 million to $72.2 million for the year
ended December 31, 2007 compared to $65.1 million for
the year ended December 31, 2006. The increase was
primarily due to the inclusion of depreciation and amortization
expense for properties acquired in 2006 and 2007 and the
acceleration of depreciation on assets related to an early lease
termination in the amount of $1.6 million, which is
included as a redevelopment property. The increase was partially
offset by the cessation of depreciation on certain properties,
or portions thereof, currently under redevelopment, which is
expected to continue into 2008, and the full amortization of
acquired intangible assets in 2007 and 2006 at certain
properties.
General and Administrative Expenses. General
and administrative expenses increased $3.8 million to
$21.9 million for the year ended December 31, 2007
compared to $18.1 million for the year ended
December 31, 2006. The increase was primarily due to growth
in the corporate infrastructure necessary to support our
expanded property portfolio and an increase in stock
compensation costs resulting from increased stock awards to
employees and the vesting of restricted stock from previous
years during 2007.
Equity in Net (Loss)/Income of Unconsolidated
Partnerships. Equity in net (loss)/income of
unconsolidated partnerships decreased $976,000 to a loss of
($893,000) for the year ended December 31, 2007 compared to
income of $83,000 for the year ended December 31, 2006. The
decrease was primarily due to our proportionate share of the
losses generated by the PREI limited liability companies since
formation in April 2007, offset by our allocation of the net
income in the McKellar Court partnership for the year ended
December 31, 2007.
Interest Expense. Interest cost incurred for
the year ended December 31, 2007 totaled $84.4 million
compared to $48.3 million for the year ended
December 31, 2006. Total interest cost incurred increased
primarily as a result of higher borrowings for development and
redevelopment activities, partially offset by decreases in
borrowings for working capital purposes and decreases in the
average interest rate on our outstanding borrowings. During the
year ended December 31, 2007, we capitalized
$56.7 million of interest compared to $7.6 million for
the year ended December 31, 2006. The increase in
capitalized interest reflects our increased development and
redevelopment activities. Capitalized interest for the year
ended December 31, 2007 was primarily comprised of amounts
relating to our Center for Life
Science | Boston
development and Pacific Research Center redevelopment projects,
which were acquired on November 17, 2006 and July 11,
2006, respectively. We expect to continue to capitalize
significant interest costs on these properties, and other
properties currently under development or redevelopment, through
the end of 2008, including the construction of new buildings at
our Fairview Avenue, Landmark at Eastview, and Towne Centre
Drive properties. Net of capitalized interest and the accretion
of debt premium, interest expense decreased $13.0 million
to $27.7 million for the year ended December 31, 2007
compared to $40.7 million for the year ended
December 31, 2006.
Minority Interests. Minority interests
increased $908,000 to ($2.5) million for the year ended
December 31, 2007 compared to ($1.6) million for year
ended December 31, 2006. The increase in minority interests
was related to an increase in income before minority interests
allocable to minority interests in our Operating Partnership and
income in minority interests in our consolidated partnerships
for the year ended December 31, 2007 compared to net losses
in our consolidated partnerships for the year ended
December 31, 2006.
Discontinued Operations. In May 2007, we
completed the sale of our Colorow property and recognized a gain
upon closing of approximately $1.1 million. The results of
operations and gain on sale of the property have been reported
as discontinued operations in the consolidated statements of
income for all periods presented. Income from discontinued
operations was approximately $1.7 million for the year
ended December 31, 2007 (representing the results of
operations through the date of sale in May and the gain on sale
of $1.1 million) compared to income of $1.5 million
from discontinued operations for the year ended
December 31, 2006.
40
Comparison
of the Year Ended December 31, 2006 to the Year Ended
December 31, 2005
The following table sets forth the basis for presenting the
historical information for same properties (all properties
except redevelopment and new properties and discontinued
operations), redevelopment/development properties (properties
that were under redevelopment or development during either of
the years ended December 31, 2006 or 2005), and new
properties (properties that were not owned for each of the full
years ended December 31, 2006 and 2005 and were not under
redevelopment/development), in thousands:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Redevelopment/Development
|
|
|
|
|
|
|
Same Properties
|
|
|
Properties
|
|
|
New Properties
|
|
|
|
2006
|
|
|
2005
|
|
|
2006
|
|
|
2005
|
|
|
2006
|
|
|
2005
|
|
|
Rental
|
|
$
|
58,087
|
|
|
$
|
58,092
|
|
|
$
|
7,959
|
|
|
$
|
33
|
|
|
$
|
98,441
|
|
|
$
|
34,465
|
|
Tenant recoveries
|
|
|
29,448
|
|
|
|
31,963
|
|
|
|
2,358
|
|
|
|
4
|
|
|
|
22,354
|
|
|
|
10,253
|
|
Other income
|
|
|
23
|
|
|
|
3,712
|
|
|
|
|
|
|
|
|
|
|
|
65
|
|
|
|
262
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
$
|
87,558
|
|
|
$
|
93,767
|
|
|
$
|
10,317
|
|
|
$
|
37
|
|
|
$
|
120,860
|
|
|
$
|
44,980
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rental operations
|
|
$
|
27,973
|
|
|
$
|
29,410
|
|
|
$
|
615
|
|
|
$
|
5
|
|
|
$
|
12,035
|
|
|
$
|
5,081
|
|
Real estate taxes
|
|
|
6,970
|
|
|
|
6,520
|
|
|
|
1,970
|
|
|
|
|
|
|
|
11,436
|
|
|
|
5,342
|
|
Depreciation and amortization
|
|
|
26,198
|
|
|
|
25,132
|
|
|
|
3,740
|
|
|
|
|
|
|
|
35,125
|
|
|
|
14,246
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
$
|
61,141
|
|
|
$
|
61,062
|
|
|
$
|
6,325
|
|
|
$
|
5
|
|
|
$
|
58,596
|
|
|
$
|
24,669
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rental Revenues. Rental revenues increased
$71.9 million to $164.5 million for the year ended
December 31, 2006 compared to $92.6 million for the
year ended December 31, 2005. The increase was primarily
due to acquisitions in 2005 and 2006 and redevelopment
properties that were generating revenue during part of 2006.
Same property rental revenues for the years ended
December 31, 2006 and 2005 were $58.1 million.
Tenant Recoveries. Revenues from tenant
reimbursements increased $12.0 million to
$54.2 million for the year ended December 31, 2006
compared to $42.2 million for the year ended
December 31, 2005. The increase was primarily due to
acquisitions in 2005 and 2006, partially offset by a decrease of
same property tenant recoveries of approximately
$2.5 million, or 7.9%, for the year ended December 31,
2006 compared to the same period in 2005. The same property
decrease is primarily the result of lower utility expenses at
certain properties.
Other Income. Other income of
$4.0 million for the year ended December 31, 2005 is
comprised primarily of a gain on early termination of a lease of
$3.5 million.
Rental Operations Expense. Rental operations
expense increased $6.1 million to $40.6 million for
the year ended December 31, 2006 compared to
$34.5 million for the year ended December 31, 2005.
The increase was primarily due to acquisitions in 2005 and 2006
and redevelopment properties that were in our operating
portfolio during part of 2006. Same property rental operations
expense decreased approximately $1.4 million, or 4.9%, for
the year ended December 31, 2006 compared to the same
period in 2005 primarily due to lower utility expenses at
certain properties.
Real Estate Tax Expense. Real estate tax
expense increased $8.5 million to $20.4 million for
the year ended December 31, 2006 compared to
$11.9 million for the year ended December 31, 2005.
Real estate tax expense increased primarily due to acquisitions
in 2005 and 2006. Same property real estate tax expense
increased $450,000, or 6.9%, for the year ended
December 31, 2006 compared to the same period in 2005,
primarily due to a reassessment of the property taxes at certain
properties.
Depreciation and Amortization
Expense. Depreciation and amortization expense
increased $25.7 million to $65.1 million for the year
ended December 31, 2006 compared to $39.4 million for
the year ended December 31, 2005. The increase was
primarily due to acquisitions in 2005 and 2006. In addition,
same property depreciation and amortization expense increased
approximately $1.1 million for the year ended
December 31, 2006 compared to the same period in 2005,
primarily as the result of the accelerated amortization of the
net remaining balance of intangible assets totaling $947,000 due
to the early termination of a lease and increased amortization
for tenant improvements placed in service during 2006 and 2005.
41
General and Administrative Expenses. General
and administrative expenses increased $4.8 million to
$18.1 million for the year ended December 31, 2006
compared to $13.3 million for the year ended
December 31, 2005. The increase was primarily due to an
increase in employees resulting in increased personnel and
infrastructure costs. The year ended December 31, 2005
included a $619,000 increase to general and administrative
expenses resulting from an adjustment to stock compensation
expense related to restricted stock grants awarded to our
executive officers and other employees at the time of our
initial public offering in August 2004 that occurred in the
periods prior to the year ended December 31, 2005.
Equity in Net (Loss)/Income of Unconsolidated
Partnerships. Equity in net (loss)/income of
unconsolidated partnerships decreased $36,000 to net income of
$83,000 for the year ended December 31, 2006 compared to
net income of $119,000 for the year ended December 31, 2005.
Interest Expense. Interest cost incurred for
the year ended December 31, 2006 totaled $48.3 million
compared to $23.9 million for the year ended
December 31, 2005. Total interest cost incurred increased
primarily as a result of higher borrowings, partially offset by
a reduction of interest expense in 2006 due to the accretion of
debt premium of $2.1 million. During the year ended
December 31, 2006, we capitalized $7.6 million of
interest compared to $704,000 for the year ended
December 31, 2005. The increase in capitalized interest
reflects our increased development and redevelopment activities.
Capitalized interest for the year ended December 31, 2006
was primarily comprised of amounts relating to our Center for
Life Science | Boston
development and Pacific Research Center redevelopment projects,
which were acquired on November 17, 2006 and July 11,
2006, respectively. Net of capitalized interest and the
accretion of debt premium, interest expense increased
$17.5 million to $40.7 million for the year ended
December 31, 2006 compared to $23.2 million for the
year ended December 31, 2005.
Minority Interests. Minority interests
increased $545,000 to ($1.5) million for the year ended
December 31, 2006, compared to ($1.0) million for the
year ended December 31, 2005. The increase in minority
interests was primarily related to an increase in income before
minority interests allocable to minority interests in our
Operating Partnership.
Discontinued Operations. In May 2007, we
completed the sale of our Colorow property and have accordingly
reflected the property as discontinued operations in the
consolidated statements of income for all periods presented.
Income from discontinued operations increased $1.4 million
to $1.5 million for the year ended December 31, 2006,
compared to $54,000 for the year ended December 31, 2005
due to the inclusion of the Colorow property for a full year in
2006 (originally acquired December 22, 2005).
Cash
Flows
The following summary discussion of our cash flows is based on
the consolidated statements of cash flows in Item 8.
Financial Statements and Supplementary Data and is not
meant to be an all inclusive discussion of the changes in our
cash flows for the periods presented below (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Net cash provided by operating activities
|
|
$
|
114,843
|
|
|
$
|
101,535
|
|
|
$
|
54,762
|
|
Net cash used in investing activities
|
|
|
(409,300
|
)
|
|
|
(1,339,463
|
)
|
|
|
(601,805
|
)
|
Net cash provided by financing activities
|
|
|
282,273
|
|
|
|
1,243,280
|
|
|
|
539,486
|
|
Ending cash and cash equivalents balance
|
|
|
13,479
|
|
|
|
25,664
|
|
|
|
20,312
|
|
Comparison
of the Year Ended December 31, 2007 to the Year Ended
December 31, 2006
Net cash provided by operating activities increased
$13.3 million to $114.8 million for the year ended
December 31, 2007 compared to $101.5 million for the
year ended December 31, 2006. The increase was primarily
due to the increases in operating income before depreciation and
amortization, partially offset by changes in operating assets
and liabilities.
42
Net cash used in investing activities decreased
$930.2 million to $409.3 million for the year ended
December 31, 2007 compared to $1.3 billion for the
year ended December 31, 2006. The decrease reflects a
decrease in the cash used to acquire investments in real estate
and related intangible assets (reflecting reduced acquisition
activity) and cash received as proceeds from the sale of a
property, partially offset by cash used for the purchases of
interests in unconsolidated partnerships and funds held in
escrow for acquisitions at December 31, 2007.
Net cash provided by financing activities decreased
$961.0 million to $282.3 million for the year ended
December 31, 2007 compared to $1.2 billion for the
year ended December 31, 2006. The decrease reflects reduced
financing requirements due to reduced acquisition activity,
partially offset by an increase in dividends paid to common and
preferred stockholders. Cash generated from the sale of
preferred stock during the year ended December 31, 2007 was
used principally to pay down the unsecured line of credit. In
addition, cash from financing activities was provided by our
unsecured line of credit and our secured construction loan
during the year ended December 31, 2007.
Comparison
of the Year Ended December 31, 2006 to the Year Ended
December 31, 2005
Net cash provided by operating activities increased
$46.8 million to $101.5 million for the year ended
December 31, 2006 compared to $54.8 million for the
year ended December 31, 2005. The increase was primarily
due to the increase in operating income before depreciation and
amortization, non-cash compensation expense related to the
vesting of restricted common stock, add back of the revenue
reduction related to the amortization of above-market lease
intangible assets, and changes in other operating assets and
liabilities.
Net cash used in investing activities increased
$737.7 million to $1.3 billion for the year ended
December 31, 2006 compared to $601.8 million for the
year ended December 31, 2005. The increase was primarily
due to amounts paid to acquire interests in real estate
properties and non-real estate assets, partially offset by a
decrease in the receipt of master lease payments.
Net cash provided by financing activities increased
$703.8 million to $1.2 billion for the year ended
December 31, 2006 compared to $539.5 million for the
year ended December 31, 2005. The increase was primarily
due to an increase in the proceeds from common stock offerings,
line of credit borrowings, exchangeable notes offering,
construction line draws, and the issuance of mortgage notes
payable, offset by principal payments on mortgage loans,
payments on the line of credit, payment of loan costs, and
payments of dividends and distributions.
Liquidity
and Capital Resources
Our short-term liquidity requirements consist primarily of funds
to pay for future distributions expected to be paid to our
stockholders, operating expenses and other expenditures directly
associated with our properties, interest expense and scheduled
principal payments on outstanding mortgage indebtedness, general
and administrative expenses, and capital expenditures, tenant
improvements and leasing commissions.
We expect to satisfy our short-term liquidity requirements
through our existing working capital and cash provided by our
operations. Our rental revenues, provided by our leases,
generally provide cash inflows to meet our debt service
obligations, pay general and administrative expenses, and fund
regular distributions.
Our long-term liquidity requirements consist primarily of funds
to pay for scheduled debt maturities, construction obligations,
renovations, expansions, capital commitments and other
non-recurring capital expenditures that need to be made
periodically, and the costs associated with acquisitions of
properties that we pursue. We expect to satisfy our long-term
liquidity requirements through our existing working capital,
cash provided by operations, long-term secured and unsecured
indebtedness, the issuance of additional equity or debt
securities and the use of net proceeds from the disposition of
non-strategic assets. We also expect to use funds available
under our unsecured line of credit and our secured construction
loan to finance acquisition and development activities and
capital expenditures on development projects on an interim basis.
Under the rules adopted by the Securities and Exchange
Commission in December 2005 regarding registration and offering
procedures, if we meet the definition of a well-known
seasoned issuer under Rule 405 of the Securities Act,
we are permitted to file an automatic shelf registration
statement that will be immediately effective
43
upon filing. On September 15, 2006, we filed such an
automatic shelf registration statement, which may permit us,
from time to time, to offer and sell debt securities, common
stock, preferred stock, warrants and other securities to the
extent necessary or advisable to meet our liquidity needs.
On January 18, 2007, we completed the issuance of
9,200,000 shares, including the exercise of an
over-allotment option of 1,200,000 shares, of 7.375%
Series A cumulative redeemable preferred stock at $25.00
per share. The net proceeds of approximately $222.4 million
were primarily used to repay outstanding borrowings on our
unsecured line of credit.
Our total capitalization at December 31, 2007 was
approximately $3.3 billion and was comprised of the
following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate
|
|
|
|
|
|
|
|
|
|
Principal
|
|
|
|
|
|
|
Shares/Units
|
|
|
Amount or
|
|
|
|
|
|
|
at December 31,
|
|
|
Dollar Value
|
|
|
Percent of Total
|
|
|
|
2007
|
|
|
Equivalent
|
|
|
Capitalization
|
|
|
|
(In thousands)
|
|
|
Debt:
|
|
|
|
|
|
|
|
|
|
|
|
|
Mortgage notes payable(1)
|
|
|
|
|
|
$
|
379,680
|
|
|
|
11.4
|
%
|
Secured construction loan
|
|
|
|
|
|
|
425,160
|
|
|
|
12.8
|
%
|
Secured term loan
|
|
|
|
|
|
|
250,000
|
|
|
|
7.5
|
%
|
Exchangeable notes
|
|
|
|
|
|
|
175,000
|
|
|
|
5.3
|
%
|
Unsecured line of credit
|
|
|
|
|
|
|
270,947
|
|
|
|
8.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total debt
|
|
|
|
|
|
|
1,500,787
|
|
|
|
45.1
|
%
|
Equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
Common shares outstanding(2)
|
|
|
65,571,304
|
|
|
|
1,519,287
|
|
|
|
45.7
|
%
|
7.375% Series A Preferred shares outstanding(3)
|
|
|
9,200,000
|
|
|
|
230,000
|
|
|
|
6.9
|
%
|
Operating partnership units outstanding(4)
|
|
|
2,863,564
|
|
|
|
66,349
|
|
|
|
2.0
|
%
|
LTIP units outstanding(4)
|
|
|
454,716
|
|
|
|
10,536
|
|
|
|
0.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total equity
|
|
|
|
|
|
|
1,826,172
|
|
|
|
54.9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total capitalization
|
|
|
|
|
|
$
|
3,326,959
|
|
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Amount includes debt premiums of $10.9 million recorded
upon the assumption of the outstanding indebtedness in
connection with our purchase of the corresponding properties. |
|
(2) |
|
Based on the market closing price of our common stock of $23.17
per share on the last trading day of the year (December 31,
2007). |
|
(3) |
|
Based on the liquidation preference of $25.00 per share for our
7.375% Series A preferred stock. |
|
(4) |
|
Our partnership and LTIP units are each individually convertible
into one share of common stock at the market closing price of
our common stock of $23.17 per share on the last trading day of
the year (December 31, 2007). |
As a result, our debt to total capitalization ratio was
approximately 45.1% at December 31, 2007 (excluding our
proportionate share of indebtedness from our unconsolidated
partnerships). Our board of directors adopted a policy of
limiting our indebtedness to approximately 60% of our total
capitalization. However, our board of directors may from time to
time modify our debt policy in light of current economic or
market conditions including, but not limited to, the relative
costs of debt and equity capital, market conditions for debt and
equity securities and fluctuations in the market price of our
common stock. Accordingly, we may increase or decrease our debt
to total capitalization ratio beyond the limit described above.
On August 1, 2007, our Operating Partnership entered into a
second amended and restated unsecured credit agreement and a
first amended and restated secured term loan agreement with
KeyBank National Association (KeyBank), as
administrative agent, and certain other lenders.
44
The second amended and restated unsecured credit agreement
increased the borrowing capacity on our unsecured line of credit
from $500.0 million to $600.0 million and extends the
maturity date to August 1, 2011. Subject to the
administrative agents reasonable discretion, we may
increase the borrowing capacity of the unsecured line of credit
to $1.0 billion upon satisfying certain conditions. In
addition, we may, in our sole discretion, extend the maturity
date of the unsecured line of credit to August 1, 2012
after satisfying certain conditions and paying an extension fee
based on the then current facility commitment. The unsecured
line of credit bears interest at a floating rate equal to, at
our option, either (1) reserve adjusted LIBOR plus a spread
which ranges from 100 to 155 basis points, depending on our
leverage, or (2) the higher of (a) the prime rate then
in effect plus a spread which ranges from 0 to 25 basis
points, or (b) the federal funds rate then in effect plus a
spread which ranges from 50 to 75 basis points, in each
case, depending on our leverage. In September 2007, we entered
into three interest rate swap agreements, which were intended to
have the effect of initially fixing the interest rate on
$205.0 million of the unsecured line of credit at a
weighted-average rate of 5.9% through September 2008. We have
deferred the loan costs associated with the subsequent
amendments to the unsecured line of credit, which are being
amortized to expense with the unamortized loan costs from the
original unsecured line of credit over the remaining term. At
December 31, 2007, we had $270.9 million in
outstanding borrowings on our unsecured line of credit, with a
weighted-average interest rate of 6.3% on the unhedged portion
of the outstanding debt.
The first amended and restated secured term loan agreement
amended the terms of our $250.0 million secured term loan,
which is secured by the Companys interests in 14 of our
properties, to, among other things, reduce the borrowing rate,
extend the maturity date of the loan to August 1, 2012 and
provide greater flexibility with respect to covenants. The
amended secured term loan bears interest at a floating rate
equal to, at our option, either (1) reserve-adjusted LIBOR
plus 165 basis points or (2) the higher of
(a) the prime rate then in effect plus 25 basis points
and (b) the federal funds rate then in effect plus
75 basis points. The secured term loan is also secured by
our interest in any distributions from these properties, a
pledge of the equity interests in a subsidiary owning one of
these properties, and a pledge of the equity interests in a
subsidiary owning an interest in another of these properties. We
entered into an interest rate swap agreement in connection with
the initial closing of the secured term loan, which has the
effect of fixing the interest rate on the secured term loan at
5.8% until the interest rate swap expires in 2010. At
December 31, 2007, we had $250.0 million in
outstanding borrowings on our secured term loan.
The terms of the credit agreements for the unsecured line of
credit and secured term loan include certain restrictions and
covenants, which limit, among other things, the payment of
dividends and the incurrence of additional indebtedness and
liens. The terms also require compliance with financial ratios
relating to the minimum amounts of net worth, fixed charge
coverage, unsecured debt service coverage, the maximum amount of
secured, and secured recourse indebtedness, leverage ratio and
certain investment limitations. The dividend restriction
referred to above provides that, except to enable us to continue
to qualify as a REIT for federal income tax purposes, we will
not make distributions with respect to common stock or other
equity interests in an aggregate amount for the preceding four
fiscal quarters in excess of 95% of funds from operations, as
defined, for such period, subject to other adjustments. We
believe that we were in compliance with the covenants as of
December 31, 2007.
45
A summary of our outstanding consolidated mortgage notes payable
as of December 31, 2007 is as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective
|
|
|
Principal Balance
|
|
|
|
|
|
Stated Fixed
|
|
|
Interest
|
|
|
December 31,
|
|
|
|
|
|
Interest Rate
|
|
|
Rate
|
|
|
2007
|
|
|
2006
|
|
|
Maturity Date
|
|
Ardentech Court
|
|
|
7.25
|
%
|
|
|
5.06
|
%
|
|
$
|
4,564
|
|
|
$
|
4,658
|
|
|
July 1, 2012
|
Bayshore Boulevard
|
|
|
4.55
|
%
|
|
|
4.55
|
%
|
|
|
15,335
|
|
|
|
15,730
|
|
|
January 1, 2010
|
Bridgeview Technology Park I
|
|
|
8.07
|
%
|
|
|
5.04
|
%
|
|
|
11,508
|
|
|
|
11,625
|
|
|
January 1, 2011
|
Eisenhower Road
|
|
|
5.80
|
%
|
|
|
4.63
|
%
|
|
|
2,113
|
|
|
|
2,164
|
|
|
May 5, 2008
|
Elliott Avenue
|
|
|
7.38
|
%
|
|
|
4.63
|
%
|
|
|
|
|
|
|
16,020
|
|
|
November 24, 2007
|
40 Erie Street
|
|
|
7.34
|
%
|
|
|
4.90
|
%
|
|
|
17,625
|
|
|
|
18,676
|
|
|
August 1, 2008
|
500 Kendall Street (Kendall D)
|
|
|
6.38
|
%
|
|
|
5.45
|
%
|
|
|
69,437
|
|
|
|
70,963
|
|
|
December 1, 2018
|
Lucent Drive
|
|
|
5.50
|
%
|
|
|
5.50
|
%
|
|
|
5,543
|
|
|
|
5,733
|
|
|
January 21, 2015
|
Monte Villa Parkway
|
|
|
4.55
|
%
|
|
|
4.55
|
%
|
|
|
9,336
|
|
|
|
9,576
|
|
|
January 1, 2010
|
6828 Nancy Ridge Drive
|
|
|
7.15
|
%
|
|
|
5.38
|
%
|
|
|
6,785
|
|
|
|
6,872
|
|
|
September 1, 2012
|
Road to the Cure
|
|
|
6.70
|
%
|
|
|
5.78
|
%
|
|
|
15,427
|
|
|
|
15,657
|
|
|
January 31, 2014
|
Science Center Drive
|
|
|
7.65
|
%
|
|
|
5.04
|
%
|
|
|
11,301
|
|
|
|
11,444
|
|
|
July 1, 2011
|
Shady Grove Road
|
|
|
5.97
|
%
|
|
|
5.97
|
%
|
|
|
147,000
|
|
|
|
147,000
|
|
|
September 1, 2016
|
Sidney Street
|
|
|
7.23
|
%
|
|
|
5.11
|
%
|
|
|
29,986
|
|
|
|
30,732
|
|
|
June 1, 2012
|
9885 Towne Centre Drive
|
|
|
4.55
|
%
|
|
|
4.55
|
%
|
|
|
21,323
|
|
|
|
21,872
|
|
|
January 1, 2010
|
900 Uniqema Boulevard
|
|
|
8.61
|
%
|
|
|
5.61
|
%
|
|
|
1,509
|
|
|
|
1,648
|
|
|
May 1, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
368,792
|
|
|
|
390,370
|
|
|
|
Unamortized premiums
|
|
|
|
|
|
|
|
|
|
|
10,888
|
|
|
|
13,466
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
379,680
|
|
|
$
|
403,836
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Premiums were recorded upon assumption of the notes at the time
of the related acquisition to account for above-market interest
rates. Amortization of these premiums is recorded as a reduction
to interest expense over the remaining term of the respective
note.
As of December 31, 2007, principal payments due for our
indebtedness (mortgage notes payable excluding debt premium of
$10.9 million, secured term loan, secured construction
loan, the exchangeable notes, and unsecured line of credit,
excluding our proportionate share of the indebtedness of our
unconsolidated partnerships) were as follows (in thousands):
|
|
|
|
|
2008
|
|
$
|
24,454
|
|
2009
|
|
|
430,186
|
|
2010
|
|
|
47,446
|
|
2011
|
|
|
297,167
|
|
2012
|
|
|
291,421
|
|
Thereafter
|
|
|
399,225
|
|
|
|
|
|
|
|
|
$
|
1,489,899
|
|
|
|
|
|
|
As noted above, we have entered into derivative contracts known
as interest rate swaps in order to hedge the risk of increase in
interest rates on our $250.0 million secured term loan, our
$600.0 million unsecured line of credit, and our
$550.0 million secured construction loan. In addition, in
connection with entering into the acquisition and construction
loan secured by our Center for Life
Science | Boston
property, we entered into four forward starting swap agreements,
which have the effect of fixing the interest rate on the
long-term debt that we expect to enter into upon completing the
construction of the project in 2008. We record all derivatives
on the balance sheet at fair-value. The accounting for changes
in the fair-value of derivatives depends on the intended use of
the derivative and the
46
resulting designation. Derivatives used to hedge the exposure to
changes in the fair-value of an asset, liability, or firm
commitment attributable to a particular risk, such as interest
rate risk, are considered fair-value hedges. Derivatives used to
hedge the exposure to variability in expected future cash flows,
or other types of forecasted transactions, are considered cash
flow hedges.
For derivatives designated as cash flow hedges, the effective
portion of changes in the fair-value of the derivative is
initially reported in other comprehensive income (outside of
earnings) and subsequently reclassified to earnings when the
hedged transaction affects earnings, and the ineffective portion
of changes in the fair-value of the derivative is recognized
directly in earnings. We assess the effectiveness of each
hedging relationship by comparing the changes in cash flows of
the derivative hedging instrument with the changes in cash flows
of the designated hedged item or transaction.
Our objective in using derivatives is to add stability to
interest expense and to manage its exposure to interest rate
movements or other identified risks. To accomplish this
objective, we primarily use interest rate swaps as part of our
cash flow hedging strategy. Interest rate swaps designated as
cash flow hedges involve the receipt of variable-rate amounts in
exchange for fixed-rate payments over the life of the agreements
without exchange of the underlying principal amount. During 2007
and 2006, such derivatives were used to hedge the variable cash
flows associated with existing variable-rate debt and future
variability in the interest related cash flows from forecasted
issuances of debt. We formally document the hedging
relationships for all derivative instruments, account for all of
our interest rate swap agreements as cash flow hedges, and do
not use derivatives for trading or speculative purposes.
As of December 31, 2007, we had four forward starting swaps
hedging a forecasted debt issuance, with a total notional value
of $450.0 million. The forward starting swaps are valued on
the accompanying consolidated balance sheets at the net present
value of the expected future cash flows on the swaps. At
maturity, we will either (a) receive payment from the
counterparties if the accumulated balance is an asset, or
(b) make payment to the counterparties if the accumulated
balance is a liability, with the resulting receipt or payment
deferred and amortized as an increase or decrease to interest
expense over the term of the resultant subsequent borrowing. No
initial net investment was made to enter into these agreements.
As of December 31, 2007, we also had five interest rate
swaps with an aggregate notional amount of $785.0 million
under which at each monthly settlement date we either
(1) receive the difference between the Strike Rate and
one-month LIBOR if the Strike Rate is less than LIBOR or
(2) pay such difference if the Strike Rate is greater than
LIBOR. One interest rate swap with a notional amount of
$250.0 million hedges our secured term loan. Each of the
remaining four interest rate swaps hedges the first interest
payments, due on the date that is on or closest after each
swaps settlement date, associated with the amount of
LIBOR-based debt equal to each swaps notional amount.
Three of these interest rate swaps have an aggregate notional
amount of $205.0 million and are initially intended to
hedge interest payments associated with our unsecured line of
credit. The remaining interest rate swap has a notional amount
of $330.0 million and is initially intended to hedge
interest payments associated with our secured construction loan.
No initial investment was made to enter into the interest rate
swap agreements.
For the years ended December 31, 2007, 2006, and 2005 an
immaterial amount of hedge ineffectiveness on cash flow hedges
due to mismatches in maturity dates of the interest rate swap
and debt was recognized in interest expense. Amounts reported in
accumulated other comprehensive income related to derivatives
will be reclassified to interest expense as interest payments
are made on our hedged debt. The change in net unrealized gains
on cash flow hedges includes a reclassification of net
unrealized gains/losses from accumulated other comprehensive
income as a reduction to interest expense of $3.1 million
and $2.3 million, and an increase of $681,000 for the years
ended December 31, 2007, 2006, and 2005, respectively.
During 2008, we estimate that an additional $3.5 million
will be reclassified as an increase to interest expense.
47
The following provides information with respect to our
contractual obligations at December 31, 2007, including the
maturities and scheduled principal repayments, but excluding
related debt premiums. We were not subject to any material
capital lease obligations or unconditional purchase obligations
as of December 31, 2007.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Obligation
|
|
2008
|
|
|
2009-2010
|
|
|
2011-2012
|
|
|
Thereafter
|
|
|
Total
|
|
|
|
(In thousands)
|
|
|
Mortgage notes payable(1)
|
|
$
|
24,454
|
|
|
$
|
52,472
|
|
|
$
|
67,641
|
|
|
$
|
224,225
|
|
|
$
|
368,792
|
|
Secured term loan
|
|
|
|
|
|
|
|
|
|
|
250,000
|
|
|
|
|
|
|
|
250,000
|
|
Secured construction loan(2)
|
|
|
|
|
|
|
425,160
|
|
|
|
|
|
|
|
|
|
|
|
425,160
|
|
Exchangeable senior notes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
175,000
|
|
|
|
175,000
|
|
Unsecured line of credit(3)
|
|
|
|
|
|
|
|
|
|
|
270,947
|
|
|
|
|
|
|
|
270,947
|
|
Share of debt of unconsolidated partnerships(4)
|
|
|
83,314
|
|
|
|
2,174
|
|
|
|
|
|
|
|
|
|
|
|
85,488
|
|
Interest payments on debt obligations(5)
|
|
|
97,037
|
|
|
|
151,402
|
|
|
|
87,833
|
|
|
|
161,463
|
|
|
|
497,735
|
|
Construction projects
|
|
|
77,166
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
77,166
|
|
Tenant obligations(6)
|
|
|
84,257
|
|
|
|
31,248
|
|
|
|
866
|
|
|
|
|
|
|
|
116,371
|
|
Lease commissions
|
|
|
6,792
|
|
|
|
962
|
|
|
|
|
|
|
|
|
|
|
|
7,754
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
373,020
|
|
|
$
|
663,418
|
|
|
$
|
677,287
|
|
|
$
|
560,688
|
|
|
$
|
2,274,413
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Balance excludes $10.9 million of unamortized debt premium. |
|
(2) |
|
The secured construction loan matures on November 16, 2009,
but we may extend the maturity date to November 16, 2010
after satisfying certain conditions and paying an additional fee. |
|
(3) |
|
The unsecured line of credit matures on August 1, 2011, but
we may extend the maturity date of the unsecured line of credit
to August 1, 2012 after satisfying certain conditions and
paying an extension fee based on the then current facility
commitment. |
|
(4) |
|
The maturity date of the secured acquisition and interim loan
held by the PREI limited liability companies was extended by one
year to April 3, 2009 in February 2008. |
|
(5) |
|
Interest payments reflect cash payments that are based on the
interest rates in effect and debt balances outstanding on
December 31, 2007, excluding the effect of the interest
rate swaps on the underlying debt. |
|
(6) |
|
Committed tenant-related obligations based on executed leases as
of December 31, 2007. |
Funds
from Operations
We present funds from operations, or FFO, available to common
shares and partnership and LTIP units because we consider it an
important supplemental measure of our operating performance and
believe it is frequently used by securities analysts, investors
and other interested parties in the evaluation of REITs, many of
which present FFO when reporting their results. FFO is intended
to exclude GAAP historical cost depreciation and amortization of
real estate and related assets, which assumes that the value of
real estate assets diminishes ratably over time. Historically,
however, real estate values have risen or fallen with market
conditions. Because FFO excludes depreciation and amortization
unique to real estate, gains and losses from property
dispositions and extraordinary items, it provides a performance
measure that, when compared year over year, reflects the impact
to operations from trends in occupancy rates, rental rates,
operating costs, development activities and interest costs,
providing perspective not immediately apparent from net income.
We compute FFO in accordance with standards established by the
Board of Governors of the National Association of Real Estate
Investment Trusts, or NAREIT, in its March 1995 White Paper (as
amended in November 1999 and April 2002). As defined by NAREIT,
FFO represents net income (computed in accordance with GAAP),
excluding gains (or losses) from sales of property, plus real
estate related depreciation and amortization (excluding
amortization of loan origination costs) and after adjustments
for
48
unconsolidated partnerships and joint ventures. Our computation
may differ from the methodology for calculating FFO utilized by
other equity REITs and, accordingly, may not be comparable to
such other REITs. Further, FFO does not represent amounts
available for managements discretionary use because of
needed capital replacement or expansion, debt service
obligations, or other commitments and uncertainties. FFO should
not be considered as an alternative to net income (loss)
(computed in accordance with GAAP) as an indicator of our
financial performance or to cash flow from operating activities
(computed in accordance with GAAP) as an indicator of our
liquidity, nor is it indicative of funds available to fund our
cash needs, including our ability to pay dividends or make
distributions.
Our FFO available to common shares and partnership and LTIP
units and a reconciliation to net income for the years ended
December 31, 2007 and 2006 (in thousands, except share
data) was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
|
|
|
2007
|
|
|
2006
|
|
|
|
|
|
Net income available to common stockholders
|
|
$
|
55,665
|
|
|
$
|
35,033
|
|
|
|
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
Minority interests in operating partnership
|
|
|
2,486
|
|
|
|
1,747
|
|
|
|
|
|
Gain on sale of real estate assets
|
|
|
(1,087
|
)
|
|
|
|
|
|
|
|
|
Depreciation and amortization unconsolidated
partnerships
|
|
|
1,139
|
|
|
|
80
|
|
|
|
|
|
Depreciation and amortization consolidated
entities-discontinued operations
|
|
|
228
|
|
|
|
550
|
|
|
|
|
|
Depreciation and amortization consolidated
entities-continuing operations
|
|
|
72,202
|
|
|
|
65,060
|
|
|
|
|
|
Depreciation and amortization allocable to minority
interest of consolidated joint ventures
|
|
|
(285
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Funds from operations available to common shares and partnership
and LTIP units
|
|
$
|
130,348
|
|
|
$
|
102,470
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Funds from operations per share diluted
|
|
$
|
1.91
|
|
|
$
|
1.74
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding diluted
|
|
|
68,269,985
|
|
|
|
59,018,004
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Off
Balance Sheet Arrangements
As of December 31, 2007, we had investments in the
following unconsolidated partnerships: (1) McKellar Court
limited partnership, which owns a single tenant occupied
property located in San Diego; and (2) two limited
liability companies with PREI, which own a portfolio of
properties primarily located in Cambridge, Massachusetts (see
Note 10 in the accompanying consolidated financial
statements).
The McKellar Court partnership is a variable interest entity as
defined in FIN 46R; however, we are not the primary
beneficiary. The limited partner at McKellar Court is the only
tenant in the property and will bear a disproportionate amount
of any losses. We, as the general partner, will receive 21% of
the operating cash flows and 75% of the gains upon sale of the
property. We account for our general partner interest using the
equity method. The assets of the McKellar Court partnership were
$16.5 million and $16.7 million and the liabilities
were $10.8 million and $10.9 million at
December 31, 2007 and 2006, respectively. Our equity in net
income of the McKellar Court partnership was $86,000, $83,000
and $119,000 for the years ended December 31, 2007, 2006,
and 2005, respectively.
PREI II LLC is a variable interest entity as defined in
FIN 46R; however, we are not the primary beneficiary. PREI
will bear the majority of any losses incurred. PREI I LLC does
not qualify as a variable interest entity as defined in
FIN 46R. In addition, consolidation under
EITF 04-5
is not required as we do not control the limited liability
companies. In connection with the formation PREI limited
liability companies in April 2007, we contributed 20% of the
initial capital. However, the amount of cash flow distributions
that we may receive may be more or less based on the nature of
the circumstances underlying the cash distributions due to
provisions in the operating agreements governing the
distribution of funds to each member and the occurrence of
extraordinary cash flow events. We account for our member
interests using the equity method for both limited liability
companies.
49
The assets of the PREI limited liability companies were
$540.3 million and the liabilities were $450.1 million
at December 31, 2007. Our equity in net loss of the PREI
limited liability companies was $988,000 for the year ended
December 31, 2007.
We are the primary beneficiary in three other variable interest
entities, which we consolidate and which are reflected in our
consolidated financial statements.
Our proportionate share of outstanding debt related to our
unconsolidated partnerships is summarized below (dollars in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal Amount(1)
|
|
|
|
|
|
Ownership
|
|
|
Interest
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
Name
|
|
Percentage
|
|
|
Rate(2)
|
|
|
2007
|
|
|
2006
|
|
|
Maturity Date
|
|
PREI I LLC and PREI II LLC(3)
|
|
|
20
|
%
|
|
|
6.04
|
|
|
$
|
83,285
|
|
|
$
|
|
|
|
April 3, 2008
|
McKellar Court partnership(4)
|
|
|
21
|
%
|
|
|
4.63
|
%
|
|
|
2,203
|
|
|
|
2,230
|
|
|
January 1, 2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
$
|
85,488
|
|
|
$
|
2,230
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Amount represents our proportionate share of the total
outstanding indebtedness for each of the unconsolidated
partnerships. |
|
(2) |
|
Effective or weighted-average interest rate of the outstanding
indebtedness as of December 31, 2007. |
|
(3) |
|
Amount represents our proportionate share of the total draws
outstanding under a secured acquisition and interim loan
facility, which bears interest at a LIBOR-indexed variable rate.
The secured acquisition and interim loan facility was utilized
by both PREI I LLC and PREI II LLC to acquire a portfolio of
properties (initial borrowings of approximately
$427.0 million) on April 4, 2007 (see Note 10 in
the accompanying consolidated financial statements). The
remaining balance will be utilized to fund future construction
costs at certain properties currently under development. On
February 19, 2008, the maturity date was extended to
April 3, 2009. |
|
(4) |
|
Amount represents our proportionate share of the principal
balance outstanding on a mortgage note payable, which is secured
by the McKellar Court property (excluding $186,000 of
unamortized debt premium). |
In connection with the acquisition of certain properties by PREI
II LLC in April 2007, it assumed an obligation related to the
remediation of environmental conditions at off-site parcels
located in Cambridge, Massachusetts. PREI II LLC has estimated
the cost of the remediation to be $3.6 million, which was
recognized at the time of acquisition as an increase to the
assets acquired and the recognition of a corresponding liability.
Inflation
Some of our leases contain provisions designed to mitigate the
adverse impact of inflation. These provisions generally increase
rental rates during the terms of the leases either at fixed
rates or indexed escalations (based on the Consumer Price Index
or other measures). We may be adversely impacted by inflation on
the leases that do not contain indexed escalation provisions. In
addition, most of our leases require the tenant to pay an
allocable share of operating expenses, including common area
maintenance costs, real estate taxes and insurance. This may
reduce our exposure to increases in costs and operating expenses
resulting from inflation, assuming our properties remain leased
and tenants fulfill their obligations to reimburse us for such
expenses.
Portions of our unsecured line of credit and secured
construction loan bear interest at a variable rate, which will
be influenced by changes in short-term interest rates, and will
be sensitive to inflation.
|
|
Item 7A.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
Our future income, cash flows and fair-values relevant to
financial instruments depend upon prevailing market interest
rates. Market risk is the exposure to loss resulting from
changes in interest rates, foreign currency exchange rates,
commodity prices and equity prices. The primary market risk to
which we believe we are exposed is interest rate risk. Many
factors, including governmental monetary and tax policies,
domestic and international economic and political considerations
and other factors that are beyond our control contribute to
interest rate risk.
50
As of December 31, 2007, our consolidated debt consisted of
the following (dollars in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
|
|
|
|
Percent of
|
|
|
Rate at
|
|
|
|
Principal Balance
|
|
|
Total Debt
|
|
|
12/31/07
|
|
|
Fixed interest rate(1)
|
|
$
|
554,680
|
|
|
|
37.0
|
%
|
|
|
5.16
|
%
|
Variable interest rate(2)
|
|
|
946,107
|
|
|
|
63.0
|
%
|
|
|
5.92
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total/weighted-average effective interest rate
|
|
$
|
1,500,787
|
|
|
|
100.0
|
%
|
|
|
5.64
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Includes 15 mortgage notes payable secured by certain of our
properties (including $10.9 million of unamortized premium)
and our exchangeable senior notes. |
|
(2) |
|
Includes our unsecured line of credit, secured term loan, and
secured construction loan, which bear interest based on a
LIBOR-indexed variable interest rate, plus a credit spread.
However, we have entered into four interest rate swaps, which
were intended to have the effect of initially fixing the
interest rates on $205.0 million of our unsecured line of
credit and $330.0 million of our secured construction loan
at 5.9% and 6.1%, respectively. We have entered into an interest
rate swap agreement that effectively fixes the interest rate on
the entire $250.0 million outstanding balance of the
secured term loan at a rate of 5.8% until the interest rate swap
expires in 2010. We have also entered into four forward starting
swap agreements, which will have the effect of fixing the
interest rate on $450.0 million of forecasted debt issuance
(after retirement of the secured construction loan) at
approximately 5.2%. |
To determine the fair-value of our outstanding indebtedness
(including our proportionate share of indebtedness of our
unconsolidated partnerships), the fixed-rate debt is discounted
at a rate based on an estimate of current lending rates,
assuming the debt is outstanding through maturity and
considering the notes collateral. At December 31,
2007, the fair-value of the fixed-rate debt was estimated to be
$547.1 million compared to the net carrying value of
$557.1 million (includes $11.1 million of premium with
our proportionate share of the debt premium related to our
McKellar Court partnership). We do not believe that the interest
rate risk represented by our fixed-rate debt was material as of
December 31, 2007 in relation to total assets of
$3.1 billion and equity market capitalization of
$1.8 billion of our common stock, operating partnership and
LTIP units, and preferred stock. At December 31, 2007, the
fair-value of the debt of our investment in unconsolidated
partnerships approximated the carrying value.
Based on the outstanding balances of our unsecured line of
credit, secured construction loan, and secured term loan and our
proportionate share of the outstanding balance for the PREI
limited liability companies secured acquisition loan at
December 31, 2007, a 1% change in interest rates would
change our interest costs by approximately $2.4 million per
year. This amount was determined by considering the impact of
hypothetical interest rates on our financial instruments. This
analysis does not consider the effect of any change in overall
economic activity that could occur in that environment. Further,
in the event of a change of the magnitude discussed above, we
may take actions to further mitigate our exposure to the change.
However, due to the uncertainty of the specific actions that
would be taken and their possible effects, this analysis assumes
no changes in our financial structure.
In order to modify and manage the interest rate characteristics
of our outstanding debt and to limit the effects of interest
rate risks on our operations, we may utilize a variety of
financial instruments, including interest rate swaps, caps and
treasury locks in order to mitigate our interest rate risk on a
related financial instrument. The use of these types of
instruments to hedge our exposure to changes in interest rates
carries additional risks, including counterparty credit risk,
the enforceability of hedging contracts and the risk that
unanticipated and significant changes in interest rates will
cause a significant loss of basis in the contract. To limit
counterparty credit risk we will seek to enter into such
agreements with major financial institutions with high credit
ratings. There can be no assurance that we will be able to
adequately protect against the foregoing risks and will
ultimately realize an economic benefit that exceeds the related
amounts incurred in connection with engaging in such hedging
activities. We do not enter into such contracts for speculative
or trading purposes.
51
|
|
Item 8.
|
Financial
Statements and Supplementary Data
|
INDEX TO
CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
|
|
|
|
Page
|
|
|
|
|
53
|
|
|
|
|
55
|
|
|
|
|
56
|
|
|
|
|
57
|
|
|
|
|
58
|
|
|
|
|
59
|
|
|
|
|
61
|
|
|
|
|
89
|
|
52
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors
BioMed Realty Trust, Inc.:
We have audited the accompanying consolidated balance sheets of
BioMed Realty Trust, Inc. and subsidiaries (the Company) as of
December 31, 2007 and 2006, and the related consolidated
statements of income, stockholders equity, comprehensive
income and cash flows for each of the years in the three-year
period ended December 31, 2007. In connection with our
audits of the consolidated financial statements, we also have
audited the accompanying financial statement schedule III
of the Company. We also have audited the Companys internal
control over financial reporting as of December 31, 2007,
based on criteria established in Internal Control
Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO). The
Companys management is responsible for these consolidated
financial statements and financial statement schedule, for
maintaining effective internal control over financial reporting,
and for its assessment of the effectiveness of internal control
over financial reporting, included in the accompanying
Managements Report on Internal Control Over Financial
Reporting. Our responsibility is to express an opinion on these
consolidated financial statements and financial statement
schedule, and an opinion on the Companys internal control
over financial reporting based on our audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are
free of material misstatement and whether effective internal
control over financial reporting was maintained in all material
respects. Our audits of the consolidated financial statements
included examining, on a test basis, evidence supporting the
amounts and disclosures in the financial statements, assessing
the accounting principles used and significant estimates made by
management, and evaluating the overall financial statement
presentation. Our audit of internal control over financial
reporting included obtaining an understanding of internal
control over financial reporting, assessing the risk that a
material weakness exists, and testing and evaluating the design
and operating effectiveness of internal control based on the
assessed risk. Our audits also included performing such other
procedures as we considered necessary in the circumstances. We
believe that our audits provide a reasonable basis for our
opinions.
A companys internal control over financial reporting is a
process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with
generally accepted accounting principles. A companys
internal control over financial reporting includes those
policies and procedures that (1) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the
company; (2) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company
are being made only in accordance with authorizations of
management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the
companys assets that could have a material effect on the
financial statements.
Because of its inherent limitations, internal control over
financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.
53
In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the financial
position of the Company as of December 31, 2007 and 2006,
and the results of its operations and its cash flows for each of
the years in the three-year period ended December 31, 2007,
in conformity with accounting principles generally accepted in
the United States of America. Additionally, in our opinion, the
related financial statement schedule, when considered in
relation to the basic consolidated financial statements taken as
a whole, presents fairly, in all material respects, the
information set forth therein. Also in our opinion, the Company
maintained, in all material respects, effective internal control
over financial reporting as of December 31, 2007, based on
criteria established in Internal Control Integrated
Framework issued by the Committee of Sponsoring Organizations of
the Treadway Commission.
KPMG LLP
San Diego, California
February 28, 2008
54
BIOMED
REALTY TRUST, INC.
CONSOLIDATED
BALANCE SHEETS
(In
thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
ASSETS
|
Investments in real estate, net
|
|
$
|
2,805,983
|
|
|
$
|
2,457,538
|
|
Investment in unconsolidated partnerships
|
|
|
22,588
|
|
|
|
2,436
|
|
Cash and cash equivalents
|
|
|
13,479
|
|
|
|
25,664
|
|
Restricted cash
|
|
|
8,867
|
|
|
|
6,426
|
|
Accounts receivable, net
|
|
|
4,457
|
|
|
|
5,985
|
|
Accrued straight-line rents, net
|
|
|
36,415
|
|
|
|
20,446
|
|
Acquired above-market leases, net
|
|
|
5,745
|
|
|
|
7,551
|
|
Deferred leasing costs, net
|
|
|
116,491
|
|
|
|
129,322
|
|
Deferred loan costs, net
|
|
|
15,567
|
|
|
|
17,608
|
|
Other assets
|
|
|
27,676
|
|
|
|
19,666
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
3,057,268
|
|
|
$
|
2,692,642
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY
|
Mortgage notes payable, net
|
|
$
|
379,680
|
|
|
$
|
403,836
|
|
Secured construction loan
|
|
|
425,160
|
|
|
|
286,355
|
|
Secured term loan
|
|
|
250,000
|
|
|
|
250,000
|
|
Exchangeable senior notes
|
|
|
175,000
|
|
|
|
175,000
|
|
Unsecured line of credit
|
|
|
270,947
|
|
|
|
228,165
|
|
Security deposits
|
|
|
7,090
|
|
|
|
7,704
|
|
Dividends and distributions payable
|
|
|
25,596
|
|
|
|
19,847
|
|
Accounts payable, accrued expenses and other liabilities
|
|
|
95,871
|
|
|
|
62,602
|
|
Acquired below-market leases, net
|
|
|
23,708
|
|
|
|
25,101
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
1,653,052
|
|
|
|
1,458,610
|
|
Minority interests
|
|
|
17,280
|
|
|
|
19,319
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
Preferred stock, $.01 par value, 15,000,000 shares
authorized: 7.375% Series A cumulative redeemable preferred
stock, $230,000,000 liquidation preference ($25.00 per share),
9,200,000 shares issued and outstanding at
December 31, 2007
|
|
|
222,413
|
|
|
|
|
|
Common stock, $.01 par value, 100,000,000 shares
authorized, 65,571,304 and 65,425,598 shares issued and
outstanding at December 31, 2007 and 2006, respectively
|
|
|
656
|
|
|
|
654
|
|
Additional paid-in capital
|
|
|
1,277,770
|
|
|
|
1,272,243
|
|
Accumulated other comprehensive (loss)/income
|
|
|
(21,762
|
)
|
|
|
8,417
|
|
Dividends in excess of earnings
|
|
|
(92,141
|
)
|
|
|
(66,601
|
)
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
1,386,936
|
|
|
|
1,214,713
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity
|
|
$
|
3,057,268
|
|
|
$
|
2,692,642
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
55
BIOMED
REALTY TRUST, INC.
CONSOLIDATED
STATEMENTS OF INCOME
(In
thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
Rental
|
|
$
|
195,996
|
|
|
$
|
164,487
|
|
|
$
|
92,590
|
|
Tenant recoveries
|
|
|
61,735
|
|
|
|
54,160
|
|
|
|
42,220
|
|
Other income
|
|
|
8,378
|
|
|
|
88
|
|
|
|
3,974
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
266,109
|
|
|
|
218,735
|
|
|
|
138,784
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Rental operations
|
|
|
50,789
|
|
|
|
40,623
|
|
|
|
34,496
|
|
Real estate taxes
|
|
|
20,353
|
|
|
|
20,376
|
|
|
|
11,862
|
|
Depreciation and amortization
|
|
|
72,202
|
|
|
|
65,063
|
|
|
|
39,378
|
|
General and administrative
|
|
|
21,870
|
|
|
|
18,085
|
|
|
|
13,278
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
165,214
|
|
|
|
144,147
|
|
|
|
99,014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations
|
|
|
100,895
|
|
|
|
74,588
|
|
|
|
39,770
|
|
Equity in net (loss)/income of unconsolidated partnerships
|
|
|
(893
|
)
|
|
|
83
|
|
|
|
119
|
|
Interest income
|
|
|
990
|
|
|
|
1,102
|
|
|
|
1,333
|
|
Interest expense
|
|
|
(27,654
|
)
|
|
|
(40,672
|
)
|
|
|
(23,226
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before minority interests
|
|
|
73,338
|
|
|
|
35,101
|
|
|
|
17,996
|
|
Minority interests in continuing operations of consolidated
partnerships
|
|
|
(45
|
)
|
|
|
137
|
|
|
|
267
|
|
Minority interests in continuing operations of operating
partnership
|
|
|
(2,412
|
)
|
|
|
(1,670
|
)
|
|
|
(1,271
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
70,881
|
|
|
|
33,568
|
|
|
|
16,992
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations before gain on sale of
assets and minority interests
|
|
|
639
|
|
|
|
1,542
|
|
|
|
57
|
|
Gain on sale of real estate assets
|
|
|
1,087
|
|
|
|
|
|
|
|
|
|
Minority interests attributable to discontinued operations
|
|
|
(74
|
)
|
|
|
(77
|
)
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations
|
|
|
1,652
|
|
|
|
1,465
|
|
|
|
54
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
72,533
|
|
|
|
35,033
|
|
|
|
17,046
|
|
Preferred stock dividends
|
|
|
(16,868
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income available to common stockholders
|
|
$
|
55,665
|
|
|
$
|
35,033
|
|
|
$
|
17,046
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations per share available to common
stockholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share
|
|
$
|
0.83
|
|
|
$
|
0.60
|
|
|
$
|
0.44
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share
|
|
$
|
0.83
|
|
|
$
|
0.60
|
|
|
$
|
0.43
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share
|
|
$
|
0.02
|
|
|
$
|
0.03
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share
|
|
$
|
0.02
|
|
|
$
|
0.02
|
|
|
$
|
0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share available to common stockholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share
|
|
$
|
0.85
|
|
|
$
|
0.63
|
|
|
$
|
0.44
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share
|
|
$
|
0.85
|
|
|
$
|
0.62
|
|
|
$
|
0.44
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
65,302,794
|
|
|
|
55,928,595
|
|
|
|
38,913,103
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
68,269,985
|
|
|
|
59,018,004
|
|
|
|
42,091,195
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
56
BIOMED
REALTY TRUST, INC.
CONSOLIDATED
STATEMENTS OF STOCKHOLDERS EQUITY
(In
thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
Series A
|
|
|
|
|
|
|
|
|
Additional
|
|
|
Other
|
|
|
Dividends in
|
|
|
|
|
|
|
Preferred
|
|
|
Common Stock
|
|
|
Paid-In
|
|
|
Comprehensive
|
|
|
Excess of
|
|
|
|
|
|
|
Stock
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
(Loss)/Income
|
|
|
Earnings
|
|
|
Total
|
|
|
Balance at December 31, 2004
|
|
$
|
|
|
|
|
31,386,333
|
|
|
$
|
314
|
|
|
$
|
429,893
|
|
|
$
|
|
|
|
$
|
(8,390
|
)
|
|
$
|
421,817
|
|
Net proceeds from sale of common stock
|
|
|
|
|
|
|
15,122,500
|
|
|
|
151
|
|
|
|
323,869
|
|
|
|
|
|
|
|
|
|
|
|
324,020
|
|
Net issuances of unvested restricted common stock
|
|
|
|
|
|
|
125,599
|
|
|
|
1
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Vesting of share-based awards
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,830
|
|
|
|
|
|
|
|
|
|
|
|
3,830
|
|
Common stock dividends
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(42,160
|
)
|
|
|
(42,160
|
)
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17,046
|
|
|
|
17,046
|
|
Unrealized gain on cash flow hedge
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,922
|
|
|
|
|
|
|
|
5,922
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2005
|
|
|
|
|
|
|
46,634,432
|
|
|
|
466
|
|
|
|
757,591
|
|
|
|
5,922
|
|
|
|
(33,504
|
)
|
|
|
730,475
|
|
Net proceeds from sale of common stock
|
|
|
|
|
|
|
18,428,750
|
|
|
|
184
|
|
|
|
506,587
|
|
|
|
|
|
|
|
|
|
|
|
506,771
|
|
Net proceeds from exercise of warrant
|
|
|
|
|
|
|
270,000
|
|
|
|
3
|
|
|
|
4,047
|
|
|
|
|
|
|
|
|
|
|
|
4,050
|
|
Net issuances of unvested restricted common stock
|
|
|
|
|
|
|
92,416
|
|
|
|
1
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Vesting of share-based awards
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,019
|
|
|
|
|
|
|
|
|
|
|
|
4,019
|
|
Common stock dividends
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(68,130
|
)
|
|
|
(68,130
|
)
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35,033
|
|
|
|
35,033
|
|
Unrealized gain on cash flow hedges
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,495
|
|
|
|
|
|
|
|
2,495
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2006
|
|
|
|
|
|
|
65,425,598
|
|
|
|
654
|
|
|
|
1,272,243
|
|
|
|
8,417
|
|
|
|
(66,601
|
)
|
|
|
1,214,713
|
|
Net proceeds from sale of preferred stock
|
|
|
222,413
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
222,413
|
|
Net issuances of unvested restricted common stock
|
|
|
|
|
|
|
145,706
|
|
|
|
2
|
|
|
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Vesting of share-based awards
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,529
|
|
|
|
|
|
|
|
|
|
|
|
5,529
|
|
Common stock dividends
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(81,205
|
)
|
|
|
(81,205
|
)
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
72,533
|
|
|
|
72,533
|
|
Preferred stock dividends
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(16,868
|
)
|
|
|
(16,868
|
)
|
Unrealized loss on cash flow hedges
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(30,179
|
)
|
|
|
|
|
|
|
(30,179
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2007
|
|
$
|
222,413
|
|
|
|
65,571,304
|
|
|
$
|
656
|
|
|
$
|
1,277,770
|
|
|
$
|
(21,762
|
)
|
|
$
|
(92,141
|
)
|
|
$
|
1,386,936
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
57
BIOMED
REALTY TRUST, INC.
CONSOLIDATED
STATEMENTS OF COMPREHENSIVE INCOME
(In
thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Net income
|
|
$
|
72,533
|
|
|
$
|
35,033
|
|
|
$
|
17,046
|
|
Preferred stock dividends
|
|
|
(16,868
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income available to common stockholders
|
|
|
55,665
|
|
|
$
|
35,033
|
|
|
|
17,046
|
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized (loss)/gain on cash flow hedges
|
|
|
(30,179
|
)
|
|
|
2,495
|
|
|
|
5,922
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
$
|
25,486
|
|
|
$
|
37,528
|
|
|
$
|
22,968
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to consolidated financial statements.
58
BIOMED
REALTY TRUST, INC.
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(In
thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
72,533
|
|
|
$
|
35,033
|
|
|
$
|
17,046
|
|
Adjustments to reconcile net income to net cash provided by
operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on sale of real estate assets
|
|
|
(1,087
|
)
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
72,429
|
|
|
|
65,610
|
|
|
|
39,378
|
|
Minority interests in consolidated partnerships
|
|
|
45
|
|
|
|
(137
|
)
|
|
|
(267
|
)
|
Minority interests in operating partnership
|
|
|
2,486
|
|
|
|
1,747
|
|
|
|
1,274
|
|
Allowance for doubtful accounts
|
|
|
232
|
|
|
|
193
|
|
|
|
257
|
|
Revenue reduction attributable to acquired above-market leases
|
|
|
2,451
|
|
|
|
2,471
|
|
|
|
1,524
|
|
Revenue recognized related to acquired below-market leases
|
|
|
(5,859
|
)
|
|
|
(4,811
|
)
|
|
|
(3,332
|
)
|
Compensation expense related to restricted common stock and LTIP
units
|
|
|
6,229
|
|
|
|
4,019
|
|
|
|
3,830
|
|
Amortization of deferred loan costs
|
|
|
3,195
|
|
|
|
1,925
|
|
|
|
1,002
|
|
Write off of deferred loan costs due to repayment and
extinguishment of debt
|
|
|
|
|
|
|
|
|
|
|
2,002
|
|
Amortization of debt premium on mortgage notes payable
|
|
|
(827
|
)
|
|
|
(2,148
|
)
|
|
|
(1,761
|
)
|
Loss/(income) from unconsolidated partnerships
|
|
|
893
|
|
|
|
(83
|
)
|
|
|
(119
|
)
|
Distributions received from unconsolidated partnerships
|
|
|
357
|
|
|
|
130
|
|
|
|
106
|
|
Distributions to minority interest in consolidated partnerships
|
|
|
(108
|
)
|
|
|
|
|
|
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted cash
|
|
|
(2,441
|
)
|
|
|
(939
|
)
|
|
|
(3,017
|
)
|
Accounts receivable
|
|
|
1,296
|
|
|
|
3,695
|
|
|
|
(8,293
|
)
|
Accrued straight-line rents
|
|
|
(15,969
|
)
|
|
|
(11,715
|
)
|
|
|
(5,425
|
)
|
Deferred leasing costs
|
|
|
(9,664
|
)
|
|
|
(3,070
|
)
|
|
|
(1,196
|
)
|
Other assets
|
|
|
(2,231
|
)
|
|
|
(3,620
|
)
|
|
|
187
|
|
Due to affiliates
|
|
|
|
|
|
|
|
|
|
|
(53
|
)
|
Security deposits
|
|
|
(587
|
)
|
|
|
79
|
|
|
|
1,000
|
|
Accounts payable, accrued expenses and other liabilities
|
|
|
(8,530
|
)
|
|
|
13,156
|
|
|
|
10,619
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
114,843
|
|
|
|
101,535
|
|
|
|
54,762
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases of interests in and additions to investments in real
estate and related intangible assets
|
|
|
(394,504
|
)
|
|
|
(1,340,204
|
)
|
|
|
(604,462
|
)
|
Purchases of interests in unconsolidated partnerships
|
|
|
(21,402
|
)
|
|
|
|
|
|
|
|
|
Proceeds from sale of real estate assets, net of selling costs
|
|
|
19,389
|
|
|
|
|
|
|
|
|
|
Minority interest investment in consolidated partnerships
|
|
|
205
|
|
|
|
449
|
|
|
|
594
|
|
Receipts of master lease payments
|
|
|
928
|
|
|
|
726
|
|
|
|
2,025
|
|
Security deposits received from prior owners of rental properties
|
|
|
|
|
|
|
720
|
|
|
|
1,074
|
|
Redemption of operating partnership units for cash
|
|
|
|
|
|
|
|
|
|
|
(173
|
)
|
Funds held in escrow for acquisitions
|
|
|
(12,900
|
)
|
|
|
|
|
|
|
(200
|
)
|
Additions to non-real estate assets
|
|
|
(1,017
|
)
|
|
|
(1,154
|
)
|
|
|
(663
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(409,301
|
)
|
|
|
(1,339,463
|
)
|
|
|
(601,805
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
59
BIOMED
REALTY TRUST, INC.
CONSOLIDATED
STATEMENTS OF CASH FLOWS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from common stock offering
|
|
|
|
|
|
|
528,783
|
|
|
|
340,257
|
|
Proceeds from exercise of stock warrant
|
|
|
|
|
|
|
4,050
|
|
|
|
|
|
Proceeds from preferred stock offering
|
|
|
230,000
|
|
|
|
|
|
|
|
|
|
Payment of common stock offering costs
|
|
|
|
|
|
|
(21,989
|
)
|
|
|
(16,678
|
)
|
Payment of preferred stock offering costs
|
|
|
(7,587
|
)
|
|
|
|
|
|
|
|
|
Payment of deferred loan costs
|
|
|
(3,856
|
)
|
|
|
(14,675
|
)
|
|
|
(6,192
|
)
|
Unsecured line of credit proceeds
|
|
|
286,237
|
|
|
|
620,476
|
|
|
|
244,175
|
|
Unsecured line of credit repayments
|
|
|
(243,455
|
)
|
|
|
(409,311
|
)
|
|
|
(227,175
|
)
|
Secured term loan proceeds
|
|
|
|
|
|
|
|
|
|
|
250,000
|
|
Unsecured term loan proceeds
|
|
|
|
|
|
|
|
|
|
|
100,000
|
|
Unsecured term loan payments
|
|
|
|
|
|
|
|
|
|
|
(100,000
|
)
|
Secured bridge loan proceeds
|
|
|
|
|
|
|
150,000
|
|
|
|
|
|
Secured bridge loan payments
|
|
|
|
|
|
|
(150,000
|
)
|
|
|
|
|
Exchangeable senior notes proceeds
|
|
|
|
|
|
|
175,000
|
|
|
|
|
|
Secured construction loan proceeds
|
|
|
138,805
|
|
|
|
286,355
|
|
|
|
|
|
Mortgage notes proceeds
|
|
|
|
|
|
|
147,000
|
|
|
|
|
|
Principal payments on mortgage notes payable
|
|
|
(21,579
|
)
|
|
|
(5,401
|
)
|
|
|
(3,759
|
)
|
Tenant improvement loan
|
|
|
|
|
|
|
(2,000
|
)
|
|
|
|
|
Tenant improvement loan repayments
|
|
|
122
|
|
|
|
53
|
|
|
|
|
|
Distributions to operating partnership unit holders
|
|
|
(3,936
|
)
|
|
|
(3,312
|
)
|
|
|
(3,098
|
)
|
Dividends paid to common stockholders
|
|
|
(79,851
|
)
|
|
|
(61,749
|
)
|
|
|
(38,044
|
)
|
Dividends paid to preferred stockholders
|
|
|
(12,627
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
282,273
|
|
|
|
1,243,280
|
|
|
|
539,486
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (decrease)/increase in cash and cash equivalents
|
|
|
(12,185
|
)
|
|
|
5,352
|
|
|
|
(7,557
|
)
|
Cash and cash equivalents at beginning of year
|
|
|
25,664
|
|
|
|
20,312
|
|
|
|
27,869
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of year
|
|
$
|
13,479
|
|
|
$
|
25,664
|
|
|
$
|
20,312
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow information:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for interest (net of amounts capitalized of $56,699,
$7,614, and $708, respectively)
|
|
$
|
25,154
|
|
|
$
|
33,965
|
|
|
$
|
20,291
|
|
Supplemental disclosure of non-cash investing and financing
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrual for common stock dividends declared
|
|
|
20,326
|
|
|
|
18,973
|
|
|
|
12,591
|
|
Accrual for preferred stock dividends declared
|
|
|
4,241
|
|
|
|
|
|
|
|
|
|
Accrual for distributions declared for operating partnership
unit and LTIP unit holders
|
|
|
1,029
|
|
|
|
874
|
|
|
|
773
|
|
Mortgage loans assumed (includes premium of $0, $1,037, and
$11,312, respectively)
|
|
|
|
|
|
|
18,460
|
|
|
|
149,517
|
|
Accrued additions to real estate and related intangible assets
|
|
|
46,783
|
|
|
|
29,680
|
|
|
|
4,812
|
|
See accompanying notes to consolidated financial statements.
60
BIOMED
REALTY TRUST, INC.
|
|
1.
|
Organization
and Description of Business
|
BioMed Realty Trust, Inc., a Maryland corporation (the
Company) was incorporated in Maryland on
April 30, 2004. On August 11, 2004, the Company
commenced operations after completing its initial public
offering. The Company operates as a fully integrated,
self-administered and self-managed real estate investment trust
(REIT) focused on acquiring, developing, owning,
leasing and managing laboratory and office space for the life
science industry principally through its subsidiary, BioMed
Realty, L.P., a Maryland limited partnership (its
Operating Partnership). The Companys tenants
primarily include biotechnology and pharmaceutical companies,
scientific research institutions, government agencies and other
entities involved in the life science industry. The
Companys properties are generally located in markets with
well established reputations as centers for scientific research,
including Boston, San Diego, San Francisco, Seattle,
Maryland, Pennsylvania and New York/New Jersey.
As of December 31, 2007, the Company owned or had interests
in 67 properties, located principally in Boston, San Diego,
San Francisco, Seattle, Maryland, Pennsylvania and New
York/New Jersey, consisting of 103 buildings with an operating
portfolio of approximately 6.6 million rentable square feet
of laboratory and office space, which was approximately 93.8%
leased to 112 tenants. Approximately 1.8 million square
feet was available for redevelopment. In addition, the Company
had properties constituting approximately 1.9 million
rentable square feet under construction and undeveloped land
that the Company estimates can support up to an additional
1.3 million rentable square feet of laboratory and office
space.
Information with respect to the number of properties, square
footage, and the percent of rentable square feet leased to
tenants is unaudited.
|
|
2.
|
Basis of
Presentation and Summary of Significant Accounting
Policies
|
Principles
of Consolidation
The consolidated financial statements include the accounts of
the Company, its wholly owned subsidiaries, partnerships and
limited liability companies it controls, and variable interest
entities for which the Company has determined itself to be the
primary beneficiary. All material intercompany transactions and
balances have been eliminated. The Company consolidates entities
the Company controls and records a minority interest for the
portions not owned by the Company. Control is determined, where
applicable, by the sufficiency of equity invested and the rights
of the equity holders, and by the ownership of a majority of the
voting interests, with consideration given to the existence of
approval or veto rights granted to the minority shareholder. If
the minority shareholder holds substantive participating rights,
it overcomes the presumption of control by the majority voting
interest holder. In contrast, if the minority shareholder simply
holds protective rights (such as consent rights over certain
actions), it does not overcome the presumption of control by the
majority voting interest holder.
Investments
in Partnerships
The Company evaluates its investments in limited liability
companies and partnerships under FASB Interpretation No. 46
(revised December 2003), Consolidation of Variable Interest
Entities (FIN 46R), an interpretation of
Accounting Research Bulletin No. 51, Consolidated
Financial Statements. FIN 46R provides guidance on the
identification of entities for which control is achieved through
means other than voting rights (variable interest
entities) and the determination of which business
enterprise should consolidate the variable interest entity (the
primary beneficiary). Generally, FIN 46R
applies when either (1) the equity investors (if any) lack
one or more of the essential characteristics of a controlling
financial interest, (2) the equity investment at risk is
insufficient to finance that entitys activities without
additional subordinated financial support or (3) the equity
investors have voting rights that are not proportionate to their
economic interests and the activities of the entity involve or
are conducted on behalf of an investor with a disproportionately
small voting interest.
If FIN 46R does not apply, the Company considers EITF Issue
No. 04-5,
Determining Whether a General Partner, or the General
Partners as a Group, Controls a Limited Partnership or Similar
Entity When the Limited
61
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Partners Have Certain Rights
(EITF 04-5),
which provides guidance in determining whether a general partner
controls a limited partnership.
EITF 04-5 states
that the general partner in a limited partnership is presumed to
control that limited partnership. The presumption may be
overcome if the limited partners have either (1) the
substantive ability to dissolve the limited partnership or
otherwise remove the general partner without cause or
(2) substantive participating rights, which provide the
limited partners with the ability to effectively participate in
significant decisions that would be expected to be made in the
ordinary course of the limited partnerships business and
thereby preclude the general partner from exercising unilateral
control over the partnership. If the criteria in
EITF 04-5
are met, the consolidation of the partnership or limited
liability company is required.
Except for investments that are consolidated in accordance with
FIN 46R or
EITF 04-5,
the Company accounts for investments in entities over which it
exercises significant influence, but does not control, under the
equity method of accounting. These investments are recorded
initially at cost and subsequently adjusted for equity in
earnings and cash contributions and distributions. Under the
equity method of accounting, the Companys net equity in
the investment is reflected in the consolidated balance sheets
and its share of net income or loss is included in the
Companys consolidated statements of income.
On a periodic basis, management assesses whether there are any
indicators that the carrying value of the Companys
investments in partnerships or limited liability companies may
be impaired on a more than temporary basis. An investment is
impaired only if managements estimate of the fair-value of
the investment is less than the carrying value of the investment
on a more than temporary basis. To the extent impairment has
occurred, the loss shall be measured as the excess of the
carrying value of the investment over the fair-value of the
investment. Management does not believe that the value of any of
the Companys investments in partnerships or limited
liability companies was impaired as of and through
December 31, 2007.
Investments
in Real Estate
Investments in real estate are carried at depreciated cost.
Depreciation and amortization are recorded on a straight-line
basis over the estimated useful lives of the assets as follows:
|
|
|
Buildings and improvements
|
|
15-40 years
|
Ground lease
|
|
Term of the related lease
|
Tenant improvements
|
|
Shorter of the useful lives or the terms of the related leases
|
Furniture, fixtures, and equipment (other assets)
|
|
3 to 5 years
|
Acquired in-place leases
|
|
Non-cancelable term of the related lease
|
Acquired management agreements
|
|
Non-cancelable term of the related agreement
|
Investments in real estate, net consists of the following (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Land
|
|
$
|
313,685
|
|
|
$
|
270,286
|
|
Ground lease(1)
|
|
|
|
|
|
|
14,210
|
|
Land under development
|
|
|
103,743
|
|
|
|
85,362
|
|
Buildings and improvements
|
|
|
1,675,530
|
|
|
|
1,598,384
|
|
Construction in progress
|
|
|
750,460
|
|
|
|
497,971
|
|
Tenant improvements
|
|
|
67,009
|
|
|
|
51,904
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,910,427
|
|
|
|
2,518,117
|
|
Accumulated depreciation
|
|
|
(104,444
|
)
|
|
|
(60,579
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
2,805,983
|
|
|
$
|
2,457,538
|
|
|
|
|
|
|
|
|
|
|
62
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
(1) |
|
During 2007, the Company acquired a fee simple interest in the
land at its Landmark at Eastview property. The balance of
$14.2 million was subsequently reclassified from ground
lease to land. |
Purchase accounting was applied, on a pro-rata basis where
appropriate, to the assets and liabilities of real estate
properties in which the Company acquired an interest or a
partial interest. The fair-value of tangible assets of an
acquired property (which includes land, buildings, and
improvements) is determined by valuing the property as if it
were vacant, and the as-if-vacant value is then
allocated to land, buildings and improvements based on
managements determination of the relative fair-value of
these assets. Factors considered by the Company in performing
these analyses include an estimate of the carrying costs during
the expected
lease-up
periods, current market conditions and costs to execute similar
leases. In estimating carrying costs, the Company includes real
estate taxes, insurance and other operating expenses and
estimates of lost rental revenue during the expected
lease-up
periods based on current market demand.
The aggregate value of other acquired intangible assets
consisting of acquired in-place leases and acquired management
agreements (see deferred leasing costs below) are recorded based
on a variety of considerations including, but not necessarily
limited to: (a) the value associated with avoiding the cost
of originating the acquired in-place leases (i.e. the market
cost to execute a lease, including leasing commissions and legal
fees, if any); (b) the value associated with lost revenue
related to tenant reimbursable operating costs estimated to be
incurred during the assumed
lease-up
period (i.e. real estate taxes and insurance); and (c) the
value associated with lost rental revenue from existing leases
during the assumed
lease-up
period. The fair-value assigned to the acquired management
agreements are recorded at the present value (using a discount
rate which reflects the risks associated with the management
agreements acquired) of the acquired management agreements with
certain tenants of the acquired properties. The values of
in-place leases and management agreements are amortized to
expense over the remaining non-cancelable period of the
respective leases or agreements. If a lease were to be
terminated prior to its stated expiration, all unamortized
amounts related to that lease would be written off.
Costs incurred in connection with the acquisition, development
or construction of properties and improvements are capitalized.
Capitalized costs include pre-construction costs essential to
the development of the property, development costs, construction
costs, interest costs, real estate taxes, salaries and related
costs and other direct costs incurred during the period of
development. The Company capitalizes costs on land and buildings
under development until construction is substantially complete
and the property is held available for occupancy. Determination
of when a development project is substantially complete and when
capitalization must cease involves a degree of judgment. The
Company considers a construction project as substantially
complete and held available for occupancy upon the completion of
tenant improvements, but no later than one year from cessation
of major construction activity. The Company ceases
capitalization on the portion substantially completed and
occupied or held available for occupancy, and capitalizes only
those costs associated with any remaining portion under
construction. Interest costs capitalized for the years ended
December 31, 2007, 2006, and 2005 were $56.7 million,
$7.6 million, and $708,000, respectively. Capitalized costs
associated with unsuccessful acquisitions are charged to expense
when an acquisition is no longer considered probable.
Repair and maintenance costs are charged to expense as incurred
and significant replacements and betterments are capitalized.
Repairs and maintenance costs include all costs that do not
extend the useful life of an asset or increase its operating
efficiency. Significant replacement and betterments represent
costs that extend an assets useful life or increase its
operating efficiency.
Impairment
of Long-Lived Assets and Long-Lived Assets to be
Disposed
The Company reviews long-lived assets and certain identifiable
intangibles for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may
not be recoverable. The review of recoverability is based on an
estimate of the future undiscounted cash flows (excluding
interest charges) expected to result from the long-lived
assets use and eventual disposition. These cash flows
consider factors such as expected
63
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
future operating income, trends and prospects, as well as the
effects of leasing demand, competition and other factors. If
impairment exists due to the inability to recover the carrying
value of a long-lived asset, an impairment loss is recorded to
the extent that the carrying value exceeds the estimated
fair-value of the property. The Company is required to make
subjective assessments as to whether there are impairments in
the values of its investments in long-lived assets. These
assessments have a direct impact on the Companys net
income because recording an impairment loss results in an
immediate negative adjustment to net income. The evaluation of
anticipated cash flows is highly subjective and is based in part
on assumptions regarding future occupancy, rental rates and
capital requirements that could differ materially from actual
results in future periods. Although the Companys strategy
is to hold its properties over the long-term, if the
Companys strategy changes or market conditions otherwise
dictate an earlier sale date, an impairment loss may be
recognized to reduce the property to the lower of the carrying
amount or fair-value less costs to sell, and such loss could be
material. If the Company determines that impairment has
occurred, the affected assets must be reduced to their
fair-value. As of and through December 31, 2007, no assets
have been identified as impaired and no such impairment losses
have been recognized.
Cash
and Cash Equivalents
Cash and cash equivalents consist of highly liquid investments
with original maturities of three months or less. We maintain
our cash at insured financial institutions. The combined account
balances at each institution periodically exceed FDIC insurance
coverage, and, as a result, there is a concentration of credit
risk related to amounts in excess of FDIC limits. The Company
believes that the risk is not significant.
Restricted
Cash
Restricted cash primarily consists of cash deposits for real
estate taxes, insurance and capital expenditures as required by
certain mortgage notes payable.
Deferred
Leasing Costs
Leasing commissions and other direct costs associated with
obtaining new or renewal leases are recorded at cost and
amortized on a straight-line basis over the terms of the
respective leases, with remaining terms ranging from two months
to sixteen years as of December 31, 2007. Deferred leasing
costs also include the net carrying value of acquired in-place
leases and acquired management agreements.
Deferred leasing costs, net at December 31, 2007 consisted
of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
Accumulated
|
|
|
|
|
|
|
December 31, 2007
|
|
|
Amortization
|
|
|
Net
|
|
|
Acquired in-place leases
|
|
$
|
167,664
|
|
|
$
|
(71,412
|
)
|
|
$
|
96,252
|
|
Acquired management agreements
|
|
|
12,921
|
|
|
|
(6,603
|
)
|
|
|
6,318
|
|
Deferred leasing and other direct costs
|
|
|
15,541
|
|
|
|
(1,620
|
)
|
|
|
13,921
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
196,126
|
|
|
$
|
(79,635
|
)
|
|
$
|
116,491
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred leasing costs, net at December 31, 2006 consisted
of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
Accumulated
|
|
|
|
|
|
|
December 31, 2006
|
|
|
Amortization
|
|
|
Net
|
|
|
Acquired in-place leases
|
|
$
|
162,935
|
|
|
$
|
(47,066
|
)
|
|
$
|
115,869
|
|
Acquired management agreements
|
|
|
12,601
|
|
|
|
(4,574
|
)
|
|
|
8,027
|
|
Deferred leasing and other direct costs
|
|
|
6,122
|
|
|
|
(696
|
)
|
|
|
5,426
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
181,658
|
|
|
$
|
(52,336
|
)
|
|
$
|
129,322
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
64
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The estimated amortization expense during the next five years
for deferred leasing costs at December 31, 2007 was as
follows (in thousands):
|
|
|
|
|
|
|
|
|
2008
|
|
|
|
|
|
$
|
23,760
|
|
2009
|
|
|
|
|
|
|
20,680
|
|
2010
|
|
|
|
|
|
|
14,093
|
|
2011
|
|
|
|
|
|
|
10,618
|
|
2012
|
|
|
|
|
|
|
9,578
|
|
Thereafter
|
|
|
|
|
|
|
37,762
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
116,491
|
|
|
|
|
|
|
|
|
|
|
Deferred
Loan Costs
External costs associated with obtaining long-term financing are
capitalized and amortized to interest expense over the terms of
the related loans using the effective-interest method.
Unamortized financing costs are charged to expense upon the
early repayment or significant modification of the financing.
Fully amortized deferred loan costs are removed from the books
upon maturity of the debt. The balance is net of
$11.0 million and $5.5 million of accumulated
amortization at December 31, 2007 and 2006, respectively.
Revenue
Recognition
The Company commences revenue recognition on its leases based on
a number of factors. In most cases, revenue recognition under a
lease begins when the lessee takes possession of or controls the
physical use of the leased asset. Generally, this occurs on the
lease commencement date. In determining what constitutes the
leased asset, the Company evaluates whether the Company or the
lessee is the owner, for accounting purposes, of the tenant
improvements. If the Company is the owner, for accounting
purposes, of the tenant improvements, then the leased asset is
the finished space and revenue recognition begins when the
lessee takes possession of the finished space, typically when
the improvements are substantially complete. If the Company
concludes that it is not the owner, for accounting purposes, of
the tenant improvements (the lessee is the owner), then the
leased asset is the unimproved space and any tenant improvement
allowances funded under the lease are treated as lease
incentives which reduce revenue recognized over the term of the
lease. In these circumstances, the Company begins revenue
recognition when the lessee takes possession of the unimproved
space for the lessee to construct improvements. The
determination of who is the owner, for accounting purposes, of
the tenant improvements determines the nature of the leased
asset and when revenue recognition under a lease begins. The
Company considers a number of different factors to evaluate
whether it or the lessee is the owner of the tenant improvements
for accounting purposes. These factors include:
|
|
|
|
|
whether the lease stipulates how and on what a tenant
improvement allowance may be spent;
|
|
|
|
whether the tenant or landlord retain legal title to the
improvements;
|
|
|
|
the uniqueness of the improvements;
|
|
|
|
the expected economic life of the tenant improvements relative
to the length of the lease;
|
|
|
|
the responsible party for construction cost overruns; and
|
|
|
|
who constructs or directs the construction of the improvements.
|
The determination of who owns the tenant improvements, for
accounting purposes, is subject to significant judgment. In
making that determination, the Company considers all of the
above factors. However, no one factor is determinative in
reaching a conclusion.
65
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
All leases are classified as operating leases and minimum rents
are recognized on a straight-line basis over the term of the
related lease. The excess of rents recognized over amounts
contractually due pursuant to the underlying leases are included
in accrued straight-line rents on the accompanying consolidated
balance sheets and contractually due but unpaid rents are
included in accounts receivable. Existing leases at acquired
properties are reviewed at the time of acquisition to determine
if contractual rents are above or below current market rents for
the acquired property. An identifiable lease intangible asset or
liability is recorded based on the present value (using a
discount rate that reflects the risks associated with the
acquired leases) of the difference between (1) the
contractual amounts to be paid pursuant to the in-place leases
and (2) the Companys estimate of the fair market
lease rates for the corresponding in-place leases at
acquisition, measured over a period equal to the remaining
non-cancelable term of the leases and any fixed rate renewal
periods (based on the Companys assessment of the
likelihood that the renewal periods will be exercised). The
capitalized above-market lease values are amortized as a
reduction of rental revenue over the remaining non-cancelable
terms of the respective leases. The capitalized below-market
lease values are amortized as an increase to rental revenue over
the remaining non-cancelable terms of the respective leases. If
a tenant vacates its space prior to the contractual termination
of the lease and no rental payments are being made on the lease,
any unamortized balance of the related intangible will be
written off.
The impact of the straight-line rent adjustment increased
revenue for the Company by $16.5 million,
$11.7 million, and $5.6 million for the years ended
December 31, 2007, 2006, and 2005, respectively.
Additionally, the impact of the amortization of acquired
above-market leases and acquired below-market leases increased
rental revenues by $3.4 million, $2.3 million, and
$1.8 million for the years ended December 31, 2007,
2006, and 2005, respectively. The amortization in 2005 includes
a $100,000 decrease to rental revenue due to the write off of an
above-market lease that was terminated at a property.
Total estimated minimum rentals under noncancelable operating
tenant leases in effect at December 31, 2007 were as
follows (in thousands):
|
|
|
|
|
|
|
|
|
2008
|
|
|
|
|
|
$
|
196,914
|
|
2009
|
|
|
|
|
|
|
221,815
|
|
2010
|
|
|
|
|
|
|
220,800
|
|
2011
|
|
|
|
|
|
|
210,427
|
|
2012
|
|
|
|
|
|
|
206,368
|
|
Thereafter
|
|
|
|
|
|
|
1,801,485
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
2,857,809
|
|
|
|
|
|
|
|
|
|
|
Acquired above-market leases, net consisted of the following (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Acquired above-market leases
|
|
$
|
12,729
|
|
|
$
|
12,084
|
|
Accumulated amortization
|
|
|
(6,984
|
)
|
|
|
(4,533
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
5,745
|
|
|
$
|
7,551
|
|
|
|
|
|
|
|
|
|
|
Acquired below-market leases, net consisted of the following (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Acquired below-market leases
|
|
$
|
37,961
|
|
|
$
|
33,495
|
|
Accumulated amortization
|
|
|
(14,253
|
)
|
|
|
(8,394
|
)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
23,708
|
|
|
$
|
25,101
|
|
|
|
|
|
|
|
|
|
|
66
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The estimated amortization during the next five years for
acquired above- and below-market leases at December 31,
2007 was as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
2009
|
|
|
2010
|
|
|
2011
|
|
|
2012
|
|
|
Thereafter
|
|
|
Total
|
|
|
Amortization of:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquired above-market leases
|
|
$
|
(1,416
|
)
|
|
$
|
(1,282
|
)
|
|
$
|
(1,222
|
)
|
|
$
|
(581
|
)
|
|
$
|
(314
|
)
|
|
$
|
(930
|
)
|
|
$
|
(5,745
|
)
|
Acquired below-market leases
|
|
|
5,800
|
|
|
|
5,220
|
|
|
|
4,167
|
|
|
|
1,618
|
|
|
|
1,618
|
|
|
|
5,285
|
|
|
|
23,708
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net rental revenues increase
|
|
$
|
4,384
|
|
|
$
|
3,938
|
|
|
$
|
2,945
|
|
|
$
|
1,037
|
|
|
$
|
1,304
|
|
|
$
|
4,355
|
|
|
$
|
17,963
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Substantially all rental operations expenses, consisting of real
estate taxes, insurance and common area maintenance costs are
recoverable from tenants under the terms of lease agreements.
Amounts recovered are dependent on several factors, including
occupancy and lease terms. Revenues are recognized in the period
the expenses are incurred. The reimbursements are recognized and
presented in accordance with
EITF 99-19,
Reporting Revenue Gross as a Principal versus Net as an Agent
(EITF 99-19).
EITF 99-19
requires that these reimbursements be recorded gross, as the
Company is generally the primary obligor with respect to
purchasing goods and services from third-party suppliers, has
discretion in selecting the supplier and bears the credit risk.
Lease termination fees are recognized when the related leases
are canceled, collectibility is assured, and we have no
continuing obligation to provide space to former tenants. A gain
on early termination of leases of $7.7 million and
$3.6 million for the years ended December 31, 2007 and
2005, respectively, is included in other income on the
consolidated statements of income. Approximately
$4.8 million of the gain on early termination of a lease
was recognized in 2007 as it did not meet revenue recognition
criteria in 2006 due to the execution of the lease termination
agreement on January 1, 2007. However, certain intangible
assets related to the lease were fully amortized as of
December 31, 2006. Lease commissions and other related
intangible assets in the amount of $1.6 million, $947,000
and $208,000 were fully amortized in the years ended
December 31, 2007, 2006, and 2005, respectively.
Payments received under master lease agreements entered into
with the sellers of the Bayshore and King of Prussia properties
to lease space that was not producing rent at the time of the
acquisition are recorded as a reduction to buildings and
improvements rather than as rental income in accordance with
EITF 85-27,
Recognition of Receipts from
Made-Up
Rental Shortfalls. Receipts under these master lease
agreements totaled $928,000, $726,000, and $2.0 million for
the years ended December 31, 2007, 2006, and 2005,
respectively.
Allowance
for Doubtful Accounts
The Company maintains an allowance for doubtful accounts for
estimated losses resulting from the inability of tenants to make
required rent and tenant recovery payments or defaults. We may
also maintain an allowance for accrued straight-line rents and
amounts due from lease terminations. The computation of this
allowance is based on the tenants payment history and
current credit status. Bad debt expense included in rental
operations expenses was $232,000, $193,000, and $257,000 for the
years ended December 31, 2007, 2006, and 2005,
respectively. The Companys allowance for doubtful accounts
was $1.5 million and $1.2 million as of
December 31, 2007 and 2006, respectively. Included in the
allowance for doubtful accounts was $1.0 million and
$532,000 related to master lease payments not expected to be
collected for the years ended December 31, 2007 and 2006,
respectively.
Share-Based
Payments
SFAS No. 123 (revised 2004), Share-Based
Payment, requires that all share-based payments to employees
be recognized in the income statement based on their fair-value.
The fair-value is recorded based on the market value of the
common stock on the grant date and is amortized to general and
administrative expense and rental operations expense over the
relevant service period, adjusted for anticipated forfeitures.
Through the year ended December 31,
67
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
2007, the Company only awarded restricted stock and LTIP unit
grants under its incentive award plan (see Note 9), which
are valued based on the market value of the underlying common
stock, and did not grant any stock options.
Derivative
Instruments
The Company records all derivatives on the balance sheet at
fair-value. The accounting for changes in the fair-value of
derivatives depends on the intended use of the derivative and
the resulting designation. Derivatives used to hedge the
exposure to changes in the fair-value of an asset, liability, or
firm commitment attributable to a particular risk, such as
interest rate risk, are considered fair-value hedges.
Derivatives used to hedge the exposure to variability in
expected future cash flows, or other types of forecasted
transactions, are considered cash flow hedges.
For derivatives designated as cash flow hedges, the effective
portion of changes in the fair-value of the derivative is
initially reported in other comprehensive income (outside of
earnings) and subsequently reclassified to earnings when the
hedged transaction affects earnings, and the ineffective portion
of changes in the fair-value of the derivative is recognized
directly in earnings. The Company assesses the effectiveness of
each hedging relationship by comparing the changes in cash flows
of the derivative hedging instrument with the changes in cash
flows of the designated hedged item or transaction.
The Companys objective in using derivatives is to add
stability to interest expense and to manage its exposure to
interest rate movements or other identified risks. To accomplish
this objective, the Company uses interest rate swaps as part of
its cash flow hedging strategy. Interest rate swaps designated
as cash flow hedges involve the receipt of variable-rate amounts
in exchange for fixed-rate payments over the life of the
agreements without exchange of the underlying principal amount.
During 2007 and 2006, such derivatives were used to hedge the
variable cash flows associated with existing variable-rate debt
and future variability in the interest related cash flows from
forecasted issuances of debt (see Notes 6 and 12). The
Company formally documents the hedging relationships for all
derivative instruments, accounts for all of its interest rate
swap agreements as cash flow hedges, and does not use
derivatives for trading or speculative purposes.
Equity
Offering Costs
Underwriting commissions and offering costs are reflected as a
reduction of proceeds.
Income
Taxes
The Company has elected to be taxed as a REIT under
Sections 856 through 860 of the Internal Revenue Code of
1986, as amended. The Company believes it has qualified and
continues to qualify as a REIT. A REIT is generally not subject
to federal income tax on that portion of its taxable income that
is distributed to its stockholders. Accordingly, no provision
has been made for federal income taxes in the accompanying
consolidated financial statements. REITs are subject to a number
of organizational and operational requirements. If the Company
fails to qualify as a REIT in any taxable year, the Company will
be subject to federal income tax (including any applicable
alternative minimum tax) and, in most of the states, state
income tax on its taxable income at regular corporate tax rates.
The Company is subject to certain state and local taxes.
The Company has formed a taxable REIT subsidiary (the
TRS). In general, the TRS may perform non-customary
services for tenants, hold assets that we cannot hold directly
and, except for the operation or management of health care
facilities or lodging facilities or the providing of any person,
under a franchise, license or otherwise, rights to any brand
name under which any lodging facility or health care facility is
operated, may engage in any real estate or non-real estate
related business. The TRS is subject to corporate federal income
taxes on its taxable income at regular corporate tax rates.
There is no tax provision for the TRS for the periods presented
in the accompanying consolidated statements of income due to net
operating losses incurred. No tax benefits have been recorded
since it is not considered more likely than not that the
deferred tax asset related to the net operating loss
carryforwards will be utilized.
68
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Dividends
and Distributions
Earnings and profits, which determine the taxability of
dividends and distributions to stockholders, will differ from
income reported for financial reporting purposes due to the
difference for federal income tax purposes in the treatment of
revenue recognition, compensation expense, and in the estimated
useful lives of real estate assets used to compute depreciation.
The income tax treatment for dividends was as follows
(unaudited):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
Per Share
|
|
|
%
|
|
|
Per Share
|
|
|
%
|
|
|
Per Share
|
|
|
%
|
|
|
Common stock:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary income
|
|
$
|
0.98
|
|
|
|
80.52
|
%
|
|
$
|
1.06
|
|
|
|
99.07
|
%
|
|
$
|
1.01
|
|
|
|
100.00
|
%
|
Capital gain
|
|
|
0.02
|
|
|
|
1.38
|
%
|
|
|
|
|
|
|
0.00
|
%
|
|
|
|
|
|
|
0.00
|
%
|
Return of capital
|
|
|
0.22
|
|
|
|
18.10
|
%
|
|
|
0.01
|
|
|
|
0.93
|
%
|
|
|
|
|
|
|
0.00
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1.22
|
|
|
|
100.00
|
%
|
|
$
|
1.07
|
|
|
|
100.00
|
%
|
|
$
|
1.01
|
|
|
|
100.00
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary income
|
|
$
|
1.35
|
|
|
|
98.54
|
%
|
|
$
|
|
|
|
|
0.00
|
%
|
|
$
|
|
|
|
|
0.00
|
%
|
Capital gain
|
|
|
0.02
|
|
|
|
1.46
|
%
|
|
|
|
|
|
|
0.00
|
%
|
|
|
|
|
|
|
0.00
|
%
|
Return of capital
|
|
|
|
|
|
|
0.00
|
%
|
|
|
|
|
|
|
0.00
|
%
|
|
|
|
|
|
|
0.00
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1.37
|
|
|
|
100.00
|
%
|
|
$
|
|
|
|
|
0.00
|
%
|
|
$
|
|
|
|
|
0.00
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Managements
Estimates
Management has made a number of estimates and assumptions
relating to the reporting of assets and liabilities and the
disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the reporting of
revenue and expenses during the reporting period to prepare
these consolidated financial statements in conformity with
U.S. generally accepted accounting principles. The Company
bases its estimates on historical experience and on various
other assumptions that are believed to be reasonable under the
circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities
and reported amounts of revenue and expenses that are not
readily apparent from other sources. Actual results could differ
from those estimates under different assumptions or conditions.
Management considers those estimates and assumptions that are
most important to the portrayal of the Companys financial
condition and results of operations, in that they require
managements most subjective judgments, to form the basis
for the accounting policies used by the Company. These estimates
and assumptions of items such as market rents, time required to
lease vacant spaces, lease terms for incoming tenants and credit
worthiness of tenants in determining the as-if-vacant value,
in-place lease value and above and below-market rents value are
utilized in allocating purchase price to tangible and identified
intangible assets upon acquisition of a property. These
accounting policies also include managements estimates of
useful lives in calculating depreciation expense on its
properties and the ultimate recoverability (or impairment) of
each property. If the useful lives of buildings and improvements
are different from the original estimate, it could result in
changes to the future results of operations of the Company.
Future adverse changes in market conditions or poor operating
results of our properties could result in losses or an inability
to recover the carrying value of the properties that may not be
reflected in the properties current carrying value,
thereby possibly requiring an impairment charge in the future.
69
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Segment
Information
The Companys properties share the following similar
economic and operating characteristics: (1) they have
similar forecasted returns (measured by capitalization rate at
acquisition), (2) they are generally occupied almost
exclusively by life science tenants that are public companies,
government agencies or their subsidiaries, (3) they are
generally located near areas of high life science concentrations
with similar demographics and site characteristics, (4) the
majority of properties are designed specifically for life
science tenants that require infrastructure improvements not
generally found in standard t properties, and (5) the
associated leases are primarily
triple-net
leases, generally with a fixed rental rate and scheduled annual
escalations, that provide for a recovery of close to 100% of
operating expenses. Consequently, the Companys properties
qualify for aggregation into one operating segment under the
provisions of SFAS No. 131, Disclosures about
Segments of an Enterprise and Related Information.
Reclassifications
Certain prior year amounts have been reclassified to conform to
the current year presentation.
Minority interests on the consolidated balance sheets relate
primarily to the partnership and LTIP units in the Operating
Partnership (collectively, the Units) that are not
owned by the Company. In conjunction with the formation of the
Company, certain persons and entities contributing interests in
properties to the Operating Partnership received partnership
units. In addition, certain limited partners of the Operating
Partnership have received LTIP units in connection with services
rendered or to be rendered to the Operating Partnership. Limited
partners who have been issued Units have the right to require
the Operating Partnership to redeem part or all of their Units
upon vesting of the Units, if applicable. The Company may elect
to acquire those Units in exchange for shares of the
Companys common stock on a one-for-one basis, subject to
adjustment in the event of stock splits, stock dividends,
issuance of stock rights, specified extraordinary distributions
and similar events, or pay cash based upon the fair market value
of an equivalent number of shares of the Companys common
stock at the time of redemption. In December 2005, a
non-managing partner of the operating partnership tendered 7,000
limited partnership units in exchange for $173,320, or $24.76
per share. The value of the Units not owned by the Company, had
such units been redeemed at December 31, 2007, was
approximately $78.9 million based on the average closing
price of the Companys common stock of $23.77 per share for
the ten consecutive trading days immediately preceding
December 31, 2007.
Vested ownership interests in the Operating Partnership were as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
Partnership Units
|
|
|
Percentage of
|
|
|
Partnership Units
|
|
|
Percentage of
|
|
|
|
and LTIP Units
|
|
|
Total
|
|
|
and LTIP Units
|
|
|
Total
|
|
|
BioMed Realty Trust
|
|
|
65,308,702
|
|
|
|
95.7
|
%
|
|
|
65,151,884
|
|
|
|
95.8
|
%
|
Minority interest consisting of:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Partnership and LTIP units held by employees and related parties
|
|
|
2,726,172
|
|
|
|
4.0
|
%
|
|
|
2,673,172
|
|
|
|
3.9
|
%
|
Partnership units held by third parties
|
|
|
190,392
|
|
|
|
0.3
|
%
|
|
|
190,392
|
|
|
|
0.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
68,225,266
|
|
|
|
100.0
|
%
|
|
|
68,015,448
|
|
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying consolidated financial statements include
investments in four variable interest entities in which the
Company is considered to be the primary beneficiary under
FIN 46R. As of December 31, 2007, the Company had a
70% interest in the limited liability company that owns the
Waples property, a 70% interest in the limited liability company
that owns the Fairview property, and an 87.5% interest in the
limited liability company
70
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
that owns the Ardenwood Venture property. These entities are
consolidated in the accompanying consolidated financial
statements. Equity interests in these partnerships not owned by
the Company are classified as minority interest on the
consolidated balance sheets as of December 31, 2007. On
October 1, 2007, pursuant to the exercise of a put option
by the minority interest limited partner in the limited
partnership that owned the King of Prussia property, the Company
completed the purchase of the remaining 11% interest for a
purchase price of approximately $1.8 million, excluding
closing costs.
During the year ended December 31, 2007, the Company issued
restricted stock awards to employees and to the members of its
board of directors totaling 141,965 shares and
12,000 shares, respectively, of common stock
(8,259 shares were forfeited during the same period), which
are included in the total of common stock outstanding as of the
period end (see Note 7). During the year ended
December 31, 2007, the Company also issued 304,050 LTIP
units to employees, which are included in the total of common
stock outstanding as of the period end (see Note 7).
In June 2007, the Company adopted a Dividend Reinvestment
Program and a Cash Option Purchase Plan (collectively, the
DRIP Plan) to provide existing stockholders of the
Company with an opportunity to invest automatically the cash
dividends paid upon shares of the Companys common stock
held by them, as well as permit existing and prospective
stockholders to make voluntary cash purchases. Participants may
elect to reinvest a portion of, or the full amount of cash
dividends paid, whereas optional cash purchases are normally
limited to a maximum amount of $10,000. In addition, the Company
may elect to establish a discount ranging from 0% to 5% from the
market price applicable to newly issued shares of common stock
purchased directly from the Company. The Company may change the
discount, initially set at 0%, at its discretion, but may not
change the discount more frequently than once in any three-month
period. Shares purchased under the DRIP Plan shall be, at the
Companys option, purchased from either
(1) authorized, but previously unissued shares of common
stock, (2) shares of common stock purchased in the open
market or privately negotiated transactions, or (3) a
combination of both.
Common
Stock, Partnership Units and LTIP Units
As of December 31, 2007, the Company had outstanding
65,571,304 shares of common stock and 2,863,564 and 454,716
partnership and LTIP units, respectively. A share of the
Companys common stock and the partnership and LTIP units
have essentially the same economic characteristics as they share
equally in the total net income or loss and distributions of the
Operating Partnership. The partnership units are further
discussed in Note 3 and the LTIP units are discussed in
Notes 3 and 9.
7.375%
Series A Cumulative Redeemable Preferred
Stock
As of December 31, 2007, the Company had outstanding
9,200,000 shares of 7.375% Series A cumulative
redeemable preferred stock, or Series A preferred stock.
Dividends are cumulative on the Series A preferred stock
from the date of original issuance in the amount of $1.84375 per
share each year, which is equivalent to 7.375% of the $25.00
liquidation preference per share. Dividends on the Series A
preferred stock are payable quarterly in arrears on or about the
15th day of January, April, July and October of each year.
Following a change in control, if the Series A preferred
stock is not listed on the New York Stock Exchange, the American
Stock Exchange or the Nasdaq Global Market, holders will be
entitled to receive (when and as authorized by the board of
directors and declared by the Company), cumulative cash
dividends from, but excluding, the first date on which both the
change of control and the delisting occurs at an increased rate
of 8.375% per annum of the $25.00 liquidation preference per
share (equivalent to an annual rate of $2.09375 per share) for
as long as the Series A preferred stock is not listed. The
Series A preferred stock does not have a stated maturity
date and is not subject to any sinking fund or mandatory
redemption provisions. Upon liquidation, dissolution or winding
up, the Series A preferred stock will rank senior to the
Companys common stock with respect to the payment of
distributions and other amounts. The Company is not allowed to
redeem the Series A preferred stock before January 18,
2012, except in limited circumstances to preserve
71
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
its status as a REIT. On or after January 18, 2012, the
Company may, at its option, redeem the Series A preferred
stock, in whole or in part, at any time or from time to time,
for cash at a redemption price of $25.00 per share, plus all
accrued and unpaid dividends on such Series A preferred
stock up to, but excluding the redemption date. Holders of the
Series A preferred stock generally have no voting rights
except for limited voting rights if the Company fails to pay
dividends for six or more quarterly periods (whether or not
consecutive) and in certain other circumstances. The
Series A preferred stock is not convertible into or
exchangeable for any other property or securities of the Company.
Dividends
and Distributions
The following table lists the dividends and distributions made
by the Company and the Operating Partnership during the year
ended December 31, 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividend and
|
|
Dividend and
|
|
|
|
|
|
Amount Per
|
|
|
|
|
Distribution
|
|
Distribution Amount
|
|
Declaration Date
|
|
Securities Class
|
|
Share/Unit
|
|
|
Period Covered
|
|
Payable Date
|
|
(In thousands)
|
|
|
March 15, 2007
|
|
Common stock and partnership and LTIP units
|
|
$
|
0.31000
|
|
|
January 1, 2007 to March 31, 2007
|
|
April 16, 2007
|
|
$
|
21,309
|
|
March 15, 2007
|
|
Series A preferred stock
|
|
$
|
0.45582
|
|
|
January 18, 2007 to April 16, 2007
|
|
April 16, 2007
|
|
$
|
4,193
|
|
June 15, 2007
|
|
Common stock and partnership and LTIP units
|
|
$
|
0.31000
|
|
|
April 1, 2007 to June 30, 2007
|
|
July 16, 2007
|
|
$
|
21,315
|
|
June 15, 2007
|
|
Series A preferred stock
|
|
$
|
0.45582
|
|
|
April 17, 2007 to July 15, 2007
|
|
July 16, 2007
|
|
$
|
4,194
|
|
September 14, 2007
|
|
Common stock and partnership and LTIP units
|
|
$
|
0.31000
|
|
|
July 1, 2007 to September 30, 2007
|
|
October 15, 2007
|
|
$
|
21,316
|
|
September 14, 2007
|
|
Series A preferred stock
|
|
$
|
0.46094
|
|
|
July 16, 2007 to October 15, 2007
|
|
October 15, 2007
|
|
$
|
4,240
|
|
December 12, 2007
|
|
Common stock and partnership and LTIP units
|
|
$
|
0.31000
|
|
|
October 1, 2007 to December 31, 2007
|
|
January 15, 2008
|
|
$
|
21,355
|
|
December 12, 2007
|
|
Series A preferred stock
|
|
$
|
0.46094
|
|
|
October 16, 2007 to January 15, 2007
|
|
January 15, 2008
|
|
$
|
4,241
|
|
Total 2007 dividends and distributions declared through
December 31, 2007:
|
|
|
|
|
Common stock, partnership units, and LTIP units
|
|
$
|
85,295
|
|
Series A preferred stock
|
|
|
16,868
|
|
|
|
|
|
|
|
|
$
|
102,163
|
|
|
|
|
|
|
72
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
5.
|
Mortgage
Notes Payable
|
A summary of the Companys outstanding consolidated
mortgage notes payable as of December 31, 2007 and 2006 was
as follows (principal balance in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective
|
|
|
Principal Balance
|
|
|
|
|
|
Stated Fixed
|
|
|
Interest
|
|
|
December 31,
|
|
|
|
|
|
Interest Rate
|
|
|
Rate
|
|
|
2007
|
|
|
2006
|
|
|
Maturity Date
|
|
Ardentech Court
|
|
|
7.25
|
%
|
|
|
5.06
|
%
|
|
$
|
4,564
|
|
|
$
|
4,658
|
|
|
July 1, 2012
|
Bayshore Boulevard
|
|
|
4.55
|
%
|
|
|
4.55
|
%
|
|
|
15,335
|
|
|
|
15,730
|
|
|
January 1, 2010
|
Bridgeview Technology Park I
|
|
|
8.07
|
%
|
|
|
5.04
|
%
|
|
|
11,508
|
|
|
|
11,625
|
|
|
January 1, 2011
|
Eisenhower Road
|
|
|
5.80
|
%
|
|
|
4.63
|
%
|
|
|
2,113
|
|
|
|
2,164
|
|
|
May 5, 2008
|
Elliott Avenue
|
|
|
7.38
|
%
|
|
|
4.63
|
%
|
|
|
|
|
|
|
16,020
|
|
|
November 24, 2007
|
40 Erie Street
|
|
|
7.34
|
%
|
|
|
4.90
|
%
|
|
|
17,625
|
|
|
|
18,676
|
|
|
August 1, 2008
|
500 Kendall Street (Kendall D)
|
|
|
6.38
|
%
|
|
|
5.45
|
%
|
|
|
69,437
|
|
|
|
70,963
|
|
|
December 1, 2018
|
Lucent Drive
|
|
|
5.50
|
%
|
|
|
5.50
|
%
|
|
|
5,543
|
|
|
|
5,733
|
|
|
January 21, 2015
|
Monte Villa Parkway
|
|
|
4.55
|
%
|
|
|
4.55
|
%
|
|
|
9,336
|
|
|
|
9,576
|
|
|
January 1, 2010
|
6828 Nancy Ridge Drive
|
|
|
7.15
|
%
|
|
|
5.38
|
%
|
|
|
6,785
|
|
|
|
6,872
|
|
|
September 1, 2012
|
Road to the Cure
|
|
|
6.70
|
%
|
|
|
5.78
|
%
|
|
|
15,427
|
|
|
|
15,657
|
|
|
January 31, 2014
|
Science Center Drive
|
|
|
7.65
|
%
|
|
|
5.04
|
%
|
|
|
11,301
|
|
|
|
11,444
|
|
|
July 1, 2011
|
Shady Grove Road
|
|
|
5.97
|
%
|
|
|
5.97
|
%
|
|
|
147,000
|
|
|
|
147,000
|
|
|
September 1, 2016
|
Sidney Street
|
|
|
7.23
|
%
|
|
|
5.11
|
%
|
|
|
29,986
|
|
|
|
30,732
|
|
|
June 1, 2012
|
9885 Towne Centre Drive
|
|
|
4.55
|
%
|
|
|
4.55
|
%
|
|
|
21,323
|
|
|
|
21,872
|
|
|
January 1, 2010
|
900 Uniqema Boulevard
|
|
|
8.61
|
%
|
|
|
5.61
|
%
|
|
|
1,509
|
|
|
|
1,648
|
|
|
May 1, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
368,792
|
|
|
|
390,370
|
|
|
|
Unamortized premiums
|
|
|
|
|
|
|
|
|
|
|
10,888
|
|
|
|
13,466
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
379,680
|
|
|
$
|
403,836
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The net carrying value of properties (investments in real
estate) secured by our mortgage notes payable was
$641.1 million and $705.7 million at December 31,
2007 and 2006, respectively.
Premiums were recorded upon assumption of the mortgage notes
payable at the time of acquisition to account for above-market
interest rates. Amortization of these premiums is recorded as a
reduction to interest expense over the remaining term of the
respective note using a method that approximates the
effective-interest method.
6. Credit
Facilities, Exchangeable Notes, and Other Debt
Instruments
Unsecured
Line of Credit
The Companys unsecured line of credit with KeyBank
National Association (KeyBank) and other lenders was
amended on August 1, 2007 to increase the borrowing
capacity from $500.0 million to $600.0 million and
extend the maturity date to August 1, 2011. The unsecured
line of credit bears interest at a floating rate equal to, at
the Companys option, either (1) reserve adjusted
LIBOR plus a spread which ranges from 100 to 155 basis
points, depending on the Companys leverage, or
(2) the higher of (a) the prime rate then in effect
plus a spread which ranges from 0 to 25 basis points, or
(b) the federal funds rate then in effect plus a spread
which ranges from 50 to 75 basis points, in each case,
depending on the Companys leverage. The Company may
increase the amount of the unsecured line of credit to
$1.0 billion subject to certain conditions. In addition,
the Company, at its sole discretion, may extend the maturity
date of the unsecured line of credit to August 1, 2012
after satisfying certain conditions and paying an extension fee
based on the then current facility commitment. In September
2007, the Company entered into three interest rate swap
agreements, which were intended to have the effect of initially
fixing the interest rate on $205.0 million of the unsecured
line of credit at a weighted-average rate of 5.9% through
September 2008. The Company has deferred the loan costs
associated with the subsequent amendments to the unsecured line
of credit,
73
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
which are being amortized to expense with the unamortized loan
costs from the original debt facility over the remaining term.
At December 31, 2007, the Company had $270.9 million
in outstanding borrowings on its unsecured line of credit, with
a weighted-average interest rate of 6.3% on the unhedged portion
of the outstanding debt of approximately $66.0 million.
Secured
Term Loan
The Companys $250.0 million secured term loan from
KeyBank and other lenders, which is secured by the
Companys interests in 14 of its properties, was amended on
August 1, 2007 and has a new maturity date of
August 1, 2012. The secured term loan bears interest at a
floating rate equal to, at the Companys option, either
(1) reserve-adjusted LIBOR plus 165 basis points or
(2) the higher of (a) the prime rate then in effect
plus 25 basis points or (b) the federal funds rate
then in effect plus 75 basis points. The secured term loan
is also secured by the Companys interest in any
distributions from these properties, a pledge of the equity
interests in a subsidiary owning one of these properties, and a
pledge of the equity interests in a subsidiary owning an
interest in another of these properties. The Company entered
into an interest rate swap agreement in connection with the
initial closing of the secured term loan, which has the effect
of fixing the interest rate on the secured term loan at 5.8%
until the interest rate swap expires in 2010. At
December 31, 2007, the Company had $250.0 million in
outstanding borrowings on its secured term loan.
The terms of the credit agreements for the unsecured line of
credit and secured term loan include certain restrictions and
covenants, which limit, among other things, the payment of
dividends and the incurrence of additional indebtedness and
liens. The terms also require compliance with financial ratios
relating to the minimum amounts of net worth, fixed charge
coverage, unsecured debt service coverage, the maximum amount of
secured, and secured recourse indebtedness, leverage ratio and
certain investment limitations. The dividend restriction
referred to above provides that, except to enable the Company to
continue to qualify as a REIT for federal income tax purposes,
the Company will not make distributions with respect to common
stock or other equity interests in an aggregate amount for the
preceding four fiscal quarters in excess of 95% of funds from
operations, as defined, for such period, subject to other
adjustments. Management believes that it was in compliance with
the covenants as of December 31, 2007.
Exchangeable
Senior Notes
On September 25, 2006, the Operating Partnership issued
$175.0 million aggregate principal amount of its 4.50%
Exchangeable Senior Notes due 2026 (the Notes). The
Notes are general senior unsecured obligations of the Operating
Partnership and rank equally in right of payment with all other
senior unsecured indebtedness of the Operating Partnership.
Interest at a rate of 4.50% per annum is payable on April 1 and
October 1 of each year, beginning on April 1, 2007, until
the stated maturity date of October 1, 2026. The terms of
the Notes are governed by an indenture, dated September 25,
2006, among the Operating Partnership, as issuer, the Company,
as guarantor, and U.S. Bank National Association, as
trustee. The Notes contain an exchange settlement feature, which
provides that the Notes may, on or after September 1, 2026
or under certain other circumstances, be exchangeable for cash
(up to the principal amount of the Notes) and, with respect to
excess exchange value, into, at the Companys option, cash,
shares of the Companys common stock or a combination of
cash and shares of common stock at the then applicable exchange
rate. The initial exchange rate is 26.4634 shares per
$1,000 principal amount of Notes, representing an exchange price
of approximately $37.79 per share. If certain designated events
occur on or prior to October 6, 2011 and a holder elects to
exchange Notes in connection with any such transaction, the
Company will increase the exchange rate by a number of
additional shares of common stock based on the date the
transaction becomes effective and the price paid per share of
common stock in the transaction, as set forth in the indenture
governing the Notes. The exchange rate may also be adjusted
under certain other circumstances, including the payment of cash
dividends in excess of $0.29 per share of common stock. The
increase in the quarterly cash dividend to $0.31 per share of
common stock for 2007 did not result in a material change to the
exchange rate. The Operating Partnership may redeem the Notes,
in whole or in part, at any time to preserve the Companys
status as a REIT or at any time on or after October 6, 2011
for cash at 100% of the principal amount plus accrued and unpaid
interest. The holders of the Notes have the right to require the
Operating Partnership to repurchase the Notes, in
74
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
whole or in part, for cash on each of October 1, 2011,
October 1, 2016 and October 1, 2021, or upon the
occurrence of a designated event, in each case for a repurchase
price equal to 100% of the principal amount of the Notes plus
accrued and unpaid interest. At December 31, 2007, the
Company had an aggregate principal amount of $175.0 million
outstanding under the Notes.
Secured
Construction Loan
The Companys $550.0 million secured construction loan
from KeyBank is secured by the Companys Center for Life
Science | Boston
property. The loan is separated into four tranches of notes,
tranches A, B-1, B-2 and C, and bears interest at a blended rate
equal to, at the Companys option, either (1) LIBOR
plus approximately 122.5 basis points or (2) the
higher of (a) the prime rate then in effect or (b) the
federal funds rate then in effect plus 50 basis points. The
loan matures on November 16, 2009, but the Company may
extend the maturity date to November 16, 2010 after
satisfying certain conditions and payment of an extension fee.
The construction loan requires interest only monthly payments
until the maturity date. The Company utilized a portion of the
borrowing capacity on the construction loan, along with
borrowings on its unsecured line of credit, to acquire the
Center for Life
Science | Boston
property and to fund construction activities. In September 2007,
the Company entered into an interest rate swap agreement, which
is intended to have the effect of initially fixing the interest
rate on $330.0 million of the secured construction loan at
a rate of 6.1% through September 2008. The loan includes certain
restrictions and covenants, which limit, among other things, the
incurrence of additional indebtedness and liens. The loan also
requires compliance with financial covenants relating to minimum
amounts of net worth, fixed charge coverage, and leverage ratio.
Management believes that it was in compliance with these
covenants as of December 31, 2007. At December 31,
2007, the Company had outstanding borrowings on the secured
construction loan of $425.2 million, with a
weighted-average interest rate of 6.2% on the unhedged portion
of the outstanding debt of approximately $95.2 million.
As of December 31, 2007, principal payments due for the
Companys consolidated indebtedness (mortgage notes payable
excluding debt premium of $10.9 million, unsecured line of
credit, secured term loan, the Notes, and the secured
construction loan, excluding the Companys proportionate
share of the indebtedness of its unconsolidated partnerships)
were as follows (in thousands):
|
|
|
|
|
2008
|
|
$
|
24,454
|
|
2009
|
|
|
430,186
|
|
2010
|
|
|
47,446
|
|
2011
|
|
|
297,167
|
|
2012
|
|
|
291,421
|
|
Thereafter
|
|
|
399,225
|
|
|
|
|
|
|
|
|
$
|
1,489,899
|
|
|
|
|
|
|
Earnings per share is calculated based on the weighted-average
number of shares of the Companys common stock outstanding
during the period. The effects of the outstanding Units, vesting
of unvested LTIP units and restricted stock that have been
granted, and a stock warrant issued in connection with the
Companys initial public offering that was exercised in
September 2006, using the treasury method, were dilutive and
included in the calculation of diluted weighted-average shares
for the year ended December 31, 2007 and 2006. No shares
were contingently issuable upon settlement of the excess
exchange value pursuant to the exchange settlement feature of
the Notes (originally issued in 2006 see
Note 6) as the weighted-average common stock price of
$25.92 and $28.97 for years ended December 31, 2007 and
2006, respectively, did not exceed the initial exchange price of
$37.79 per share. Therefore, potentially issuable shares
resulting from settlement of the Notes were not included in the
calculation of diluted weighted-average shares. No other shares
were considered antidilutive for the years ended
December 31, 2007, 2006, and 2005.
75
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Computations of basic and diluted earnings per share in
accordance with SFAS No. 128, Earnings per Share
(in thousands, except share data) were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Income from continuing operations and net income available
for common stockholders (basic earnings per share):
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
70,881
|
|
|
$
|
33,568
|
|
|
$
|
16,992
|
|
Preferred stock dividends
|
|
|
(16,868
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations available to common
stockholders
|
|
|
54,013
|
|
|
|
33,568
|
|
|
|
16,992
|
|
Income from discontinued operations
|
|
|
1,652
|
|
|
|
1,465
|
|
|
|
54
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income available to common stockholders
|
|
$
|
55,665
|
|
|
$
|
35,033
|
|
|
$
|
17,046
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations and net income available
for common stockholders (diluted earnings per share):
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations available to common
stockholders
|
|
$
|
54,013
|
|
|
$
|
33,568
|
|
|
$
|
16,992
|
|
Minority interests in continuing operations of operating
partnership
|
|
|
2,412
|
|
|
|
1,670
|
|
|
|
1,271
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations available to common
stockholders before minority interests in continuing operations
|
|
|
56,425
|
|
|
|
35,238
|
|
|
|
18,263
|
|
Income from discontinued operations
|
|
|
1,652
|
|
|
|
1,465
|
|
|
|
54
|
|
Minority interest in discontinued operations of operating
partnership
|
|
|
74
|
|
|
|
77
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income available to common stockholders before minority
interests
|
|
$
|
58,151
|
|
|
$
|
36,780
|
|
|
$
|
18,320
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
65,302,794
|
|
|
|
55,928,595
|
|
|
|
38,913,103
|
|
Incremental shares from assumed conversion/exercise:
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock warrant
|
|
|
|
|
|
|
94,155
|
|
|
|
92,488
|
|
Unvested restricted stock and LTIP units using the treasury
method
|
|
|
50,869
|
|
|
|
131,690
|
|
|
|
215,078
|
|
Operating partnership and LTIP units
|
|
|
2,916,322
|
|
|
|
2,863,564
|
|
|
|
2,870,526
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
68,269,985
|
|
|
|
59,018,004
|
|
|
|
42,091,195
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted earnings per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Income per share basic:
|
|
|
|
|
|
|
|
|
|
|
|
|
Income per share from continuing operations available to common
stockholders
|
|
$
|
0.83
|
|
|
$
|
0.60
|
|
|
$
|
0.44
|
|
Income per share from discontinued operations
|
|
|
0.02
|
|
|
|
0.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share available to common stockholders
|
|
$
|
0.85
|
|
|
$
|
0.63
|
|
|
$
|
0.44
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income per share diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
Income per share from continuing operations available to common
stockholders
|
|
$
|
0.83
|
|
|
$
|
0.60
|
|
|
$
|
0.43
|
|
Income per share from discontinued operations
|
|
|
0.02
|
|
|
|
0.02
|
|
|
|
0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share available to common stockholders
|
|
$
|
0.85
|
|
|
$
|
0.62
|
|
|
$
|
0.44
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
76
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
8.
|
Fair-Value
of Financial Instruments
|
SFAS No. 107, Disclosure about Fair-value of
Financial Instruments, requires the Company to disclose
fair-value information about all financial instruments, whether
or not recognized in the balance sheets, for which it is
practicable to estimate fair-value. The Companys
disclosures of estimated fair-value of financial instruments at
December 31, 2007 and 2006, respectively, were determined
using available market information and appropriate valuation
methods. Considerable judgment is necessary to interpret market
data and develop estimated fair-value. The use of different
market assumptions or estimation methods may have a material
effect on the estimated fair-value amounts.
The carrying amounts for cash and cash equivalents, restricted
cash, accounts receivable, security deposits, accounts payable,
accrued expenses and other liabilities approximate fair-value
due to the short-term nature of these instruments.
The Company calculates the fair-value of its mortgage notes
payable and other fixed rate debt based on a currently available
market rate assuming the loans are outstanding through maturity
and considering the collateral. In determining the current
market rate for fixed rate debt, a market spread is added to the
quoted yields on federal government treasury securities with
similar terms to debt.
The fair-value of variable rate debt approximates book value
because the interest rate is based on LIBOR plus a spread, which
approximates a market interest rate. In accordance with
SFAS No. 133, Accounting for Derivative Investment
and Hedging Activities, the carrying value of interest rate
swaps, as well as the underlying hedged liability, if
applicable, are reflected at their fair-value. The Company
relies on quotations from a third party to determine these
fair-values.
At December 31, 2007, the aggregate fair-value of the
Companys consolidated mortgage notes payable, unsecured
line of credit, secured construction loan, Notes, and secured
term loan was estimated to be $1.49 billion compared to the
carrying value of $1.50 billion. At December 31, 2006,
the aggregate fair-value of the Companys mortgage notes
payable, unsecured line of credit and secured term loan was
estimated to be $1.31 billion compared to the carrying
value of $1.34 billion. As of December 31, 2007 and
2006, the fair-value of the Companys proportionate share
of indebtedness in the unconsolidated partnerships approximated
its carrying value.
The Company has adopted the BioMed Realty Trust, Inc. and BioMed
Realty, L.P. 2004 Incentive Award Plan (the Plan).
The Plan provides for grants to directors, employees and
consultants of the Company and the Operating Partnership (and
their respective subsidiaries) of stock options, restricted
stock, LTIP units, stock appreciation rights, dividend
equivalents, and other incentive awards. The Company has
reserved 2,500,000 shares of common stock for issuance
pursuant to the Plan, subject to adjustments as set forth in the
Plan. As of December 31, 2007, 1,345,230 shares of
common stock or awards convertible into or exchangeable for
common stock remained available for future issuance under the
Plan. Each LTIP unit issued will count as one share of common
stock for purposes of calculating the limit on shares that may
be issued. Compensation cost for these incentive awards is
measured based on the fair-value of the award on the grant date
(fair value is calculated based on the closing price of the
Companys common stock on the date of grant) and is
recognized as expense over the respective vesting period, which
for restricted stock awards and LTIP units is generally two to
five years. Fully vested incentive awards may be settled for
either cash or stock depending on the Companys election
and the type of award granted. Participants are entitled to cash
dividends and may vote such awarded shares, but the sale or
transfer of such shares is limited during the restricted or
vesting period. Since inception, the Company has only awarded
restricted stock grants and LTIP units. The restricted stock
grants may only be settled for stock whereas the LTIP units may
be redeemed for either cash or common stock, at the
Companys election.
LTIP units represent a profits interest in the Operating
Partnership for services rendered or to be rendered by the LTIP
unit holder in its capacity as a partner, or in anticipation of
becoming a partner, in the Operating
77
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Partnership. Initially, LTIP units do not have full parity with
common units of the Operating Partnership with respect to
liquidating distributions, although LTIP unit holders receive
the same quarterly per unit distributions as common units and
may vote the LTIP units from the date of issuance. The LTIP
units are subject to vesting requirements, which lapse over a
specified period of time (normally three or five years from the
date of issuance). In addition, the LTIP units are generally
subject to a two-year
lock-up
period during which time the LTIP units may not be redeemed or
sold by the LTIP unit holder. Upon the occurrence of specified
events, LTIP units may over time achieve full parity with common
units of the Operating Partnership for all purposes. Upon
achieving full parity, and after the expiration of any vesting
and lock-up
periods, LTIP units may be redeemed for an equal number of the
Companys common stock or cash, at the Companys
election.
During the years ended December 31, 2007, 2006, and 2005
the Company granted 458,015 shares of unvested restricted
stock and LTIP units with an aggregate value of
$12.9 million, 243,232 shares of unvested restricted
stock and LTIP units with an aggregate value of
$6.7 million, and 129,674 shares of unvested
restricted stock with an aggregate value of $2.9 million
under the Plan, respectively. For the years ended
December 31, 2007, 2006, and 2005, a total of
209,818 shares, 163,194 shares, and
117,440 shares of restricted stock and LTIP units vested,
with fair-values of $6.0 million, $4.0 million, and
$2.6 million, respectively. For the years ended
December 31, 2007, 2006, and 2005 $6.2 million,
$4.0 million, and $3.8 million, respectively, of
stock-based compensation expense was recognized in general and
administrative expenses and rental operations expense. As of
December 31, 2007, total compensation expense related to
unvested awards of $13.0 million will be recognized in the
future over a weighted-average period of 3.2 years.
A summary of the Companys unvested restricted stock and
LTIP units is presented below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
Unvested Restricted
|
|
|
Average Grant-
|
|
|
|
Shares/LTIP Units
|
|
|
Date Fair-Value
|
|
|
Balance at December 31, 2004
|
|
|
336,333
|
|
|
$
|
15.03
|
|
Granted
|
|
|
129,674
|
|
|
|
22.31
|
|
Vested
|
|
|
(117,440
|
)
|
|
|
15.02
|
|
Forfeited
|
|
|
(4,075
|
)
|
|
|
20.99
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2005
|
|
|
344,492
|
|
|
|
17.70
|
|
Granted
|
|
|
243,232
|
|
|
|
27.75
|
|
Vested
|
|
|
(163,194
|
)
|
|
|
16.82
|
|
Forfeited
|
|
|
(150
|
)
|
|
|
26.70
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2006
|
|
|
424,380
|
|
|
|
23.79
|
|
Granted
|
|
|
458,015
|
|
|
|
28.14
|
|
Vested
|
|
|
(209,818
|
)
|
|
|
20.37
|
|
Forfeited
|
|
|
(8,259
|
)
|
|
|
28.17
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2007
|
|
|
664,318
|
|
|
$
|
27.81
|
|
|
|
|
|
|
|
|
|
|
78
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
10.
|
Investment
in Unconsolidated Partnerships
|
The accompanying consolidated financial statements include
investments in two limited liability companies with PREI, which
were formed in the second quarter of 2007, and in 10165 McKellar
Court, L.P. (McKellar Court), a limited partnership
with Quidel Corporation, the tenant which occupies the McKellar
Court property. One of the PREI limited liability companies,
PREI II LLC, is a variable interest entity as defined in
FIN 46R; however, the Company is not the primary
beneficiary. PREI will bear the majority of any losses. The
other PREI limited liability company, PREI I LLC, does not
qualify as a variable interest entity as defined in
FIN 46R. In addition, consolidation under
EITF 04-5
is not required as the Company does not control the limited
liability companies. The McKellar Court partnership is a
variable interest entity as defined in FIN 46R; however,
the Company is not the primary beneficiary. The limited partner
at McKellar Court is the only tenant in the property and will
bear the majority of any losses. As it does not control the
limited liability companies or the partnership, the Company
accounts for them under the equity method of accounting.
Significant accounting policies used by the unconsolidated
partnerships that own these properties are similar to those used
by the Company. General information on the PREI limited
liability companies and the McKellar Court partnership (each
referred to in this footnote individually as a
partnership and collectively as the
partnerships) as of December 31, 2007 (dollars
in thousands) was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Companys
|
|
|
Companys
|
|
|
|
|
|
|
|
|
|
|
Ownership
|
|
|
Economic
|
|
|
|
|
Acquisition
|
|
Name
|
|
Partner
|
|
Interest
|
|
|
Interest
|
|
|
Date Acquired
|
|
Price(1)
|
|
|
PREI I(2)
|
|
PREI
|
|
|
20
|
%
|
|
|
20%
|
|
|
April 4, 2007
|
|
$
|
466,252
|
|
PREI II(3)
|
|
PREI
|
|
|
20
|
%
|
|
|
20%
|
|
|
April 4, 2007
|
|
|
40,472
|
|
McKellar Court(4)
|
|
Quidel Corporation
|
|
|
21
|
%
|
|
|
21%(5
|
)
|
|
September 30, 2004
|
|
|
2,058
|
|
|
|
|
(1) |
|
The acquisition price represents the total purchase price for
the properties acquired by each partnership, excluding closing
costs. |
|
(2) |
|
PREI I LLC acquired a portfolio of properties in Cambridge,
Massachusetts comprised of a stabilized laboratory/building
totaling 184,445 square feet located at 320 Bent Street, a
37-unit
apartment building, an operating garage facility on Rogers
Street with 503 spaces, an operating below grade garage facility
at Kendall Square with approximately 1,400 spaces, and two
buildings currently under construction at 301 Binney Street and
650 East Kendall Street that the Company believes can support up
to 700,000 rentable square feet of laboratory and office
space. The 650 East Kendall Street site will also include a
below grade parking facility that the Company estimates can
support up to 560 spaces upon completion. |
|
|
|
Each of the PREI operating agreements includes a put/call option
whereby either member can cause the limited liability company to
sell certain properties in which it holds leasehold interests to
the Company at any time after the fifth anniversary and before
the seventh anniversary of the acquisition date. However, the
put/call option may be terminated prior to exercise under
certain circumstances. The put/call option purchase price is
based on a predetermined return on capital invested by PREI. If
the put/call option is exercised, the Company believes that it
would have adequate resources to fund the purchase price. |
|
|
|
The PREI limited liability companies jointly entered into a
secured acquisition and interim loan facility with KeyBank in
which the partnerships utilized approximately
$427.0 million to fund a portion of the purchase price for
the properties acquired in April 2007. The remaining funds
available will be utilized to fund future construction costs at
certain properties currently under development. Pursuant to the
loan facility, the Company executed guaranty agreements in which
it guaranteed the full completion of the construction at the 301
Binney Street property if PREI I LLC is unable or unwilling to
complete the project. |
|
(3) |
|
PREI II LLC acquired a portfolio of properties comprised of a
development parcel in Houston, Texas; a laboratory/office
building totaling 259,706 rentable square feet and fee
simple and leasehold interests in surrounding land parcels
located at the Science Park at Yale in New Haven, Connecticut;
and 25,000 rentable square feet of retail space and
additional pad sites for future development in Cambridge,
Massachusetts. On |
79
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
August 2, 2007, PREI II LLC completed the disposition of
the 25,000 square feet of retail and additional pad sites
in Cambridge, Massachusetts. The total sale price included
approximately $4.0 million contingently payable in June
2012 pursuant to a put/call option, exercisable on the earlier
of the extinguishment or expiration of development restrictions
placed on a portion of the development rights included in the
disposition. On September 28, 2007, PREI II LLC completed
the disposition of the laboratory/office building and the fee
simple and leasehold interests in surrounding land parcels in
New Haven, Connecticut. On December 28, 2007, PREI II LLC
completed the disposition of the development parcel in Houston,
Texas. None of the sales resulted in the recognition of a
material gain or loss. The Companys remaining investment
in PREI II LLC (maximum exposure to losses) was approximately
$809,000 at December 31, 2007. |
|
(4) |
|
The McKellar Court partnership holds a property comprised of a
two-story laboratory/office building totaling
72,863 rentable square feet located in San Diego,
California. The Companys investment in the McKellar Court
partnership (maximum exposure to losses) was approximately
$2.4 million at December 31, 2007. |
|
(5) |
|
The Companys economic interest in the McKellar Court
partnership entitles it to 75% of the gains upon a sale of the
property and 21% of the operating cash flows. |
The Company acts as the operating member or partner, as
applicable, and day-to-day manager for the partnerships. The
Company is entitled to receive fees for providing construction
and development services (as applicable) and management services
to the PREI limited liability companies. The Company earned
approximately $889,000 in fees for the year ended
December 31, 2007 for services provided to the PREI limited
liability companies.
The condensed combined balance sheets for all of the
Companys unconsolidated partnerships were as follows (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
Investments in real estate, net
|
|
$
|
522,277
|
|
|
$
|
15,061
|
|
Cash and cash equivalents (including restricted cash)
|
|
|
8,430
|
|
|
|
605
|
|
Intangible assets, net
|
|
|
17,552
|
|
|
|
|
|
Other assets
|
|
|
8,488
|
|
|
|
1,078
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
556,747
|
|
|
$
|
16,744
|
|
|
|
|
|
|
|
|
|
|
Liabilities and members equity:
|
|
|
|
|
|
|
|
|
Mortgage notes payable and secured loan
|
|
$
|
426,914
|
|
|
$
|
10,619
|
|
Other liabilities
|
|
|
23,215
|
|
|
|
285
|
|
Members equity
|
|
|
106,618
|
|
|
|
5,840
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and equity
|
|
$
|
556,747
|
|
|
$
|
16,744
|
|
|
|
|
|
|
|
|
|
|
Companys net investment in unconsolidated partnerships
|
|
$
|
22,588
|
|
|
$
|
2,436
|
|
|
|
|
|
|
|
|
|
|
In connection with the acquisition of certain properties by PREI
II LLC, the partnership assumed an obligation related to the
remediation of environmental conditions at parcels located in
Cambridge, Massachusetts. PREI II LLC has estimated the costs of
the remediation to be $3.6 million, which was recorded as
an increase to the assets acquired and the recognition of a
corresponding liability.
80
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The condensed combined statements of (loss)/income for the
unconsolidated partnerships were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Total revenues
|
|
$
|
18,945
|
|
|
$
|
1,911
|
|
|
$
|
1,907
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rental operations expenses and real estate taxes
|
|
|
8,854
|
|
|
|
197
|
|
|
|
199
|
|
Depreciation and amortization
|
|
|
5,674
|
|
|
|
381
|
|
|
|
236
|
|
Interest expense, net of interest income
|
|
|
8,946
|
|
|
|
928
|
|
|
|
894
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
23,474
|
|
|
|
1,506
|
|
|
|
1,329
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss)/income
|
|
$
|
(4,529
|
)
|
|
$
|
405
|
|
|
$
|
578
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Companys equity in net (loss)/income of unconsolidated
partnerships
|
|
$
|
(893
|
)
|
|
$
|
83
|
|
|
$
|
119
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.
|
Discontinued
Operations
|
During the year ended December 31, 2007, the Company sold
the following property (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original
|
|
|
|
|
|
|
|
Property
|
|
Date of Sale
|
|
|
Acquisition Date
|
|
|
Sales Price
|
|
|
Gain on Sale
|
|
|
Colorow Drive
|
|
|
May 30, 2007
|
|
|
|
December 22, 2005
|
|
|
$
|
20,000
|
|
|
$
|
1,087
|
|
The results of operations of the above property are reported as
discontinued operations for all periods presented in the
accompanying consolidated financial statements. The following is
a summary of the revenue and expense components that comprise
income from discontinued operations (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Total revenues
|
|
$
|
1,111
|
|
|
$
|
2,675
|
|
|
$
|
72
|
|
Total expenses
|
|
|
472
|
|
|
|
1,133
|
|
|
|
15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before minority interests and gain on sale
|
|
|
639
|
|
|
|
1,542
|
|
|
|
57
|
|
Gain on sale of real estate assets
|
|
|
1,087
|
|
|
|
|
|
|
|
|
|
Minority interests attributable to discontinued operations
|
|
|
(74
|
)
|
|
|
(77
|
)
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations
|
|
$
|
1,652
|
|
|
$
|
1,465
|
|
|
$
|
54
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.
|
Derivative
and Other Financial Instruments
|
As of December 31, 2007, the Company had four forward
starting swaps hedging a forecasted debt issuance, with a total
notional value of $450.0 million, which are valued on the
accompanying consolidated balance sheets at the net present
value of the expected future cash flows on the swaps. At
maturity, the Company will either (a) receive payment from
the counterparties if the accumulated balance is an asset, or
(b) make payment to the counterparties if the accumulated
balance is a liability with the resulting receipt or payment
deferred and amortized as an increase or decrease to interest
expense over the term of the forecasted borrowing.
As of December 31, 2007, the Company also had five interest
rate swaps with an aggregate notional amount of
$785.0 million under which at each monthly settlement date
the Company either (1) receives the difference between the
Strike Rate and one-month LIBOR if the Strike Rate is less than
LIBOR or (2) pays such difference if the Strike Rate is
greater than LIBOR. One interest rate swap with a notional
amount of $250.0 million hedges the Companys secured
term loan. Each of the remaining four interest rate swaps hedges
the first interest payments, due on the date
81
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
that is on or closest after each swaps settlement date,
associated with the amount of LIBOR-based debt equal to each
swaps notional amount. Three of these interest rate swaps
have an aggregate notional amount of $205.0 million and are
initially intended to hedge interest payments associated with
the Companys unsecured line of credit. The remaining
interest rate swap has a notional amount of $330.0 million
and is initially intended to hedge interest payments associated
with the Companys secured construction loan. No initial
investment was made to enter into the interest rate swap
agreements.
The following is a summary of the terms of the forward starting
swaps and the interest rate swaps and their
fair-values,
which are included in other assets or (other liabilities) on the
accompanying consolidated balance sheets (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
|
|
|
|
|
|
|
|
|
|
Fair-Value
|
|
Notional
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
Amount
|
|
|
Strike Rate
|
|
|
Effective Date
|
|
Expiration Date
|
|
2007
|
|
|
2006
|
|
|
$
|
250,000
|
|
|
|
4.157
|
%
|
|
June 1, 2005
|
|
June 1, 2010
|
|
$
|
(2,830
|
)
|
|
$
|
6,263
|
|
|
150,000
|
|
|
|
5.162
|
%
|
|
December 30, 2008
|
|
December 30, 2018
|
|
|
(4,254
|
)
|
|
|
704
|
|
|
50,000
|
|
|
|
5.167
|
%
|
|
December 30, 2008
|
|
December 30, 2018
|
|
|
(1,437
|
)
|
|
|
217
|
|
|
100,000
|
|
|
|
5.167
|
%
|
|
December 30, 2008
|
|
December 30, 2018
|
|
|
(2,874
|
)
|
|
|
434
|
|
|
150,000
|
|
|
|
5.152
|
%
|
|
December 30, 2008
|
|
December 30, 2018
|
|
|
(4,139
|
)
|
|
|
808
|
|
|
115,000
|
|
|
|
4.673
|
%
|
|
October 1, 2007
|
|
August 1, 2011
|
|
|
(3,261
|
)
|
|
|
|
|
|
35,000
|
|
|
|
4.700
|
%
|
|
October 10, 2007
|
|
August 1, 2011
|
|
|
(1,019
|
)
|
|
|
|
|
|
330,000
|
|
|
|
4.825
|
%
|
|
September 25, 2007
|
|
September 25, 2008
|
|
|
(1,700
|
)
|
|
|
|
|
|
55,000
|
|
|
|
4.760
|
%
|
|
September 20, 2007
|
|
September 20, 2008
|
|
|
(254
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,235,000
|
|
|
|
|
|
|
|
|
|
|
$
|
(21,768
|
)
|
|
$
|
8,426
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The (decrease)/increase in net unrealized (losses)/gains of
($30.2) million, $2.5 million, and $5.9 million
for the years ended December 31, 2007, 2006, and 2005,
respectively, for derivatives designated as cash flow hedges are
separately disclosed in the consolidated financial statements in
stockholders equity as a component of accumulated other
comprehensive income. For the years ended December 31,
2007, 2006, and 2005 an immaterial amount of hedge
ineffectiveness on cash flow hedges due to mismatches in
maturity dates of the interest rate swap and debt was recognized
in interest expense.
Amounts reported in accumulated other comprehensive income
related to derivatives will be reclassified to interest expense
as interest payments are made on the Companys hedged debt.
The change in net unrealized gains on cash flow hedges includes
a reclassification of net unrealized gains/losses from
accumulated other comprehensive income as a reduction to
interest expense of $3.1 million and $2.3 million, and
an increase to interest expense of $681,000 for the years ended
December 31, 2007, 2006, and 2005, respectively. During
2008, the Company estimates that an additional $3.5 million
will be reclassified as an increase to interest expense.
The limited partner in the King of Prussia limited partnership
had a put option that would require the Company to purchase the
limited partners interest in the property beginning
August 21, 2007 through November 11, 2007 for
$1.8 million less any distributions paid to the limited
partner. The net fair-value of the put and call options was
$384,000 at December 31, 2006, and was recorded as a net
accrued liability included in accounts payable and accrued
expenses on the consolidated balance sheet at that date. In
addition, the Company recorded net changes in fair-value of the
put and call options of $48,000, $67,000, and $31,000 for the
years ended December 31, 2007, 2006, and 2005,
respectively, as a charge to income on the consolidated
statements of income. On October 1, 2007, the limited
partner exercised its put option, resulting in the
Companys purchase of the minority interest in the property
for a purchase price of approximately $1.8 million,
excluding closing costs (see Note 3).
The other member in the Waples limited liability company has a
put option that would require the Company to purchase the
members interest in the property. The Company has a call
option to purchase the other members
82
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
interest, subject to certain conditions. If neither option is
exercised, then the limited liability company will continue in
existence under the terms of the limited liability company
agreement. The agreement provides that the put and call option
prices will be based on the fair-value of the property at the
time of exercise. The Company believes the fair-value of the
project is equal to, or in excess of, the carrying value of the
project as of December 31, 2007. In addition, if the other
member exercises the put option, the Company believes that it
has adequate resources to settle the option.
The other member in the Fairview limited liability company has a
put option that would require the Company to purchase the
members interest in the property at any time after the
first anniversary and before the fifth anniversary of the
project completion date. The Company has a call option to
purchase the other members interest at any time after the
first anniversary and before the fifth anniversary of the
project completion date. If neither option is exercised, then
the limited liability company will continue in existence under
the terms of the limited liability company agreement. The
agreement provides that the put and call option prices will be
based on an intrinsic value of the project at the time of
exercise. The Company recorded a net change in the fair-value of
the put option of approximately $127,000 for the year ended
December 31, 2007. In addition, if the other member
exercises the put option, the Company believes that it has
adequate resources to settle the option.
The Company has the right to purchase the other members
interest or sell its own interest (collectively, the
Buy-Sell Option) in the Ardenwood limited liability
company at any time after the later of (1) the second
anniversary of the date that the related property is at least
ninety percent leased with remaining lease terms of at least
five years and (2) the date that a term loan is obtained
pursuant to the agreement. If the Buy-Sell Option is exercised
by the Company, the other member has the right to determine
whether to acquire the Companys membership interest or to
sell its own membership interest to the Company. The agreement
provides that the Buy-Sell Option price will be based on the
fair-value of the assets at the time of exercise. The Company
believes the fair-value of the project is equal to, or in excess
of, the carrying value of the project as of December 31,
2007. In addition, if the other member exercises the Buy-Sell
Option, the Company believes that it has adequate resources to
settle the option.
|
|
13.
|
Commitments
and Contingencies
|
Concentration
of Credit Risk
Life science entities comprise the vast majority of the
Companys tenant base. Because of the dependence on a
single industry, adverse conditions affecting that industry will
more adversely affect our business. Two of the Companys
tenants, Human Genome Sciences, Inc. and Vertex Pharmaceuticals,
comprised 24.4% and 14.6%, or $48.0 million and
$28.8 million, respectively, of rental revenues for the
year ended December 31, 2007; and 17.4% and 15.7%, or
$29.0 million and $26.1 million, respectively, of
rental revenues for the year ended December 31, 2006. These
tenants are located in the Companys Maryland and Boston
markets, respectively. Two of the Companys tenants, Vertex
Pharmaceuticals and Genzyme Corporation, comprised 15.8% and
10.5%, or $14.7 million and $9.7 million,
respectively, of rental revenues for the year ended
December 31, 2005. These tenants are located in the
Companys Boston market. The inability of these tenants to
make lease payments could materially adversely affect the
Companys business.
The Company generally does not require collateral or other
security from our tenants, other than security deposits or
letters of credit in select cases.
Construction
and Other Related Commitments
As of December 31, 2007, the Company had approximately
$201.3 million outstanding in construction and other
related commitments related to construction, development, tenant
improvements, renovation costs, leasing commissions, and general
property-related capital expenditures, with approximately
$168.2 million expected to be paid in 2008, approximately
$32.2 million expected to be paid in 2009 and 2010, and the
remaining amount, approximately $866,000, expected to be paid in
2011 and 2012.
83
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Insurance
The Company carries insurance coverage on its properties with
policy specifications and insured limits that it believes are
adequate given the relative risk of loss, cost of the coverage
and standard industry practice. However, certain types of losses
(such as from earthquakes and floods) may be either uninsurable
or not economically insurable. Further, certain of the
properties are located in areas that are subject to earthquake
activity and floods. Should a property sustain damage as a
result of an earthquake or flood, the Company may incur losses
due to insurance deductibles, co-payments on insured losses or
uninsured losses. Should an uninsured loss occur, the Company
could lose some or all of its capital investment, cash flow and
anticipated profits related to one or more properties.
Environmental
Matters
The Company follows a policy of monitoring its properties for
the presence of hazardous or toxic substances. The Company is
not aware of any environmental liability with respect to the
properties that would have a material adverse effect on the
Companys business, assets or results of operations. There
can be no assurance that such a material environmental liability
does not exist. The existence of any such material environmental
liability could have an adverse effect on the Companys
results of operations and cash flow. The Company carries
environmental remediation insurance for its properties. This
insurance, subject to certain exclusions and deductibles, covers
the cost to remediate environmental damage caused by future
spills or the historic presence of previously undiscovered
hazardous substances, as well as third-party bodily injury and
property damage claims related to the release of hazardous
substances.
Repurchase
Agreements
A lease at the King of Prussia Road property contains a
provision whereby the tenant, Centocor, Inc.
(Centocor), holds a right to purchase the property
(the Purchase Option) from the Company. The Purchase
Option is exercisable through the expiration of the underlying
lease in March 2014 (the purchase option may also be extended
for an additional ten years in the event that Centocor exercises
each of two five-year lease extension options). The purchase
price is a specified amount within the amended lease agreement
if the purchase option is exercised prior to March 31, 2012
(with an annual increase of 3% on April 1 of each subsequent
year), but may also be increased for costs incurred (with an
implied return to determine estimated triple net rental rates
with respect to the costs incurred) and a capitalization rate of
8% if the Company has begun construction of new buildings on the
property.
The acquisition of the Belward Campus Drive
(Belward) and Shady Grove Road (Shady
Grove) properties include provisions whereby the seller
could repurchase the properties from the Company (individually,
the Repurchase Option) under specific terms in the
future. The Belward Repurchase Option is exercisable at any time
during the first three years after the acquisition date, subject
to a twelve-month notice provision, at a to-be-determined
repurchase price that would result in a 15% unleveraged internal
rate of return for the Company (taking into consideration all
rents paid to the Company). The Shady Grove Repurchase Option is
a one-time option at approximately the tenth anniversary of the
acquisition date, subject to a twelve-month notice provision, at
a repurchase price of approximately $300.0 million in cash.
As each Repurchase Option may be executed only by the seller and
will exceed the acquisition prices paid by the Company, no gain
will be recorded by the Company unless either Repurchase Option
is exercised.
Other
Agreements
In connection with the acquisition of the Center for Life
Science | Boston
property on November 17, 2006, the Company assumed an
agreement (the Turnkey Garage Agreement) between the
seller and Beth Israel Deaconess Medical Center
(BIDMC) for the construction of a below-grade
parking facility and the sale of a portion of the total
anticipated parking spaces to BIDMC for a fixed purchase price
of $28.8 million, subject to adjustment for
84
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
actual costs incurred on the construction pursuant to specific
provisions of the Turnkey Garage Agreement. Pursuant to the
execution of the Turnkey Garage Agreement, BIDMC issued an
irrevocable letter of credit for the full purchase price of
$28.8 million upon which the Company, as beneficiary, upon
substantial completion of the garage facility, would be
permitted to draw.
Tax
Indemnification Agreements and Minimum Debt
Requirements
As a result of the contribution of properties to the Operating
Partnership, the Company has indemnified the contributors of the
properties against adverse tax consequences if it directly or
indirectly sells, exchanges or otherwise disposes of the
properties in a taxable transaction before the tenth anniversary
of the completion of the Companys initial public offering
(the Offering). The Company also has agreed to use
its reasonable best efforts to maintain at least
$8.0 million of debt, some of which must be property
specific, for a period of ten years following the date of the
Offering to enable certain contributors to guarantee the debt in
order to defer potential taxable gain they may incur if the
Operating Partnership repays the existing debt.
Legal
Proceedings
Although the Company is involved in legal proceedings arising in
the ordinary course of business, as of December 31, 2007,
the Company is not currently a party to any legal proceedings
nor, to its knowledge, is any legal proceeding threatened
against it that it believes would have a material adverse effect
on its financial position, results of operations or liquidity.
|
|
14.
|
Property
Acquisitions
|
The Company acquired the following properties during the year
ended December 31, 2007 (dollars in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquired
|
|
|
Deferred Leasing
|
|
|
Acquired
|
|
|
|
|
|
|
|
|
|
|
|
|
Above
|
|
|
Costs
|
|
|
Below
|
|
|
|
|
|
|
Acquisition
|
|
|
Investment in
|
|
|
Market
|
|
|
In-Place
|
|
|
Management
|
|
|
Market
|
|
|
Total Cash
|
|
Property
|
|
Date
|
|
|
Real Estate
|
|
|
Lease
|
|
|
Lease
|
|
|
Fee
|
|
|
Lease
|
|
|
Consideration
|
|
|
Torreyana Road
|
|
|
3/22/2007
|
|
|
$
|
32,128
|
|
|
$
|
|
|
|
$
|
1,937
|
|
|
$
|
57
|
|
|
$
|
(1,082
|
)
|
|
$
|
33,040
|
|
6114-6154
Nancy Ridge Drive
|
|
|
5/2/2007
|
|
|
|
37,711
|
|
|
|
645
|
|
|
|
|
|
|
|
|
|
|
|
(126
|
)
|
|
|
38,230
|
|
9920 Belward Campus Drive
|
|
|
5/8/2007
|
|
|
|
15,141
|
|
|
|
|
|
|
|
1,282
|
|
|
|
145
|
|
|
|
(1,483
|
)
|
|
|
15,085
|
|
Pacific Center Boulevard
|
|
|
8/24/2007
|
|
|
|
16,893
|
|
|
|
|
|
|
|
623
|
|
|
|
118
|
|
|
|
(855
|
)
|
|
|
16,779
|
|
Forbes Boulevard
|
|
|
9/5/2007
|
|
|
|
32,584
|
|
|
|
|
|
|
|
886
|
|
|
|
|
|
|
|
(919
|
)
|
|
|
32,551
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
134,457
|
|
|
$
|
645
|
|
|
$
|
4,728
|
|
|
$
|
320
|
|
|
$
|
(4,465
|
)
|
|
$
|
135,685
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average intangible amortization life (in months)
|
|
|
|
|
|
|
|
|
|
|
241
|
|
|
|
42
|
|
|
|
58
|
|
|
|
54
|
|
|
|
|
|
85
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Company acquired the following properties during the year
ended December 31, 2006 (dollars in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred Leasing
|
|
|
Acquired
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquired
|
|
|
Costs
|
|
|
Below
|
|
|
Mortgage
|
|
|
Mortgage
|
|
|
|
|
|
|
Acquisition
|
|
|
Investment in
|
|
|
Above Market
|
|
|
In-Place
|
|
|
Management
|
|
|
Market
|
|
|
Note
|
|
|
Note
|
|
|
Total Cash
|
|
Property
|
|
Date
|
|
|
Real Estate
|
|
|
Lease
|
|
|
Lease
|
|
|
Fee
|
|
|
Lease
|
|
|
Assumed
|
|
|
Premium
|
|
|
Consideration
|
|
|
Ardenwood Venture
|
|
|
6/14/2006
|
|
|
$
|
14,153
|
|
|
$
|
|
|
|
$
|
313
|
|
|
$
|
10
|
|
|
$
|
(74
|
)
|
|
$
|
|
|
|
$
|
|
|
|
$
|
14,402
|
|
Belward Campus Drive
|
|
|
5/24/2006
|
|
|
|
200,974
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,974
|
|
Center for Life
Science | Boston
|
|
|
11/17/2006
|
|
|
|
467,417
|
|
|
|
|
|
|
|
4,155
|
|
|
|
1,370
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
472,942
|
|
Charles Street
|
|
|
4/7/2006
|
|
|
|
12,033
|
|
|
|
327
|
|
|
|
1,043
|
|
|
|
|
|
|
|
(178
|
)
|
|
|
|
|
|
|
|
|
|
|
13,225
|
|
Fairview Avenue
|
|
|
1/12/2006
|
|
|
|
2,703
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,703
|
|
John Hopkins Court
|
|
|
8/16/2006
|
|
|
|
23,086
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23,086
|
|
One Research Way
|
|
|
5/31/2006
|
|
|
|
8,267
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,267
|
|
Pacific Research Center
|
|
|
7/11/2006
|
|
|
|
214,900
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214,900
|
|
Road to the Cure
|
|
|
12/14/2006
|
|
|
|
23,559
|
|
|
|
145
|
|
|
|
462
|
|
|
|
54
|
|
|
|
|
|
|
|
(15,657
|
)
|
|
|
(801
|
)
|
|
|
7,762
|
|
Shady Grove Road
|
|
|
5/24/2006
|
|
|
|
226,149
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
226,149
|
|
Sorrento Valley Boulevard
|
|
|
12/7/2006
|
|
|
|
19,174
|
|
|
|
19
|
|
|
|
1,055
|
|
|
|
91
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,339
|
|
Spring Mill Drive
|
|
|
7/20/2006
|
|
|
|
9,022
|
|
|
|
13
|
|
|
|
704
|
|
|
|
87
|
|
|
|
(12
|
)
|
|
|
|
|
|
|
|
|
|
|
9,814
|
|
Trade Centre Avenue
|
|
|
8/9/2006
|
|
|
|
18,679
|
|
|
|
|
|
|
|
1,947
|
|
|
|
92
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,718
|
|
900 Uniqema Boulevard
|
|
|
1/13/2006
|
|
|
|
4,096
|
|
|
|
700
|
|
|
|
310
|
|
|
|
|
|
|
|
|
|
|
|
(1,766
|
)
|
|
|
(236
|
)
|
|
|
3,104
|
|
Walnut Street
|
|
|
7/7/2006
|
|
|
|
41,268
|
|
|
|
|
|
|
|
3,634
|
|
|
|
180
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45,082
|
|
217th Place
|
|
|
11/21/2006
|
|
|
|
10,654
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,654
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,296,134
|
|
|
$
|
1,204
|
|
|
$
|
13,623
|
|
|
$
|
1,884
|
|
|
$
|
(264
|
)
|
|
$
|
(17,423
|
)
|
|
$
|
(1,037
|
)
|
|
$
|
1,294,121
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average intangible amortization life (in months)
|
|
|
|
|
|
|
|
|
|
|
74
|
|
|
|
113
|
|
|
|
150
|
|
|
|
20
|
|
|
|
|
|
|
|
92
|
|
|
|
|
|
In connection with the acquisition of the Trade Centre Avenue
and Walnut Street properties, the Company extended funds
totaling $300,000 and $1.7 million, respectively, in the
form of tenant allowances to the tenants to cover the reasonable
costs of constructing tenant improvements to the premises. The
tenant allowances were fully paid to the tenants through escrow
at closing and will be repaid monthly over the term of their
respective leases, with interest calculated at the rate of 10.5%
per annum. As a result of the prepayment of the funds and the
Companys limited approval rights regarding the use of
those funds, the Company determined that the tenant allowances
should be reflected as the extension of a tenant improvement
loan, which is included in other assets in the accompanying
balance sheets as of December 31, 2007 and 2006. Monthly
repayments for the years ended December 31, 2007 and 2006
totaling $321,000 and $151,000, respectively, were recorded as a
reduction of the outstanding principal balance and the receipt
of interest income.
|
|
15.
|
Newly
Issued Accounting Pronouncements
|
In June 2006, the FASB issued Interpretation No. 48,
Accounting for Uncertainty in Income Taxes, an Interpretation
of FASB Statement No. 109 (FIN 48).
FIN 48 clarifies the accounting for uncertainty in income
taxes recognized in a companys financial statements and
prescribes a recognition threshold and measurement attribute for
the financial statement recognition and measurement of a tax
position taken or expected to be taken in a tax return.
FIN 48 is effective for fiscal years beginning after
December 15, 2006. The adoption of FIN 48 for the
fiscal year beginning January 1, 2007 did not have an
impact on the Companys consolidated financial statements.
In September 2006, the FASB issued SFAS No. 157,
Fair-Value Measurements (SFAS 157).
SFAS 157 defines fair-value, establishes a framework for
measuring fair-value in generally accepted accounting
principles,
86
BIOMED
REALTY TRUST, INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
and expands disclosures about fair-value measurements.
SFAS 157 applies under other accounting pronouncements that
require or permit fair-value measurements, but does not require
new fair-value measurements. SFAS 157 is effective for
fiscal years beginning after November 15, 2007, and interim
periods within those fiscal years. However, on December 14,
2007, the FASB issued a proposed staff position, which would
delay the effective date of SFAS 157 for non-financial
assets and liabilities to fiscal years beginning after
November 15, 2008. The Company is currently evaluating the
requirements of this statement and its impact on the valuation
of the Companys derivative instruments and other
fair-value disclosures, but has not yet determined its effect on
the Companys consolidated financial statements when it is
adopted in the fiscal year beginning January 1, 2008.
In February 2007, the FASB issued SFAS No. 159, The
Fair-Value Option for Financial Assets and Financial Liabilities
(SFAS 159). SFAS 159 permits entities
to choose to measure many financial instruments and certain
other items at fair-value. The objective is to improve financial
reporting by providing entities with the opportunity to mitigate
volatility in reported earnings caused by measuring related
assets and liabilities differently without having to apply
complex hedge accounting provisions. SFAS 159 also
establishes presentation and disclosure requirements designed to
facilitate comparison between entities that choose different
measurement attributes for similar types of assets and
liabilities. This statement is effective for fiscal years
beginning after November 15, 2007. The Company is currently
evaluating the requirements of this statement and has not yet
determined its effect on the Companys consolidated
financial statements. However, the Company does not presently
expect to elect fair-value measurement of any assets and
liabilities other than those derivative instruments that are
currently carried at fair-value in accordance with
SFAS No. 133, Accounting for Derivative Instruments
and Hedging Activities.
In December 2007, the FASB issued SFAS No. 141
(revised 2007), Business Combinations
(SFAS 141(R)). SFAS 141(R) retains the
fundamental requirements that purchase method of accounting be
used for all business combinations, for an acquirer to be
identified for each business combination, and retains the
guidance for identifying and recognizing intangible assets
separately from goodwill. This statement requires an acquirer to
recognize the assets acquired, liabilities assumed and any
noncontrolling interest in the acquiree at the acquisition date,
measured at their fair-values as of that date, changes the
recognition of assets acquired and liabilities assumed arising
from contingencies, and changes the recognition and measurement
of contingent consideration. In addition, this statement
requires that costs incurred to effect the acquisition and
restructuring costs that the acquirer expected, but is not
obligated to incur, be recognized as an expense separately from
the business combination. SFAS 141(R) will also require
additional disclosure of information surrounding a business
combination, such that users of the entitys financial
statements can fully understand the nature and financial impact
of the business combination. SFAS 141(R) applies
prospectively to business combinations for which the acquisition
date is on or after the beginning of the first annual reporting
period beginning on or after December 15, 2008. The Company
is currently evaluating the requirements of this statement and
has not yet determined its effect on the Companys future
acquisitions or consolidated financial statements.
In December 2007, the FASB issued SFAS No. 160,
Noncontrolling Interests in Consolidated Financial Statements
(SFAS 160). SFAS 160 clarifies that a
noncontrolling interest in a subsidiary is an ownership interest
in the consolidated entity that should be reported as equity in
the consolidated financial statements. This statement also
requires consolidated net income to be reported at amounts that
include the amounts attributable to both the parent and the
noncontrolling interest and requires disclosure, on the face of
the consolidated statement of income, of the amounts of
consolidated net income attributable to the parent and to the
noncontrolling interest. In addition, this statement establishes
a single method of accounting for changes in a parents
ownership interest in a subsidiary that does not result in
deconsolidation and requires that a parent recognize a gain or
loss in net income when a subsidiary is deconsolidated.
SFAS 160 is effective for fiscal years, and interim periods
within those fiscal years, beginning on or after
December 15, 2008. This statement will be applied
prospectively, except for the presentation and disclosure
requirements, which will be applied retrospectively for all
periods presented. The Company is currently evaluating the
requirements of this statement and has not yet determined its
effect on the Companys consolidated financial statements.
87
On February 13, 2008, a wholly owned entity of PREI I LLC
entered into a secured construction loan facility with Wachovia
Bank, National Association and certain other lenders to provide
borrowings of up to approximately $245.0 million in
connection with the construction of 650 East Kendall Street
(Kendall B), a life sciences building located in Cambridge,
Massachusetts. Proceeds from the secured construction loan were
used in part to repay a portion of the secured acquisition and
interim loan facility held by the PREI limited liability
companies and will also be used to fund the balance of the
anticipated cost to complete construction of the project. In
addition, on February 19, 2008, the PREI limited liability
companies extended the term of the secured acquisition and
interim loan facility by one year to April 3, 2009, with no
additional changes to the pricing or terms of the facility.
|
|
17.
|
Quarterly
Financial Information (unaudited)
|
The Companys selected quarterly information for the years
ended December 31, 2007 and 2006 (in thousands, except per
share data) was as follows.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2007 Quarter Ended
|
|
|
|
December 31
|
|
|
September 30
|
|
|
June 30
|
|
|
March 31
|
|
|
Total revenues
|
|
$
|
64,050
|
|
|
$
|
64,832
|
|
|
$
|
68,429
|
|
|
$
|
68,798
|
|
Income from continuing operations before minority interests
|
|
|
18,044
|
|
|
|
16,951
|
|
|
|
17,773
|
|
|
|
20,571
|
|
Minority interests
|
|
|
(574
|
)
|
|
|
(494
|
)
|
|
|
(690
|
)
|
|
|
(699
|
)
|
Income from continuing operations
|
|
|
17,470
|
|
|
|
16,457
|
|
|
|
17,083
|
|
|
|
19,872
|
|
(Loss)/income from discontinued operations
|
|
|
|
|
|
|
(1
|
)
|
|
|
1,283
|
|
|
|
371
|
|
Net income
|
|
|
17,470
|
|
|
|
16,456
|
|
|
|
18,366
|
|
|
|
20,243
|
|
Net income available to common stockholders
|
|
$
|
13,229
|
|
|
$
|
12,215
|
|
|
$
|
14,172
|
|
|
$
|
16,049
|
|
Income from continuing operations per share available to common
stockholders basic and diluted(1)
|
|
$
|
0.20
|
|
|
$
|
0.19
|
|
|
$
|
0.20
|
|
|
$
|
0.24
|
|
Net income per share available to common
stockholders basic and diluted(1)
|
|
$
|
0.20
|
|
|
$
|
0.19
|
|
|
$
|
0.22
|
|
|
$
|
0.25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006 Quarter Ended
|
|
|
|
December 31
|
|
|
September 30
|
|
|
June 30
|
|
|
March 31
|
|
|
Total revenues
|
|
$
|
62,978
|
|
|
$
|
63,837
|
|
|
$
|
48,790
|
|
|
$
|
43,130
|
|
Income from continuing operations before minority interests
|
|
|
12,736
|
|
|
|
10,928
|
|
|
|
7,128
|
|
|
|
4,310
|
|
Minority interests
|
|
|
(517
|
)
|
|
|
(482
|
)
|
|
|
(335
|
)
|
|
|
(200
|
)
|
Income from continuing operations
|
|
|
12,219
|
|
|
|
10,446
|
|
|
|
6,793
|
|
|
|
4,110
|
|
Income from discontinued operations
|
|
|
370
|
|
|
|
366
|
|
|
|
365
|
|
|
|
364
|
|
Net income
|
|
|
12,589
|
|
|
|
10,812
|
|
|
|
7,158
|
|
|
|
4,474
|
|
Income from continuing operations per share available to common
stockholders basic and diluted(1)
|
|
$
|
0.19
|
|
|
$
|
0.17
|
|
|
$
|
0.13
|
|
|
$
|
0.09
|
|
Net income per share available to common
stockholders basic and diluted(1)
|
|
$
|
0.19
|
|
|
$
|
0.18
|
|
|
$
|
0.14
|
|
|
$
|
0.10
|
|
|
|
|
(1) |
|
The sum of quarterly financial data may vary from the annual
data due to rounding. |
The quarterly financial information does not equal the amounts
reported on the Companys quarterly reports on
Form 10-Q
due to reclassification of net income to discontinued operations.
88
SCHEDULE III
REAL ESTATE AND ACCUMULATED DEPRECIATION
As of December 31, 2007
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross amount carried at December 31,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Initial Cost
|
|
|
Costs
|
|
|
2007
|
|
|
|
|
|
|
|
|
|
Year
|
|
|
|
|
|
|
|
|
|
|
|
Buildings
|
|
|
Capitalized
|
|
|
|
|
|
Buildings
|
|
|
|
|
|
|
|
|
|
|
|
|
Built/
|
|
|
|
|
|
|
|
|
Ground
|
|
|
and
|
|
|
Subsequent
|
|
|
|
|
|
and
|
|
|
|
|
|
Accumulated
|
|
|
|
|
Property
|
|
Renovated
|
|
|
Encumbrances
|
|
|
Land
|
|
|
Lease
|
|
|
Improvements
|
|
|
to Acquisition
|
|
|
Land
|
|
|
Improvements
|
|
|
Total
|
|
|
Depreciation
|
|
|
Net
|
|
|
|
|
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2)
|
|
|
(3)
|
|
|
|
|
|
Albany Street
|
|
|
1922/1998
|
|
|
$
|
|
|
|
$
|
1,942
|
|
|
$
|
|
|
|
$
|
31,293
|
|
|
$
|
48
|
|
|
$
|
1,942
|
|
|
$
|
31,341
|
|
|
$
|
33,283
|
|
|
$
|
(2,035
|
)
|
|
$
|
31,248
|
|
Ardentech Court(4)
|
|
|
1997/2001
|
|
|
|
4,564
|
|
|
|
2,742
|
|
|
|
|
|
|
|
5,379
|
|
|
|
4,782
|
|
|
|
2,742
|
|
|
|
10,161
|
|
|
|
12,903
|
|
|
|
(420
|
)
|
|
|
12,483
|
|
Ardenwood Venture
|
|
|
1985
|
|
|
|
|
|
|
|
3,550
|
|
|
|
|
|
|
|
10,603
|
|
|
|
|
|
|
|
3,550
|
|
|
|
10,603
|
|
|
|
14,153
|
|
|
|
(469
|
)
|
|
|
13,684
|
|
Balboa Avenue
|
|
|
1968/2000
|
|
|
|
|
|
|
|
1,316
|
|
|
|
|
|
|
|
9,493
|
|
|
|
134
|
|
|
|
1,316
|
|
|
|
9,627
|
|
|
|
10,943
|
|
|
|
(843
|
)
|
|
|
10,100
|
|
Bayshore Boulevard
|
|
|
2000
|
|
|
|
15,335
|
|
|
|
3,667
|
|
|
|
|
|
|
|
22,593
|
|
|
|
7,353
|
|
|
|
3,667
|
|
|
|
29,946
|
|
|
|
33,613
|
|
|
|
(2,943
|
)
|
|
|
30,670
|
|
Beckley Street
|
|
|
1999
|
|
|
|
|
|
|
|
1,480
|
|
|
|
|
|
|
|
17,590
|
|
|
|
|
|
|
|
1,480
|
|
|
|
17,590
|
|
|
|
19,070
|
|
|
|
(1,337
|
)
|
|
|
17,733
|
|
Bernardo Center Drive
|
|
|
1974/1992
|
|
|
|
|
|
|
|
2,580
|
|
|
|
|
|
|
|
13,714
|
|
|
|
4,209
|
|
|
|
2,580
|
|
|
|
17,923
|
|
|
|
20,503
|
|
|
|
(1,012
|
)
|
|
|
19,491
|
|
9911 Belward Campus Drive
|
|
|
2001
|
|
|
|
|
|
|
|
4,160
|
|
|
|
|
|
|
|
196,814
|
|
|
|
|
|
|
|
4,160
|
|
|
|
196,814
|
|
|
|
200,974
|
|
|
|
(8,205
|
)
|
|
|
192,769
|
|
9920 Belward Campus Drive
|
|
|
2000
|
|
|
|
|
|
|
|
3,935
|
|
|
|
|
|
|
|
11,206
|
|
|
|
|
|
|
|
3,935
|
|
|
|
11,206
|
|
|
|
15,141
|
|
|
|
(235
|
)
|
|
|
14,906
|
|
Center for Life
Science |
Boston(4)
|
|
|
|
|
|
|
425,160
|
|
|
|
60,000
|
|
|
|
|
|
|
|
407,747
|
|
|
|
196,129
|
|
|
|
60,000
|
|
|
|
603,876
|
|
|
|
663,876
|
|
|
|
|
|
|
|
663,876
|
|
Bridgeview Technology Park I
|
|
|
1977/2002
|
|
|
|
11,508
|
|
|
|
1,315
|
|
|
|
|
|
|
|
14,716
|
|
|
|
4,051
|
|
|
|
2,494
|
|
|
|
17,588
|
|
|
|
20,082
|
|
|
|
(1,502
|
)
|
|
|
18,580
|
|
Bridgeview Technology Park II
|
|
|
1977/2002
|
|
|
|
|
|
|
|
1,522
|
|
|
|
|
|
|
|
13,066
|
|
|
|
|
|
|
|
1,522
|
|
|
|
13,066
|
|
|
|
14,588
|
|
|
|
(911
|
)
|
|
|
13,677
|
|
Charles Street
|
|
|
1986
|
|
|
|
|
|
|
|
5,000
|
|
|
|
|
|
|
|
7,033
|
|
|
|
|
|
|
|
5,000
|
|
|
|
7,033
|
|
|
|
12,033
|
|
|
|
(384
|
)
|
|
|
11,649
|
|
Coolidge Avenue
|
|
|
1962/1999
|
|
|
|
|
|
|
|
2,760
|
|
|
|
|
|
|
|
7,102
|
|
|
|
|
|
|
|
2,760
|
|
|
|
7,102
|
|
|
|
9,862
|
|
|
|
(480
|
)
|
|
|
9,382
|
|
Dumbarton Circle
|
|
|
1990
|
|
|
|
|
|
|
|
2,723
|
|
|
|
|
|
|
|
5,096
|
|
|
|
93
|
|
|
|
2,723
|
|
|
|
5,189
|
|
|
|
7,912
|
|
|
|
(1,041
|
)
|
|
|
6,871
|
|
Eccles Avenue
|
|
|
1965/1995
|
|
|
|
|
|
|
|
21,257
|
|
|
|
|
|
|
|
608
|
|
|
|
570
|
|
|
|
21,257
|
|
|
|
1,178
|
|
|
|
22,435
|
|
|
|
(608
|
)
|
|
|
21,827
|
|
Eisenhower Road
|
|
|
1973/2000
|
|
|
|
2,113
|
|
|
|
416
|
|
|
|
|
|
|
|
2,614
|
|
|
|
62
|
|
|
|
416
|
|
|
|
2,676
|
|
|
|
3,092
|
|
|
|
(221
|
)
|
|
|
2,871
|
|
Elliott Avenue
|
|
|
1925/2004
|
|
|
|
|
|
|
|
10,124
|
|
|
|
|
|
|
|
38,911
|
|
|
|
4,583
|
|
|
|
10,124
|
|
|
|
43,494
|
|
|
|
53,618
|
|
|
|
(2,770
|
)
|
|
|
50,848
|
|
21 Erie Street
|
|
|
1925/2004
|
|
|
|
|
|
|
|
3,366
|
|
|
|
|
|
|
|
18,372
|
|
|
|
59
|
|
|
|
3,366
|
|
|
|
18,431
|
|
|
|
21,797
|
|
|
|
(1,195
|
)
|
|
|
20,602
|
|
40 Erie Street
|
|
|
1996
|
|
|
|
17,625
|
|
|
|
7,593
|
|
|
|
|
|
|
|
33,765
|
|
|
|
121
|
|
|
|
7,593
|
|
|
|
33,886
|
|
|
|
41,479
|
|
|
|
(2,190
|
)
|
|
|
39,289
|
|
Fairview Avenue(4)
|
|
|
|
|
|
|
|
|
|
|
2,703
|
|
|
|
|
|
|
|
694
|
|
|
|
17,321
|
|
|
|
2,703
|
|
|
|
18,015
|
|
|
|
20,718
|
|
|
|
|
|
|
|
20,718
|
|
Faraday Avenue
|
|
|
1986
|
|
|
|
|
|
|
|
1,370
|
|
|
|
|
|
|
|
7,201
|
|
|
|
|
|
|
|
1,370
|
|
|
|
7,201
|
|
|
|
8,571
|
|
|
|
(410
|
)
|
|
|
8,161
|
|
Forbes Boulevard
|
|
|
1978
|
|
|
|
|
|
|
|
19,250
|
|
|
|
|
|
|
|
13,334
|
|
|
|
|
|
|
|
19,250
|
|
|
|
13,334
|
|
|
|
32,584
|
|
|
|
(111
|
)
|
|
|
32,473
|
|
Fresh Pond Research Park
|
|
|
1948/2002
|
|
|
|
|
|
|
|
3,500
|
|
|
|
|
|
|
|
18,322
|
|
|
|
279
|
|
|
|
3,500
|
|
|
|
18,601
|
|
|
|
22,101
|
|
|
|
(1,273
|
)
|
|
|
20,828
|
|
George Patterson Boulevard
|
|
|
1996/2005
|
|
|
|
|
|
|
|
1,575
|
|
|
|
|
|
|
|
11,029
|
|
|
|
276
|
|
|
|
1,575
|
|
|
|
11,305
|
|
|
|
12,880
|
|
|
|
(605
|
)
|
|
|
12,275
|
|
Graphics Drive
|
|
|
1992/2007
|
|
|
|
|
|
|
|
800
|
|
|
|
|
|
|
|
6,577
|
|
|
|
5,067
|
|
|
|
800
|
|
|
|
11,644
|
|
|
|
12,444
|
|
|
|
(825
|
)
|
|
|
11,619
|
|
Industrial Road
|
|
|
2001/2005
|
|
|
|
|
|
|
|
12,000
|
|
|
|
|
|
|
|
41,718
|
|
|
|
14,081
|
|
|
|
12,000
|
|
|
|
55,799
|
|
|
|
67,799
|
|
|
|
(7,393
|
)
|
|
|
60,406
|
|
John Hopkins Court(4)
|
|
|
1991
|
|
|
|
|
|
|
|
3,560
|
|
|
|
|
|
|
|
19,526
|
|
|
|
4,464
|
|
|
|
3,560
|
|
|
|
23,990
|
|
|
|
27,550
|
|
|
|
|
|
|
|
27,550
|
|
Kaiser Drive
|
|
|
1990
|
|
|
|
|
|
|
|
3,430
|
|
|
|
|
|
|
|
6,093
|
|
|
|
1,119
|
|
|
|
3,430
|
|
|
|
7,212
|
|
|
|
10,642
|
|
|
|
(204
|
)
|
|
|
10,438
|
|
500 Kendall Street (Kendall D)
|
|
|
2002
|
|
|
|
69,437
|
|
|
|
3,572
|
|
|
|
|
|
|
|
166,308
|
|
|
|
572
|
|
|
|
3,572
|
|
|
|
166,880
|
|
|
|
170,452
|
|
|
|
(10,829
|
)
|
|
|
159,623
|
|
King of Prussia Road
|
|
|
1954/2004
|
|
|
|
|
|
|
|
12,813
|
|
|
|
|
|
|
|
66,525
|
|
|
|
325
|
|
|
|
12,813
|
|
|
|
66,850
|
|
|
|
79,663
|
|
|
|
(5,686
|
)
|
|
|
73,977
|
|
Landmark at Eastview(5)
|
|
|
1958/1999
|
|
|
|
|
|
|
|
|
|
|
|
14,210
|
|
|
|
61,996
|
|
|
|
47,102
|
|
|
|
14,345
|
|
|
|
108,963
|
|
|
|
123,308
|
|
|
|
(6,761
|
)
|
|
|
116,547
|
|
Lucent Drive
|
|
|
2004
|
|
|
|
5,543
|
|
|
|
265
|
|
|
|
|
|
|
|
5,888
|
|
|
|
|
|
|
|
265
|
|
|
|
5,888
|
|
|
|
6,153
|
|
|
|
(380
|
)
|
|
|
5,773
|
|
Monte Villa Parkway
|
|
|
1996/2002
|
|
|
|
9,336
|
|
|
|
1,020
|
|
|
|
|
|
|
|
10,711
|
|
|
|
|
|
|
|
1,020
|
|
|
|
10,711
|
|
|
|
11,731
|
|
|
|
(904
|
)
|
|
|
10,827
|
|
6114-6154
Nancy Ridge Drive
|
|
|
1994
|
|
|
|
|
|
|
|
10,100
|
|
|
|
|
|
|
|
27,611
|
|
|
|
|
|
|
|
10,100
|
|
|
|
27,611
|
|
|
|
37,711
|
|
|
|
(479
|
)
|
|
|
37,232
|
|
6828 Nancy Ridge Drive
|
|
|
1983/2001
|
|
|
|
6,785
|
|
|
|
2,344
|
|
|
|
|
|
|
|
9,611
|
|
|
|
484
|
|
|
|
2,344
|
|
|
|
10,095
|
|
|
|
12,439
|
|
|
|
(790
|
)
|
|
|
11,649
|
|
One Research Way(4)
|
|
|
1980
|
|
|
|
|
|
|
|
1,813
|
|
|
|
|
|
|
|
6,454
|
|
|
|
2,047
|
|
|
|
1,813
|
|
|
|
8,501
|
|
|
|
10,314
|
|
|
|
|
|
|
|
10,314
|
|
89
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross amount carried at December 31,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Initial Cost
|
|
|
Costs
|
|
|
2007
|
|
|
|
|
|
|
|
|
|
Year
|
|
|
|
|
|
|
|
|
|
|
|
Buildings
|
|
|
Capitalized
|
|
|
|
|
|
Buildings
|
|
|
|
|
|
|
|
|
|
|
|
|
Built/
|
|
|
|
|
|
|
|
|
Ground
|
|
|
and
|
|
|
Subsequent
|
|
|
|
|
|
and
|
|
|
|
|
|
Accumulated
|
|
|
|
|
Property
|
|
Renovated
|
|
|
Encumbrances
|
|
|
Land
|
|
|
Lease
|
|
|
Improvements
|
|
|
to Acquisition
|
|
|
Land
|
|
|
Improvements
|
|
|
Total
|
|
|
Depreciation
|
|
|
Net
|
|
|
|
|
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2)
|
|
|
(3)
|
|
|
|
|
|
Pacific Center Boulevard
|
|
|
1991
|
|
|
|
|
|
|
|
5,400
|
|
|
|
|
|
|
|
11,493
|
|
|
|
221
|
|
|
|
5,400
|
|
|
|
11,714
|
|
|
|
17,114
|
|
|
|
(108
|
)
|
|
|
17,006
|
|
Pacific Research Center(4)
|
|
|
2000
|
|
|
|
|
|
|
|
74,147
|
|
|
|
|
|
|
|
142,437
|
|
|
|
20,720
|
|
|
|
74,147
|
|
|
|
163,157
|
|
|
|
237,304
|
|
|
|
(3,983
|
)
|
|
|
233,321
|
|
Phoenixville Pike
|
|
|
1989
|
|
|
|
|
|
|
|
1,204
|
|
|
|
|
|
|
|
10,879
|
|
|
|
5,429
|
|
|
|
1,204
|
|
|
|
16,308
|
|
|
|
17,512
|
|
|
|
(1,002
|
)
|
|
|
16,510
|
|
Road to the Cure
|
|
|
1977
|
|
|
|
15,427
|
|
|
|
4,430
|
|
|
|
|
|
|
|
19,129
|
|
|
|
615
|
|
|
|
4,430
|
|
|
|
19,744
|
|
|
|
24,174
|
|
|
|
(195
|
)
|
|
|
23,979
|
|
San Diego Science Center
|
|
|
1973/2002
|
|
|
|
|
|
|
|
3,871
|
|
|
|
|
|
|
|
21,875
|
|
|
|
251
|
|
|
|
3,871
|
|
|
|
22,126
|
|
|
|
25,997
|
|
|
|
(1,776
|
)
|
|
|
24,221
|
|
Science Center Drive
|
|
|
1995
|
|
|
|
11,301
|
|
|
|
2,630
|
|
|
|
|
|
|
|
16,440
|
|
|
|
|
|
|
|
2,630
|
|
|
|
16,440
|
|
|
|
19,070
|
|
|
|
(1,350
|
)
|
|
|
17,720
|
|
Shady Grove Road
|
|
|
2003
|
|
|
|
147,000
|
|
|
|
28,601
|
|
|
|
|
|
|
|
197,548
|
|
|
|
1,290
|
|
|
|
28,639
|
|
|
|
198,800
|
|
|
|
227,439
|
|
|
|
(8,364
|
)
|
|
|
219,075
|
|
Sidney Street
|
|
|
2000
|
|
|
|
29,986
|
|
|
|
7,580
|
|
|
|
|
|
|
|
50,459
|
|
|
|
29
|
|
|
|
7,580
|
|
|
|
50,488
|
|
|
|
58,068
|
|
|
|
(3,267
|
)
|
|
|
54,801
|
|
Sorrento Valley Boulevard
|
|
|
1982
|
|
|
|
|
|
|
|
4,140
|
|
|
|
|
|
|
|
15,034
|
|
|
|
|
|
|
|
4,140
|
|
|
|
15,034
|
|
|
|
19,174
|
|
|
|
(518
|
)
|
|
|
18,656
|
|
Spring Mill Drive
|
|
|
1988
|
|
|
|
|
|
|
|
1,074
|
|
|
|
|
|
|
|
7,948
|
|
|
|
139
|
|
|
|
1,074
|
|
|
|
8,087
|
|
|
|
9,161
|
|
|
|
(426
|
)
|
|
|
8,735
|
|
Trade Centre Avenue
|
|
|
1997
|
|
|
|
|
|
|
|
3,275
|
|
|
|
|
|
|
|
15,404
|
|
|
|
|
|
|
|
3,275
|
|
|
|
15,404
|
|
|
|
18,679
|
|
|
|
(670
|
)
|
|
|
18,009
|
|
Torreyana Road
|
|
|
1980/1997
|
|
|
|
|
|
|
|
7,660
|
|
|
|
|
|
|
|
24,468
|
|
|
|
|
|
|
|
7,660
|
|
|
|
24,468
|
|
|
|
32,128
|
|
|
|
(511
|
)
|
|
|
31,617
|
|
9865 Towne Centre Drive(4)
|
|
|
|
|
|
|
|
|
|
|
5,738
|
|
|
|
|
|
|
|
2,991
|
|
|
|
10,684
|
|
|
|
5,738
|
|
|
|
13,675
|
|
|
|
19,413
|
|
|
|
(252
|
)
|
|
|
19,161
|
|
9885 Towne Centre Drive
|
|
|
2001
|
|
|
|
21,323
|
|
|
|
4,982
|
|
|
|
|
|
|
|
28,513
|
|
|
|
|
|
|
|
4,982
|
|
|
|
28,513
|
|
|
|
33,495
|
|
|
|
(2,406
|
)
|
|
|
31,089
|
|
Tributary Street
|
|
|
1983/1998
|
|
|
|
|
|
|
|
2,060
|
|
|
|
|
|
|
|
10,597
|
|
|
|
|
|
|
|
2,060
|
|
|
|
10,597
|
|
|
|
12,657
|
|
|
|
(806
|
)
|
|
|
11,851
|
|
900 Uniqema Boulevard
|
|
|
2000
|
|
|
|
1,509
|
|
|
|
404
|
|
|
|
|
|
|
|
3,692
|
|
|
|
|
|
|
|
404
|
|
|
|
3,692
|
|
|
|
4,096
|
|
|
|
(196
|
)
|
|
|
3,900
|
|
1000 Uniqema Boulevard
|
|
|
1999
|
|
|
|
|
|
|
|
1,350
|
|
|
|
|
|
|
|
13,229
|
|
|
|
|
|
|
|
1,350
|
|
|
|
13,229
|
|
|
|
14,579
|
|
|
|
(744
|
)
|
|
|
13,835
|
|
Vassar Street
|
|
|
1950/1998
|
|
|
|
|
|
|
|
2,040
|
|
|
|
|
|
|
|
13,841
|
|
|
|
|
|
|
|
2,040
|
|
|
|
13,841
|
|
|
|
15,881
|
|
|
|
(894
|
)
|
|
|
14,987
|
|
Waples Street
|
|
|
1983/2005
|
|
|
|
|
|
|
|
2,470
|
|
|
|
|
|
|
|
2,907
|
|
|
|
9,820
|
|
|
|
2,470
|
|
|
|
12,727
|
|
|
|
15,197
|
|
|
|
(2,055
|
)
|
|
|
13,142
|
|
Walnut Street
|
|
|
2004
|
|
|
|
|
|
|
|
5,200
|
|
|
|
|
|
|
|
36,068
|
|
|
|
|
|
|
|
5,200
|
|
|
|
36,068
|
|
|
|
41,268
|
|
|
|
(1,606
|
)
|
|
|
39,662
|
|
675 West Kendall Street (Kendall A)
|
|
|
2002
|
|
|
|
|
|
|
|
4,922
|
|
|
|
|
|
|
|
121,182
|
|
|
|
|
|
|
|
4,922
|
|
|
|
121,182
|
|
|
|
126,104
|
|
|
|
(7,826
|
)
|
|
|
118,278
|
|
217th Place
|
|
|
1987/2007
|
|
|
|
|
|
|
|
7,125
|
|
|
|
|
|
|
|
3,529
|
|
|
|
12,846
|
|
|
|
7,125
|
|
|
|
16,375
|
|
|
|
23,500
|
|
|
|
(38
|
)
|
|
|
23,462
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
$
|
793,952
|
|
|
$
|
401,866
|
|
|
$
|
14,210
|
|
|
$
|
2,116,976
|
|
|
$
|
377,375
|
|
|
$
|
417,428
|
|
|
$
|
2,492,999
|
|
|
$
|
2,910,427
|
|
|
$
|
(104,444
|
)
|
|
$
|
2,805,983
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Includes secured construction loan secured by the Center for
Life Science | Boston
property, but excludes unamortized debt premium of $10,888. |
|
(2) |
|
The aggregate gross cost of the Companys rental property
for federal income tax purposes approximated $3.0 billion
as of December 31, 2007 (unaudited). |
|
(3) |
|
Depreciation of building and improvements is recorded on a
straight-line basis over the estimated useful lives ranging from
15 years to 40 years. |
|
(4) |
|
The entire property was under development or redevelopment as of
December 31, 2007. |
|
(5) |
|
During 2007, the Company acquired a fee simple interest in the
land at its Landmark at Eastview property. The balance of
$14.2 million was subsequently reclassified from ground
lease to land. |
90
The following table reconciles the historical cost and related
accumulated depreciation as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
Investment in real estate:
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at beginning of year
|
|
$
|
2,518,117
|
|
|
$
|
1,151,275
|
|
|
$
|
471,799
|
|
Property acquisitions
|
|
|
134,457
|
|
|
|
1,296,134
|
|
|
|
650,642
|
|
Improvements
|
|
|
257,853
|
|
|
|
70,708
|
|
|
|
28,834
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at end of year
|
|
$
|
2,910,427
|
|
|
$
|
2,518,117
|
|
|
$
|
1,151,275
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Depreciation:
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at beginning of year
|
|
$
|
(60,579
|
)
|
|
$
|
(21,904
|
)
|
|
$
|
(3,269
|
)
|
Depreciation expense
|
|
|
(43,865
|
)
|
|
|
(38,675
|
)
|
|
|
(18,635
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at end of year
|
|
$
|
(104,444
|
)
|
|
$
|
(60,579
|
)
|
|
$
|
(21,904
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying report of independent registered public
accounting firm.
91
|
|
Item 9.
|
Changes
in and Disagreements with Accountants on Accounting and
Financial Disclosure
|
None.
|
|
Item 9A.
|
Controls
and Procedures
|
Evaluation
of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed
to ensure that information required to be disclosed in our
Exchange Act reports is recorded, processed, summarized and
reported within the time periods specified in the Securities and
Exchange Commissions rules and forms, and that such
information is accumulated and communicated to our management,
including our Chief Executive Officer and Chief Financial
Officer, as appropriate, to allow for timely decisions regarding
required disclosure. In designing and evaluating the disclosure
controls and procedures, management recognizes that any controls
and procedures, no matter how well designed and operated, can
provide only reasonable assurance of achieving the desired
control objectives, and management is required to apply its
judgment in evaluating the cost-benefit relationship of possible
controls and procedures. Also, we have an investment in
unconsolidated entities. As we manage these entities, our
disclosure controls and procedures with respect to such entities
are essentially consistent with those we maintain with respect
to our consolidated entities. As required by
Rule 13a-15(b)
under the Exchange Act, we carried out an evaluation, under the
supervision and with the participation of our management,
including our Chief Executive Officer and Chief Financial
Officer, of the effectiveness of the design and operation of our
disclosure controls and procedures. Based on the foregoing, our
Chief Executive Officer and Chief Financial Officer concluded
that, as of the end of the period covered by this report, our
disclosure controls and procedures were effective and were
operating at a reasonable assurance level.
Managements
Report on Internal Control Over Financial Reporting
Internal control over financial reporting refers to the process
designed by, or under the supervision of, our Chief Executive
Officer and Chief Financial Officer, and effected by our board
of directors, management and other personnel, to provide
reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for
external purposes in accordance with U.S. generally
accepted accounting principles, and includes those policies and
procedures that: (1) pertain to the maintenance of records
that in reasonable detail accurately and fairly reflect the
transactions and dispositions of the assets of the company;
(2) provide reasonable assurance that transactions are
recorded as necessary to permit preparation of financial
statements in accordance with U.S. generally accepted
accounting principles, and that receipts and expenditures of the
company are being made only in accordance with authorizations of
management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of the
companys assets that could have a material effect on the
financial statements.
Internal control over financial reporting cannot provide
absolute assurance of achieving financial reporting objectives
because of its inherent limitations. Internal control over
financial reporting is a process that involves human diligence
and compliance and is subject to lapses in judgment and
breakdowns resulting from human failures. Internal control over
financial reporting also can be circumvented by collusion or
improper management override. Because of such limitations, there
is a risk that material misstatements may not be prevented or
detected on a timely basis by internal control over financial
reporting. However, these inherent limitations are known
features of the financial reporting process. Therefore, it is
possible to design into the process safeguards to reduce, though
not eliminate, this risk.
Management is responsible for establishing and maintaining
adequate internal control over financial reporting for the
company, as such term is defined in
Rule 13a-15(f)
under the Exchange Act. Under the supervision and with the
participation of our management, including our Chief Executive
Officer and Chief Financial Officer, we conducted an evaluation
of the effectiveness of our internal control over financial
reporting. Management has used the framework set forth in the
report entitled Internal Control Integrated
Framework published by the Committee of Sponsoring
Organizations of the Treadway Commission to evaluate the
effectiveness of the companys internal control over
financial reporting. Based on its evaluation, management has
concluded that
92
the companys internal control over financial reporting was
effective as of December 31, 2007, the end of the
companys most recent fiscal year.
Changes
in Internal Control over Financial Reporting
There has been no change in our internal control over financial
reporting during the quarter ended December 31, 2007 that
has materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.
|
|
Item 9B.
|
Other
Information
|
None.
PART III
|
|
Item 10.
|
Directors,
Executive Officers and Corporate Governance
|
As required by Section 303A.12(a) of the NYSE Listed
Company Manual, our Chief Executive Officer made his annual
certification to the NYSE on June 14, 2007 stating that he
was not aware of any violation by our company of the corporate
governance listing standards of the NYSE. In addition, we have
filed, as exhibits to this Annual Report on
Form 10-K,
the certifications of our Chief Executive Officer and Chief
Financial Officer required under Section 302 of the
Sarbanes-Oxley Act of 2002 to be filed with the Securities and
Exchange Commission regarding the quality of our public
disclosure.
The information concerning our directors, executive officers and
corporate governance required by Item 10 will be included
in the Proxy Statement to be filed relating to our 2008 Annual
Meeting of Stockholders and is incorporated herein by reference.
Pursuant to instruction G(3) to
Form 10-K,
information concerning audit committee financial expert
disclosure set forth under the heading Information
Regarding the Board Committees of the
Board Audit Committee will be included in the
Proxy Statement to be filed relating to our 2008 Annual Meeting
of Stockholders and is incorporated herein by reference.
Pursuant to instruction G(3) to
Form 10-K,
information concerning compliance with Section 16(a) of the
Exchange Act concerning our directors and executive officers set
forth under the heading entitled General
Section 16(a) Beneficial Ownership Reporting
Compliance will be included in the Proxy Statement to be
filed relating to our 2008 Annual Meeting of Stockholders and is
incorporated herein by reference.
|
|
Item 11.
|
Executive
Compensation
|
The information concerning our executive compensation required
by Item 11 will be included in the Proxy Statement to be
filed relating to our 2008 Annual Meeting of Stockholders and is
incorporated herein by reference.
|
|
Item 12.
|
Security
Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters
|
The information concerning the security ownership of certain
beneficial owners and management and related stockholder matters
required by Item 12 will be included in the Proxy Statement
to be filed relating to our 2008 Annual Meeting of Stockholders
and is incorporated herein by reference.
|
|
Item 13.
|
Certain
Relationships and Related Transactions, and Director
Independence
|
The information concerning certain relationships and related
transactions and director independence required by Item 13
will be included in the Proxy Statement to be filed relating to
our 2008 Annual Meeting of Stockholders and is incorporated
herein by reference.
93
|
|
Item 14.
|
Principal
Accountant Fees and Services
|
The information concerning our principal accountant fees and
services required by Item 14 will be included in the Proxy
Statement to be filed relating to our 2008 Annual Meeting of
Stockholders and is incorporated herein by reference.
|
|
Item 15.
|
Exhibits
and Financial Statement Schedules
|
|
|
|
Exhibit
|
|
|
Number
|
|
Description
|
|
3.1
|
|
Articles of Amendment and Restatement of BioMed Realty Trust,
Inc.(1)
|
3.2
|
|
Amended and Restated Bylaws of BioMed Realty Trust, Inc.(1)
|
3.3
|
|
Articles Supplementary Classifying BioMed Realty Trust,
Inc.s 7.375% Series A Cumulative Redeemable Preferred
Stock.(2)
|
4.1
|
|
Form of Certificate for Common Stock of BioMed Realty Trust,
Inc.(3)
|
4.2
|
|
Form of Certificate for 7.375% Series A Cumulative
Redeemable Preferred Stock of BioMed Realty Trust, Inc.(2)
|
4.3
|
|
Indenture, dated September 25, 2006, among BioMed Realty,
L.P., BioMed Realty Trust, Inc. and U.S. Bank National
Association, as trustee, including the form of 4.50%
Exchangeable Senior Notes due 2026.(4)
|
10.1
|
|
Fourth Amended and Restated Agreement of Limited Partnership of
BioMed Realty, L.P. dated as of January 18, 2007.(5)
|
10.2
|
|
Registration Rights Agreement dated as of August 13, 2004
among BioMed Realty Trust, Inc. and the persons named therein.(1)
|
10.3
|
|
2004 Incentive Award Plan, as amended.(6)
|
10.4
|
|
Form of Restricted Stock Award Agreement under the 2004
Incentive Award Plan.(7)
|
10.5
|
|
Form of Long Term Incentive Plan Unit Award Agreement.(6)
|
10.6
|
|
Form of Indemnification Agreement between BioMed Realty Trust,
Inc. and each of its directors and officers.(3)
|
10.7
|
|
Amended and Restated Employment Agreement dated as of
December 14, 2007 between BioMed Realty Trust, Inc. and
Alan D. Gold.(8)
|
10.8
|
|
Amended and Restated Employment Agreement dated as of
December 14, 2007 between BioMed Realty Trust, Inc. and
Gary A. Kreitzer.(8)
|
10.9
|
|
Amended and Restated Employment Agreement dated as of
December 14, 2007 between BioMed Realty Trust, Inc. and R.
Kent Griffin, Jr.(8)
|
10.10
|
|
Amended and Restated Employment Agreement dated as of
December 14, 2007 between BioMed Realty Trust, Inc. and
John F. Wilson, II.(8)
|
10.11
|
|
Amended and Restated Employment Agreement dated as of
December 14, 2007 between BioMed Realty Trust, Inc. and
Matthew G. McDevitt.(8)
|
10.12
|
|
Contribution Agreement between Alan D. Gold and BioMed Realty,
L.P. dated as of May 4, 2004.(3)
|
10.13
|
|
Contribution Agreement between Gary A. Kreitzer and BioMed
Realty, L.P. dated as of May 4, 2004.(3)
|
10.14
|
|
Contribution Agreement between John F. Wilson, II and
BioMed Realty, L.P. dated as of May 4, 2004.(3)
|
10.15
|
|
Contribution Agreement between Matthew G. McDevitt and BioMed
Realty, L.P. dated as of May 4, 2004.(3)
|
10.16
|
|
Form of Contribution Agreement between the additional
contributors and BioMed Realty, L.P. dated as of May 4,
2004.(3)
|
10.17
|
|
BioMed Realty 401(k) Retirement Savings Plan.(7)
|
10.18
|
|
First Amendment to the BioMed Realty 401(k) Retirement Savings
Plan.(7)
|
10.19
|
|
Second Amendment to the BioMed Realty 401(k) Retirement Savings
Plan.(7)
|
10.20
|
|
Good Faith Amendment to the BioMed Realty 401(k) Retirement
Savings Plan.(9)
|
94
|
|
|
Exhibit
|
|
|
Number
|
|
Description
|
|
10.21
|
|
Third Amendment to the BioMed Realty 401(k) Retirement Savings
Plan.(9)
|
10.22
|
|
Amendment to the BioMed Realty 401(k) Retirement Savings Plan.(5)
|
10.23
|
|
Agreement for Purchase of Real Estate, dated as of
April 15, 2005, between BioMed Realty, L.P. and The Lyme
Timber Company.(10)
|
10.24
|
|
Form of Secured Term Loan Note.(11)
|
10.25
|
|
First Amended and Restated Secured Term Loan Agreement, dated as
of August 1, 2007, by and among BioMed Realty, L.P.,
KeyBank National Association, as Administrative Agent, and
certain lenders party thereto.(12)
|
10.26
|
|
Form of Line Note under Unsecured Credit Agreement.(11)
|
10.27
|
|
Form of Term Note under Unsecured Credit Agreement.(11)
|
10.28
|
|
Second Amended and Restated Unsecured Credit Agreement, dated as
of August 1, 2007, by and among BioMed Realty, L.P.,
KeyBank National Association, as Administrative Agent, and
certain lenders party thereto.(12)
|
10.29
|
|
Assumption, Consent and Loan Modification Agreement, dated as of
May 31, 2005, by and among KS Parcel D, LLC, The Lyme
Timber Company, BioMed Realty Trust, Inc., BMR-500 Kendall
Street LLC and The Variable Annuity Life Insurance Company.(11)
|
10.30
|
|
Promissory Note, dated as of November 21, 2003, to The
Variable Annuity Life Insurance Company.(11)
|
10.31
|
|
Mortgage, Security Agreement, Fixture Filing, Financing
Statement and Assignment of Leases and Rents, dated as of
November 21, 2003, in favor of The Variable Annuity Life
Insurance Company.(11)
|
10.32
|
|
Lease, dated as of January 18, 2001, by and between Kendall
Square, LLC and Vertex Pharmaceuticals Incorporated.(11)
|
10.33
|
|
First Amendment to Lease, dated as of May 9, 2002, by and
between Kendall Square, LLC and Vertex Pharmaceuticals
Incorporated.(11)
|
10.34
|
|
Second Amendment to Lease, dated as of September 16, 2003,
by and between KS Parcel A, LLC, as successor to Kendall Square,
LLC, and Vertex Pharmaceuticals Incorporated.(11)
|
10.35
|
|
Third Amendment to Lease, dated as of December 22, 2003, by
and between KS Parcel A, LLC, as successor to Kendall Square,
LLC, and Vertex Pharmaceuticals Incorporated.(11)
|
10.36
|
|
Fourth Amendment to Lease, dated as of September 30, 2004,
by and between KS Parcel A, LLC, as successor to Kendall Square,
LLC, and Vertex Pharmaceuticals Incorporated.(11)
|
10.37
|
|
Fifth Amendment to Lease, dated as of April 15, 2005, by
and between KS Parcel A, LLC, as successor to Kendall Square,
LLC, and Vertex Pharmaceuticals Incorporated.(11)
|
10.38
|
|
Sixth Amendment to Lease, dated as of September 23, 2005,
by and between BMR-675 West Kendall Street LLC, as
successor to Kendall Square, LLC, and Vertex Pharmaceuticals
Incorporated.(13)
|
10.39
|
|
Seventh Amendment to Lease, dated as of January 23, 2006,
by and between BMR-675 West Kendall Street LLC, as
successor to Kendall Square, LLC, and Vertex Pharmaceuticals
Incorporated.(9)
|
10.40
|
|
Lease, dated as of September 17, 1999, by and between
Trustees of Fort Washington Realty Trust and Vertex
Pharmaceuticals Incorporated.(11)
|
10.41
|
|
Lease, dated March 3, 1995, by and between
Fort Washington Limited Partnership and Vertex
Pharmaceuticals Incorporated.(11)
|
10.42
|
|
First Amendment to Lease, dated as of December 1996, by and
between David E. Clem and David M. Roby, as Trustees of
Fort Washington Realty Trust, and Vertex Pharmaceuticals
Incorporated.(11)
|
10.43
|
|
Second Amendment to Lease, dated as of June 13, 1997, by
and between David E. Clem and David M. Roby, as Trustees of
Fort Washington Realty Trust, and Vertex Pharmaceuticals
Incorporated.(11)
|
10.44
|
|
Third Amendment to Lease, dated as of October 1, 1998, by
and between David E. Clem and David M. Roby, as Trustees of
Fort Washington Realty Trust, and Vertex Pharmaceuticals
Incorporated.(11)
|
10.45
|
|
Fourth Amendment to Lease, dated as of February 22, 2000,
by and between David E. Clem and David M. Roby, as Trustees of
Fort Washington Realty Trust, and Vertex Pharmaceuticals
Incorporated.(11)
|
95
|
|
|
Exhibit
|
|
|
Number
|
|
Description
|
|
10.46
|
|
Fifth Amendment to Lease, dated as of May 1, 1999, by and
between David E. Clem and David M. Roby, as Trustees of
Fort Washington Realty Trust, and Vertex Pharmaceuticals
Incorporated.(11)
|
10.47
|
|
Sixth Amendment to Lease, dated as of April 6, 2005, by and
between David E. Clem and David M. Roby, as Trustees of
Fort Washington Realty Trust, and Vertex Pharmaceuticals
Incorporated.(11)
|
10.48
|
|
Seventh Amendment to Lease, dated as of October 15, 2007,
by and between BMR-40 Erie Street LLC, as successor to
Fort Washington Limited Partnership, and Vertex
Pharmaceuticals Incorporated.(14)
|
10.49
|
|
Lease, dated November 14, 2006, between BMR-21 Erie Street
LLC and Vertex Pharmaceuticals Incorporated.(15)
|
10.50
|
|
First Amendment to Lease, dated as of February 28, 2007, by
and between BMR-21 Erie Street LLC and Vertex Pharmaceuticals
Incorporated.(14)
|
10.51
|
|
Multi-Tenant Industrial Lease, dated as of April 7, 1997,
by and between AEW/LBA Acquisition Co. II, LLC and Aurora
Biosciences Corporation.(14)
|
10.52
|
|
First Amendment to Multi-Tenant Industrial Lease, dated as of
September 1, 1997, by and between AEW/LBA Acquisition Co.
II, LLC and Aurora Biosciences Corporation.(14)
|
10.53
|
|
Second Amendment to Multi-Tenant Industrial Lease, dated as of
August 21, 2007, by and between BMR-Torreyana LLC, as
successor to AEW/LBA Acquisition Co. II, LLC, and Vertex
Pharmaceuticals (San Diego) LLC, as successor to Aurora
Biosciences Corporation.(14)
|
10.54
|
|
Agreement of Purchase and Sale, dated as of May 2, 2006,
between Human Genome Sciences, Inc. and BioMed Realty, L.P.(16)
|
10.55
|
|
Lease Agreement, dated as of May 24, 2006, between
BMR-Belward Campus Drive LSM LLC and Human Genome Sciences,
Inc.(17)
|
10.56
|
|
Lease Agreement, dated as of May 24, 2006, between
BMR-Shady Grove Road HQ LLC and Human Genome Sciences, Inc.(17)
|
10.57
|
|
Secured Bridge Loan Agreement, dated as of May 24, 2006, by
and among BioMed Realty, L.P., KeyBank National Association, as
Administrative Agent, and certain lenders party thereto.(17)
|
10.58
|
|
Form of Note under Secured Bridge Loan Agreement.(17)
|
10.59
|
|
First Amendment to Secured Bridge Loan Agreement, dated as of
July 5, 2006, by and among BioMed Realty, L.P. and KeyBank
National Association, individually and as Administrative
Agent.(18)
|
10.60
|
|
Purchase and Sale Agreement, dated as of June 7, 2006,
between Sun Microsystems, Inc. and BioMed Realty, L.P.(19)
|
10.61
|
|
First Amendment to Purchase and Sale Agreement, dated as of
June 22, 2006, between Sun Microsystems, Inc. and BioMed
Realty, L.P.(19)
|
10.62
|
|
Second Amendment to Purchase and Sale Agreement, dated as of
June 23, 2006, between Sun Microsystems, Inc. and BioMed
Realty, L.P.(19)
|
10.63
|
|
Registration Rights Agreement, dated September 25, 2006,
among BioMed Realty Trust, Inc., BioMed Realty, L.P., Credit
Suisse Securities (USA) LLC and Morgan Stanley & Co.
Incorporated.(4)
|
10.64
|
|
Promissory Note, dated August 23, 2006, by BMR-Shady Grove
B LLC in favor of KeyBank National Association.(20)
|
10.65
|
|
Indemnity Deed of Trust, Assignment of Leases and Rents,
Security Agreement, and Fixture Filing, dated August 23,
2006, by BMR-Shady Grove Road HQ LLC in favor of KeyBank
National Association.(20)
|
10.66
|
|
Real Estate Purchase and Sale Agreement, dated as of
October 20, 2006, among BioMed Realty, L.P., CLSB I,
LLC and CLSB II, LLC.(21)
|
10.67
|
|
First Amendment to Real Estate Purchase and Sale Agreement,
dated as of November 2, 2006, among BioMed Realty, L.P.,
CLSB I, LLC and CLSB II, LLC.(22)
|
10.68
|
|
Secured Acquisition and Construction Loan Agreement, dated as of
November 17, 2006, among BMR-Blackfan Circle LLC, KeyBank
National Association, as Administrative Agent, and certain other
lenders party thereto.(15)
|
10.69
|
|
Promissory Note, dated November 17, 2006, by BMR-Blackfan
Circle LLC in favor of KeyBank National Association.(15)
|
96
|
|
|
Exhibit
|
|
|
Number
|
|
Description
|
|
10.70
|
|
Amended and Restated Secured Acquisition and Construction Loan
Agreement, dated as of December 21, 2006, among
BMR-Blackfan Circle LLC, KeyBank National Association, as
Administrative Agent, and certain other lenders party
thereto.(23)
|
10.71
|
|
Purchase and Sale Agreement, dated as of January 29, 2007,
among Rogers Street, LLC, Lyme/Houston Development I, LP,
Kendall Square LLC and BioMed Realty, L.P.(5)
|
10.72
|
|
First Amendment to Real Estate Purchase and Sale Agreement,
dated as of February 16, 2007, among Rogers Street, LLC,
Lyme/Houston Development I, LP, Kendall Square LLC and
BioMed Realty, L.P.(5)
|
10.73
|
|
Purchase and Sale Agreement, dated as of January 29, 2007,
among SP-K Development, LLC, SP-B1 Development, LLC, SP-A
Development, LLC, SP-B2 Development, LLC, SP-D Development, LLC,
SP-E
Development, LLC, SP-J Development, LLC, 110 Munson Street, LLC,
SP-C Development, LLC, Lyme Properties LLC and BioMed Realty,
L.P.(5)
|
10.74
|
|
First Amendment to Real Estate Purchase and Sale Agreement,
dated as of February 16, 2007, among
SP-K
Development, LLC, SP-B1 Development, LLC, SP-A Development, LLC,
SP-B2 Development, LLC, SP-D Development, LLC, SP-E Development,
LLC, SP-J Development, LLC, 110 Munson Street, LLC, SP-C
Development, LLC, Lyme Properties LLC and BioMed Realty, L.P.(5)
|
10.75
|
|
Second Amendment to Real Estate Purchase and Sale Agreement,
dated as of April 3, 2007, among SP-K Development, LLC,
SP-B1 Development, LLC, SP-A Development, LLC, SP-B2
Development, LLC, SP-D Development, LLC, SP-E Development, LLC,
SP-J Development, LLC, 110 Munson Street, LLC, SP-C Development,
LLC, Lyme Properties LLC and BioMed Realty, L.P.(24)
|
10.77
|
|
Director Compensation Policy.(25)
|
10.78
|
|
Dividend Reinvestment and Stock Purchase Plan.(26)
|
12.1
|
|
Ratio of Earnings to Fixed Charges.(27)
|
21.1
|
|
List of Subsidiaries of BioMed Realty Trust, Inc.(27)
|
23.1
|
|
Consent of KPMG LLP.(27)
|
31.1
|
|
Certification of Chief Executive Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.(27)
|
31.2
|
|
Certification of Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.(27)
|
32.1
|
|
Certifications of Chief Executive Officer and Chief Financial
Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.(27)
|
|
|
|
(1) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Quarterly Report on
Form 10-Q
filed with the Securities and Exchange Commission on
September 20, 2004. |
|
(2) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Registration Statement on
Form 8-A
filed with the Securities and Exchange Commission on
January 17, 2007. |
|
(3) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Registration Statement of
Form S-11,
as amended (File No.
333-115204),
filed with the Securities and Exchange Commission on May 5,
2004. |
|
(4) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
September 26, 2006. |
|
(5) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Annual Report on
Form 10-K
filed with the Securities and Exchange Commission on
February 28, 2007. |
|
(6) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
January 5, 2007. |
|
(7) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
January 14, 2005. |
|
(8) |
|
Incorporated by reference to BioMed Realty Trust, Inc.s
Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
December 18, 2007. |
|
(9) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Annual Report on
Form 10-K
filed with the Securities and Exchange Commission on
March 15, 2006. |
97
|
|
|
(10) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
April 19, 2005. |
|
(11) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
June 3, 2005. |
|
(12) |
|
Incorporated by reference to BioMed Realty Trust, Inc.s
Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
August 7, 2007. |
|
(13) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
September 29, 2005. |
|
(14) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Quarterly Report on
Form 10-Q
filed with the Securities and Exchange Commission on
November 8, 2007. |
|
(15) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
November 20, 2006. |
|
(16) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Current Report on
Form 8-K
filed with the Securities and Exchange Commission on May 5,
2006. |
|
(17) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
May 26, 2006. |
|
(18) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Quarterly Report on
Form 10-Q
filed with the Securities and Exchange Commission on
August 8, 2006. |
|
(19) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
July 17, 2006. |
|
(20) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
August 28, 2006. |
|
(21) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
October 24, 2006. |
|
(22) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Quarterly Report on
Form 10-Q
filed with the Securities and Exchange Commission on
November 8, 2006. |
|
(23) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
December 28, 2006. |
|
(24) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Quarterly Report on
Form 10-Q
filed with the Securities and Exchange Commission on May 4,
2007. |
|
(25) |
|
Incorporated by reference to BioMed Realty Trust, Inc.s
Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
February 6, 2007. |
|
(26) |
|
Incorporated herein by reference to BioMed Realty Trust,
Inc.s Registration Statement on
Form S-3
(File
No. 333-143658),
filed with the Securities and Exchange Commission on
June 11, 2007. |
|
(27) |
|
Filed herewith. |
98
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned
thereunto duly authorized.
BioMed Realty Trust, Inc.
Alan D. Gold
Chairman of the Board, President and
Chief Executive Officer
(Principal Executive Officer)
Kent Griffin
Chief Financial Officer
(Principal Financial Officer)
Greg N. Lubushkin
Vice President Chief Accounting Officer
(Principal Accounting Officer)
Dated: February 28, 2008
Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons
on behalf of the registrant and in the capacities and on the
dates indicated.
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
/s/ BARBARA
R. CAMBON
Barbara
R. Cambon
|
|
Director
|
|
February 28, 2008
|
|
|
|
|
|
/s/ EDWARD
A. DENNIS
Edward
A. Dennis
|
|
Director
|
|
February 28, 2008
|
|
|
|
|
|
/s/ RICHARD
I. GILCHRIST
Richard
I. Gilchrist
|
|
Director
|
|
February 28, 2008
|
|
|
|
|
|
/s/ GARY
A. KREITZER
Gary
A. Kreitzer
|
|
Executive Vice President, General Counsel, Secretary and Director
|
|
February 28, 2008
|
|
|
|
|
|
/s/ MARK
J. RIEDY
Mark
J. Riedy
|
|
Director
|
|
February 28, 2008
|
|
|
|
|
|
/s/ THEODORE
D. ROTH
Theodore
D. Roth
|
|
Director
|
|
February 28, 2008
|
|
|
|
|
|
/s/ M.
FAYE WILSON
M.
Faye Wilson
|
|
Director
|
|
February 28, 2008
|
99